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62012 a successful year and a period of changes
2012 is the penultimate year of financial sup-
port by the CPER 2007-2013 for ETOILE’s re-
search program, sustained by the PRRH at the
University Claude Bernard. As with each edi-
tion we make the annual review of the research
in this group, so active for over 12 years now.
Over the difficulties in the decision-making
process for the implementation of the ETOILE
Center, towards which all our efforts are fo-
cussed, some “themes” (work packages) were
strengthened, others have progressed, or have
been dropped. This is the case of the eighth
theme (technological developments), centered
around the technology for rotative beam dis-
tribution heads (gantries) and, after being syn-
chronized with the developments of ULICE’s
WP6, remained so by ceasing its activities, co-
inciding also with the retirement of its historic
leader at IPNL, Marcel Bajard. Topic number 5
(“In silico simulations”) has suffered the depar-
ture of its leader, Benjamin Ribba, although the
work has still been provided by Branka Bernard,
a former postdoctoral fellow in Lyon Sud, and
now back home in Croatia, still in contract with
UCBL for the ULICE project.
Aside from these two issues (and the fact
that the theme “Medico-economical simula-
tions" is now directly linked to the first one
(“Medical Project”), the rest of the teams are
growing, as evidenced by the publication statis-
tics at the beginning of this report. This is obvi-
ously due to the financial support of our always
faithful regional institutions, but also to the
synergy that the previous years, the European
projects, the arrival of the PRIMES LabEx, and
the national France Hadron infrastructure have
managed to impulse.
The Rhone-Alpes hadron team, which natu-
rally includes the researchers of LPC at Cler-
mont, should also see its influence result in
a strong presence in France Hadron’s regional
node, which is being organized. The future of
this regional research is not yet fully guaran-
teed, especially in the still uncertain context of
ETOILE, but the tracks are beginning to emerge
to allow past and present efforts translate into a
long future that we all want to see established.
Each of the researchers in PRRH is aware
that 2013 will be (and already is) the year of
great challenge : for ETOILE, for the PRRH,
for hadron therapy in France, for French hadron-
therapy in Europe (after the opening and begin-
ning of treatments in the German [HIT Heidel-
berg, Marburg], Italian [CNAO, Pavia] and Aus-
trian [MedAustron, Wien Neuerstadt]) centers.
Let us meet again in early 2014 for a compre-
hensive review of the past and a perspective for
the future ...
Pr. J. Remillieux & Pr. J-M. Moreau
University Claude Bernard Lyon 1
ETOILE’s Scientific Management (PRRH)
Villeurbanne, June 15, 2013.
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Chapter 1
Medical project
Scientific coordinator
• Prof. Jacques Balosso, radiotherapist, PUPH, (CHU de Grenoble),
Institutions & laboratories involved
• GCS ETOILE
• Université Claude Bernard (UCBL)
• Hospices Civils de Lyon (HCL)
• Université Joseph Fourier (UJF) / CHU de Grenoble
• Centre Léon Bérard (CRLCC de Lyon)
• Institut Lucien Neuwirth (ex Institut de Cancérologie de la Loire, Saint-Étienne)
• Centre Alexis Vautrin (Nancy)
• Université Jean Moulin Lyon III
• Centre François Baclesse (Caen)
• CHU de Besançon
• Institut Claudius Regaud (CRLCC de Toulouse)
General organization, full- or part-time researchers with institutional links
Set up of national and european network‡
– Prof. Jacques Balosso, radiotherapist, PUPH, (CHU de Grenoble),
– Dr. Guillaume Vogin, radiotherapist (Assistant Département de radiothérapie, Centre
Alexis Vautrin, Nancy et CHR Metz-Thionville),
Evaluation in hadrontherapy:
– Clinical trials:
∗ Main Investigator: Dr. Pascal Pommier, radiotherapist, (Centre de lutte contre le
cancer Léon Bérard,Lyon).
‡Professor Jean Louis Habrand (Radiotherapist oncologist specializing in pediatrics, Head of the radiation de-
partment, Centre François Baclesse, Caen) may also be cited for his contribution.
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∗ Dr Marie-Hélène Baron, radiotherapist (PH, CHU de Besançon).
– Epidemiological and geographical studies:
∗ Project manager: Stéphanie Patin, epidemiologist, coordinator of the OMéRRIC
network (GCS ETOILE),
∗ Yohan Fayet, PhD – Health geograph (Université Jean Moulin Lyon III),
∗ Isabelle Ray-Coquard, MD, PhD, medical oncologist (Centre Léon Bérard),
∗ Dr. Françoise Ducimetiere, Scientific Coordinator of the Medical Evaluation of
Sarcomas (EMS – Centre Léon Bérard)
– Medico-economical evaluation:
∗ Christell Ganne, (Pôle d’Information Médicale Evaluation Recherche des Hospices
Civils de Lyon)
∗ Dr Yi Hu, MD, methodologist (UCBL, UMR5558, département de pharmacologie
clinique).
Biological study: Pr Claire Rodriguez-Lafrasse, UF Oncologie Moléculaire et Transfert -
Centre de Biologie Sud, Centre Hospitalier Lyon-Sud 69495 Pierre Bénite
Medical literature study:
– Coordinator: Dr. Yi Hu, médecin, methodologist (UCBL, UMR5558, département de
pharmacologie clinique).
– Dr Anne Laprie, Radiotherapist, specialized center (Institut Claudius Regaud, Toulouse).
Other scientifc and medical consultants:
– Laurence Vial, medical physicist, (Institut Lucien Neuwirth, St Etienne).
– Marie-Claude Biston, medical physicists, (Centre Léon Bérard).
1.1 Overall 2012 assessment
1.1.1 Context
2012 was the time to start preparing for the end of several funding programmes, which allowed
the emergence of the hadrontherapy discipline at the local level (CPER 2007-2013) and at the
European level (the ULICE project: September 2009-August 2013), and to prepare the ground
for the organizations that will follow, in particular in the framework of the investment scheme
initiated by the French Government (« Investissements d’Avenir »).
As for the medical aspects, the National Infrastructure project, France HADRON, was vali-
dated in 2012, with a strong recommendation for clinical research, and the ULICE program will
end with the set-up of an organization and coordination group for clinical research in Hadronther-
apy at the European level. In this regard, the so-called franco-german ETOILE-HIT prospective
and comparative study is a model.
1.1.2 Organization of the French and European networks
France Hadron
To enable the consolidation of all the medical, scientific and technical forces in hadron therapy
in France, the actors in this area, mainly located in major universities and national research
institutions (CNRS, CEA, INSERM, IRSN) decided to join their forces to present the France
Hadron project in response to the “National Infrastructure for Biology and Health1” call for
projects. The scientific project includes four work packages (WP). The ETOILE center is the
1Link toward Investissements d’Avenir.
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leader of WP1 and coordinator of the whole project. The objective is to develop knowledge
of emphEvidence-Based Medicine in the field of particle therapy by proton therapy and carbon
therapy, in relation to the most advanced techniques of photon therapy (X and gamma rays).
WP1 participates as a whole to meet the second cancer plan (Plan Cancer 2009-2013).
Project evolution for 2012 this infrastructure was authorized to sign contracts with the
National Agency for Research (ANR) on April 16, 2012. In the months that followed, proposals
of financial use have been pooled to be included in the file that was prepared at the end of 2012,
to be submitted to the ANR in January 2013.
Coordination of the construction of the European clinical research infrastructure in
hadrontherapy
The ETOILE Center takes part in the coordination of the construction of the evaluation method-
ology in the ULICE program (Union of LIght Ions Centres in Europe). It is mainly concerned
with phase III clinical studies in the hope of comparing Carbone therapy with the more advanced
treatments in radiotherapy. The methodologies will be adapted to the specific constraints of
hadrontherapy: 1) the necessary multicentric activities at an international level, 2) the need for
common databases and for powerful and secure data exchange tools, 3) the need for an inter-
national, multidisciplinary, and detailed case analysis to include in clinical studies, 4) the low
incidences of patients and the necessary time hindsight for the comparison of survival quantifica-
tion and of the economical efficiency.
Project evolution for 2012 the methodology, tools and regulatory solutions developed for the
construction of the Phase III clinical trials, the above-mentioned ETOILE-HIT PHRC, serve to
define and to test practical aspects to take into account in the framework of European cooperation.
1.1.3 Evaluation in hadron therapy
Clinical study
The PHRC ETOILE-HIT project consists in a randomized prospective and comparative carbon
ion radiotherapy study based on patients with localized, non resectable (or in R2 resection) and
radioresistant cancers: the axial skeleton chordomas (skull excluded), adenoid cystic carcinoma of
the head and neck sarcomas, with a comparison between the results of carbon therapy (performed
abroad, at the HIT center in Germany) and alternative radiotherapeutic modalities (in France).
The funding of this project was accepted by INCa through the 2011 PHRC (Hospital Clinical
Research Program). This study aggregate 33 teams (university hospitals or anti-cancer centers,
plus the HIT Center), and its promotion is ensured by Hospices Civils de Lyon (HCL).
Project evolution for 2012: the protocol has been fully defined, regulatory barriers identified
and solutions proposed. The HIT center is involved. The documents are ready to be submitted to
the CPP (Comité de Protection des Personnes) and the ANSM (Agence Nationale de Sécurité du
Médicament et des Produits de Santé) early 2013. Parallel evolution of this project is presented
and analyzed in the framework of WP2 to ULICE in connection with the Austrian collaborators
(MedAustron Project) in charge of this WP with us. It will be the first international multicenter
carbon therapy study. The study should include its first patient in the second half of 2013.
Epidemiological and geographical study
Study of the socio-epidemiological factors in the hadrontherapy care pathways for
Rhône-Alpes area sarcoma affected patients Funding for this project was provided by
INCA in response to the call for projects “Free research projects in Humanities and Social Sciences,
Epidemiology and Public Health 2012”. The objective of the EMS-ETOILE study is to investigate
the epidemiological factors of access to care and their impact on survival, for patients affected
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
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with sarcoma who will be eligible for hadrontherapy treatment in the Rhône-Alpes Region. Thus
the health care pathways, the role of social and geographical inequalities, will be demonstrated
in the treatment of patients. This study will be performed on an exhaustive cohort of patients
initiated in 2005 in the Rhône-Alpes area.
Project evolution for 2012: the study started and runs as expected in the general agenda of
the project. A second selection of the patients was performed in the EMS database. Indeed, some
patients present in the first cohort were removed because they had not been strictly enough selected
about their clinical condition during the first selection. This approach increased the relevance
of the representative population for Hadrontherapy. A list of 10 socio-economic variables was
established and these are the subject of a specific collection in paper medical records of patients
included in the study to answer its epidemiological aspects. An approach to geographic indicators
is underway. Thus, three broad categories of territorial quality have been explored: life area, social
space and resources space.
Medico-economical studies
a. The medico-economical study on the cost of ACC (adenoid cystic carcinoma). This study
was launched in late 2010 with 31 diagnosed patients. In 2012, 90 patients diagnosed between
late 2011 and early 2001 were added (including 18 patients of the Centre Hospitalier Lyon
Sud, 55 of the Centre Léon Bérard (with one consulting both centres), and 18 of the CHU of
Saint-Etienne) to form a total cohort of 121 patients. The average age of patients was 54.5
years, the ratio F/M is 72:49 (1.46:1). Clinical data have already been identified. We will
continue this study in 2013 with cases of the Croix Rousse Hospital and presumably of the
Hospital in Clermont-Ferrand, in function of the total number of patients included. Access
to economic data is being negotiated with the CPAM of patients.
b. The medico-economical study from the ancillary study to the PHRC ETOILE–HIT study.
The aim is to inform public deciders in the allocation of resources. Two perspectives will
be considered: that of the fund bringer (health insurance) and that of society. The main
objective of the study is to compare, according to two dimensions of costs and results,
two radiotherapy-based strategies (carbon therapy compared to conventional therapy) for
selected indications. A cost-effective analysis will allow a survival measurement. A second
cost-effectiveness analysis will be performed with a measurement result expressed in terms
of recurrences avoided. In further analysis, a cost-benefit study will be conducted to assess
the duration of life gained, quality-adjusted life year (QALY), between the carbon therapy
strategy and the strategy without carbon ions. This study is funded through the PHRC-
hadron budgets and is managed by the Medical Information Sector and Evaluation Research
of the Hospices Civils de Lyon in connection with the CNAMTS.
Project evolution: this study will start when the PHRC ETOILE-HIT study includes its first
patient.
1.1.4 Medical literature analysis
Monographs
To learn more about rare cancers that represent the main indications for Hadrontherapy which
will be recruited at ETOILE Center opening, we decided to gather as monographs all relevant
information, useful to clinicians on these tumors. The diseases in question are: adenoid cystic
carcinomas, chordomas, chondrosarcomas of the axial skeleton, tumors of the paranasal sinuses,
adenocarcinoma of the head and neck mucosal melanomas, desmoid tumors, pelvic recurrences of
rectum cancer, aggressive forms of meningiomas and pituitary carcinomas (very rare form of pitu-
itary tumor in contrast to adenomas). Different aspects are covered: epidemiology, histopathology,
carcinogenesis, symptoms, diagnosis, clinical manifestations and natural history, treatment, treat-
ment efficacy, toxicity, prognostic factors... Manuscripts for the following pathologies are finalized:
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adenoid cystic carcinomas, melanomas mucosal chordomas, chondrosarcomas of the axial skeleton,
desmoid tumors, pelvic recurrences of rectal cancer and aggressive forms of meningiomas.
Keeping up to date and scientific veille monitoring
Throughout the acquisition process, data are updated if necessary. In 2012 we updated the data
upon sarcomas and brain tumors in children. This topic resulted in a manuscript being finalized.
1.1.5 Communications
The methodology of the EpiHadron study “Epidemiological study of the incidence of cancers
eligible for proton or carbon ions therapy” was presented in an oral communication during the
Fifth International Congress of Epidemiology ADELF EPITER held in Brussels from 12 to 14
September 2012.
1.2 References for the chapter
[BCR+12] G. Buiret, P. Céruse, A. Ramade, C. Carrie, and P. Pommier. Acinic cell carcinoma of
the parotid gland with skull base invasion: case study, managed by exclusive external
3d radiation therapy. European Annals of Otorhinolaryngology, Head and Neck Disease,
129(2):111–114, April 2012.
[BMF+12] G. Buiret, X. Montbarbon, B. Fleury, M. Poupart, JC. Pignat, C. Carrie, and P. Pom-
mier. Inverted papilloma with associated carcinoma of the nasal cavity and paranasal
sinuses: treatment outcomes. Acta Otolaryngol, 132(1):80–85, January 2012.
[PMP+12] P. Pommier, M. Morelle, L. Perrier, R. De Crevoisier, A. Laplanche, P. Dudouet, MA.
Mahé, B. Chauvet, TD. Nguyen, G. Créhange, A. Zawadi, O. Chapet, I. Latorzeff,
A. Bossi, V. Beckendorf, E. Touboul, X. Muracciole, JM. Bachaud, S. Supiot, and
J-L. Lagrange. Prospective economic evaluation of image-guided radiation therapy for
prostate cancer in the framework of the national programme for innovative and costly
therapies assessment. Cancer Radiotherapy, 16(5-6):444–451, September 2012.
[PPH+12] S. Patin, P. Pommier, Y. Hu, M-H. Baron, and J. Balosso. Étude d’incidence des
cancers éligibles pour une hadronthérapie : méthodologie. Revue d’épidémiologie et de
santé publique, 60(supplément 2):S64–S65, September 2012.
[TVT+12] J. Thariat, PO. Védrine, S. Temam, AM. Ali, D. Orbach, G. Odin, M. Makeieff,
R. Nicollas, M. Penicaud, B. Toussaint, S. Vergez, A. Laprie, M. Rives, K. Montagne,
N. Teissier, and L. Castillo. The role of radiation therapy in pediatric mucoepidermoid
carcinomas of the salivary glands. J. Pediatry, 6, November 2012.
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Medico-economical simulations
Scientific coordinators
• Dr. Pascal Pommier (HDR, Centre Léon Bérard)
2.1 Overall 2011 assessment
This year again, the research in this theme are very closely linked to the “Programme de Recherche
Hospitalier de Recherche Clinique” (PHRC) 2011 and hence to the medical project. All the 2012
actions in the medico-economical theme are described in the previous chapter.
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Chapter 3
In silico modeling of therapeutic
effects
Scientific coordinators
• Benjamin Ribba (CR, INRIA, NUMED team)
• Branka Cajavec-Bernard (ULICE project, Split, Croatie/UCBL)
Institutions & laboratories involved
• INRIA
• UCBL
• Split Polytechnic, Croatie
3.1 Overall 2012 assessment
This year again, Branka Cajavec-Bernard has been involved in the ULICE project (WP3: “Biologically-
based expert system for individualised patient allocation”). In the collaboration with University
of Dresden, group lead by Prof. Wolfgang Enghardt, software is being developed for the compar-
ison of photon- and proton-based treatment plans. Exchange of treatment plans between proton
and photon treatment facilities, and upload of photon-based treatment plans, has been resolved.
With the availability of clinical data, we plan to use this technical basis to include biologically
related models for treatment planning. This common project was discussed at the joint meeting
of PARTNER, ENLIGHT, and ULICE Annual Meeting, September 14-16, 2012, at the CNAO
Center, Pavia, Italy.
The manuscript with developed mathematical model that successfully describes low-grade
glioma (LGG) tumor size evolution and predicts tumor response in patients treated with chemother-
apy and radiotherapy, was published [?]. In the future, this model might be used to predict
treatment efficacy in LGG patients and could constitute a rational tool to conceive more effective
chemotherapy schedules.
Aware of the gap that needs to be bridged between clinical research and the complementing
methodologies developed in computational cancer research groups, we are creating COMPLE-
MENT a Clinicians Computational Cancer Models Guide and Database. For a particular tumor
type, COMPLEMENT gives information on available models, questions that can be tested by that
model, input data needed to test that question, and a contact for associated research groups. Can-
cer clinical trials complemented with computational cancer models may contribute to the design
of rational, tailored treatments. Computational models developed along a clinical trial present a
14
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necessary step towards virtual clinical trials and a decision on the benefit of a particular treat-
ment modality for an individual patient. To address this need, we are developing COMPLEMENT
also as a guide for clinicians on how a clinical trial tailored computational model is created and
implemented.
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Chapter 4
Basic physical measures and
on-line control
Scientific coordinators
• Denis Dauvergne (DR CNRS – IPNLyon)
• Gérard Montarou (DR CNRS – LPC-Clermont)
Institutions & laboratories involved
• IPNL, CNRS/IN2P3 and Université Lyon 1
• CREATIS, INSA et CNRS and INSERM and Lyon 1 University
• LPC-Clermont, CNRS/IN2P3 and Clermont University
Full-time researchers with institutional links
• IPNL : M. Dahoumane (IR CNRS), D. Dauvergne (DR CNRS), J. Krimmer (CR-CDD
CNRS), C. Ray (MdC UCBL), E. Testa (MdC UCBL), H. Mathez (IR CNRS), Y. Zoccaratto
(IR CNRS)
+ M. De Rydt (post-doc), G. Dedes (post-doc Envision) S. Deng (Th 2012), J.-L. Ley
(Th 2015)M. Pinto (Th 2014), V. Reithinger (Th 2014), M-H. Richard (Th 2012), A. L.
Pequegnot (M2)
• CREATIS : N. Freud (MdC INSA), J.M. Létang (MdC INSA), V. Maxim (MdC INSA), R.
Prost (Pr INSA)
• LPC-Clermont : G. Montarou (DR CNRS), P. Force (Pr Clermont Université), N. Pauna
(MdC Clermont Université), F. Martin (Pr Clermont Université), B. Joly (IR CDD), D.
Lambert (IR CNRS), PE. Vert (IR CNRS), G. Blanchard (IR CNRS), L. Royer (IR CNRS),
C. Insa (IR CNRS), B. Boutin (T UBP)
+ L. Lestand (Th 2012), O. Bouhadida (Th 2013)
4.1 Main objectives
4.1.1 General issues
Online monitoring and quality control of ion therapy is a crucial issue due to the ballistic precision
and – for carbon – the large biologic efficiency of ions at the end of their range in matter (at the
16
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Bragg peak). Indeed, a small deviation from the planned dose is the consequence of a possible
patient mispositioning or uncertainties in the patient morphology (e.g. anatomy evolution during
the treatment), or uncertainties in the determination of the stoechiometric composition, that is
deduced from X-ray CT.
Unlike photons, incident ions are stopped inside the body, and techniques based on the obser-
vation of secondary particles – induced by nuclear fragmentation – are needed. The objectives of
the present research field are the following:
• by means of simulations, feasibility experiments at large accelerator facilities and/or ion
therapy centres, and through research and development programs, we intend to elaborate
innovative techniques to monitor online the dose delivered to the patient. These techniques
are based on the detection of secondary radiations: beta+ annihilation, prompt gamma
photons, and light charged particles. The final quality control system could involve several
of these modalities. In addition, prospective studies were undertaken to assess the clinical
advantages of proton radiography over X-ray radiography, in terms of accuracy in density
identification and absolute dose delivered during the examination.
• We contribute to the acquisition and the compilation of basic physical data for nuclear
fragmentation. The objective is twofold:
i to test and validate the physical models used for the treatment planning systems, and
ii to obtain the required accuracy in the prediction of secondary radiation imaging.
4.1.2 Context
This research is undertaken in multiple frames of various scales, which shows the importance of
improving the quality of ion-therapy treatments:
• The Programme Régional de Recherche en Hadronthérapie, supported by the Région Rhône
Alpes and the Grand Lyon (CPER 2007 – 2013);
• At a larger regional scale (Cancéropôle CLARA: Lyon, Grenoble, St Étienne, Clermont-
Ferrand), a Labex project, PRIMES (Physique, Rayonnement, Imagerie Médicale et Simu-
lations), was selected (Investissements d’Avenir 2011) andas started in March 2012. Three
workpackages over five are related to the research for ion therapy (WP1: innovative imaging
for radiotherapy, WP3: Radiobiology, WP5 : simulation and modelling for imaging and
therapy);
• The Research Groupement GDR MI2B, driven by the National Research Center CNRS
(IN2P3), is leading a federative program “Instrumentation and Nuclear Methods against
Cancer”; this GDR was reconducted for the period 2012-2015;
• The national research program in ion-therapy (PNRH) was reactivated in 2011 through the
Infrastructure program for Biology and Health France-HADRON (Investissements d’Avenir
2011), that was approved for the period 2012-2020. This program aims at coordinating the
research driven by the various clinical and research centers in France.
• The European network ENLIGHT++, a federative network that involves the various Euro-
pean centers, coordinates the collective response to research calls launched by the European
Community. Online imaging of the dose during ion therapy is one of the major axes de-
veloped within this collaboration between clinical centers and research laboratories (project
ENVISION 2009-2013). The educational part is also well represented (PARTNER and EN-
TERVISION Marie-Curie ITN programmes).
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4.2 Overall 2011 assessment
4.2.1 Prompt-gamma SPECT imaging
We demonstrated, during a first experiment in 2007 at GANIL (Caen), that the emission profile
of prompt gamma rays as a function of the target depth can be measured by means of a detection
system with limited shielding. Thanks to the time of flight technique, it is possible to discern the
arrival time of photons and massive particles emitted under ion impact on a phantom target. This
emission profile is correlated to the range of the primary ions, and thus allows one to localize the
Bragg peak. Moreover, the counting rates obtained are encouraging in view of a system for on-line
and real-time monitoring of the dose.
This modality of on-line control was the object of a patent registration with PCT extension.
Within the frameworks of a project ANR (Gamhadron) grouping together the IPNL, CREATIS,
the CEA / LIST and the LPC-Clermont, and the European project ENVISION (driven by the
ENLIGHT++ network), we develop a system of SPECT imaging which includes the following
studies: one R&D on a collimated gamma camera, another one on a Compton camera, a simulation
work for modelling prompt gamma emission, a R&D for a beam hodoscope, and a tomographic
reconstruction task for the Compton camera.
Collimated gamma camera
Since 2007, new series of measurements at GANIL, GSI, Essen and HIT-Heidelberg, allowed us
to confirm the suitability of prompt gamma rays detection with time-of-flight discrimination. We
have shown that the correlation between the primary ion range and the gamma profile is kept
at higher energies (for 15-20 cm ion ranges). Fast neutrons cannot be used to measure the dose
profile, and therefore constitute a major background. Time-of-flight (TOF) selection is used in
order to eliminate them and enhance signal-to-background ratio. Moreover, we have shown that
the target composition and size do have an influence on the gamma count rate, but this does not
prevent SPECT imaging from being efficient for dose monitoring. The time structure of the beam
is not an obstacle, provided a beam fast-monitor is used to get a beam tagging for time-of-flight
measurements.
LYSO scintillating detectors have been specially designed for the detection of high energy
gamma rays through a multi-slit collimator. Their typical dimensions are 5 cm long (thick) ×
5 cm high × 5 mm width, allowing good efficiency for the transmitted photons, and a minimum
sensitivity to the background of neutrons and scattered gamma rays. This provides a significant
improvement of the signal to background ratio, compared to the large volume detector used ini-
tially. Using an optimized detection setup under design-study, the Bragg peak position can be
visualized with an accuracy of about 3 mm within the first pencil beam spot of a proton patient
treatment, as illustrated on Figure 4.1.
For carbon ion therapy, the yield of prompt gamma is smaller, and control at the energy
slice scale (some tens of spots) is foreseen with a reasonable size camera. Thanks to combined
experiments at Essen (collaboration with IBA) and HIT in 2012, we could compare prompt gamma
profiles for proton and carbon beams of the same range in matter. Gamma yield profiles have been
measured in the protontherapy center of Essen with a proton beam of 160 MeV, in collaboration
with the IBA research group. Figure 4.2 shows the results obtained with and without TOF
selection (note that a time window of 5 ns was used, which is not as severe a selection as one
would use in an optimized setup, therefore the background reduction is not maximum). This
figure shows that TOF improves in any case the signal to background ratio, and, for carbon ions,
it is mandatory to extract an information correlated to the ion range.
Yields correspond to energy deposition larger than 1 MeV with a time-of-flight selection of
prompt-gamma rays (green line) and without time-of-flight selection (red line).
Further measurements were performed at GSI (cave A) in August 2012, in order to evaluate
the realistic background for various shielding and collimation systems. These data will be used
for the design of an optimized collimation system.
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Figure 4.1: Prompt gamma resolution study on proton range, for 160 MeV protons incident on a
30 cm long, 15 cm diameter, cylindric PMMA target. Measurements are obtained with a LYSO
scintillator (40 mm x 3 mm entrance surface and 50 mm thickness) placed behind a tungsten alloy
collimator with a thickness of 10 cm and a single slit of 2 mm. Left: analytical fit of the measured
scans, each point corresponding to 1010 incident protons. Right, determination, for sub-data sets
of reduced statistics, of the rms dispersion of the prompt-gamma rise at target entrance, falloff at
Bragg peak and their difference (range), as a function of the incident proton number.
Figure 4.2: Prompt gamma profiles obtained with 160 MeV proton beam in a PMMA target, and
with 310 MeV/u carbon ions at HIT, with the same detection setup, with and without time-of-flight
selection (refer to text).
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Compton camera
For single photon emission computed tomography (SPECT), a Compton camera has the advantage
of a much greater efficiency than a classical collimated gamma-camera, since no mechanical colli-
mation is needed. Thus the efficiency can be improved in principle by several orders of magnitude.
The aim of the Gamhadron ANR project (2009-2013) is the design and setup of a time-of-flight
Compton camera for online prompt-gamma monitoring of ion-therapy. This topic is also supported
by the Envision project (WP3).
Simulations and detector design Design studies have been undertaken at IPNL and CRE-
ATIS to assess the performances of such a device, in terms of efficiency and spatial resolution. This
is the subject of the thesis work of Marie Hélène Richard, co-directed by CREATIS and IPNL.
Two concepts have been followed. A first one concerns a double Compton-scattering camera,
made of two thick (1 cm) silicon scatterer detectors and an absorber scintillator. The advantage of
two scattering events is that there is no need for measuring the full energy of the residual photon in
the absorber detector. It has nevertheless a limited efficiency, comparable to the collimated camera
efficiency [RCD+11]. A second design dealt with a single Compton-scattering camera, made of a
stack of about ten thin (2 mm) silicon scatter detectors and one absorber. This second system
has a much better efficiency (about one order of magnitude), since only one Compton scattering
and the absorption of the residual photon in the absorber are required. In this case, the spatial
resolution is only slightly degraded; the point-spread function has an 8 mm FWHM [RRC+11].
After the adoption of the single Compton scattering system, our studies concentrated on the
choice of the absorber scintillator material. As illustrated in Figure 4.3, our simulations show
that, according to a realistic prompt gamma energy spectrum, a heavy scintillator like LYSO
provides the best performances for the Compton camera, in terms of efficiency and spatial res-
olution [RDD+11]. BGO appears also as a good candidate, despite poorer energy and timing
resolutions, since the most important property is the spatial resolution. The latter depends mostly
on the photoabsorption probability, i.e on the effective atomic number of the material.
Figure 4.3: Simulation of a Compton camera performance according to the nature and thickness
of the absorber scintillator [RDD+11].
A simulation experiment was performed at HIT-Heidelberg, where a reduced size Compton
camera prototype was used: a 12 × 12 mm2 area, 2 mm thick silicon detector was used as scatter
detector, and a 2.5 cm diameter, 5 cm thick cylindrical LaBr3 scintillator served as absorber (see
figure 4.4-a). Carbon and proton beams were sent onto a 25 cm thick PMMA target. The aim of
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this experiment was to measure single and coincidence count rates in a realistic beam environment,
and to extrapolate such count rates for the real size Compton camera shown in Figure 4.4-b.
(a)
(b)
Figure 4.4: (a): Compton-camera-like setup at HIT-Heidelberg. (b): designed setup of the Comp-
ton camera for online control of the ion range during therapy.
The extrapolation was made by means of GEANT4 simulations. The expected count rates
of the Compton camera presented in Figure ??-b are reported in Table ??. The conclusions are
that high counting rates, especially for proton beams, may be a crucial issue, in particular for the
absorber detector. Therefore, segmentation of this detector will be necessary in order to keep the
camera efficiency acceptable.
Proton beam Carbon beam
Typical beam intensity (Hz) 1010 108
First Si detector count rate (Hz) 4× 106 1× 106
Absorber count rate (Hz) 2.5× 107 3× 106
Coincidence 10 Si – Absorber rate (Hz) 3× 105 8× 104
Table 4.1: iSimulated count rates in clinical conditions for the Compton camera schematized in
Figure 4.4-b, according to measured count rates at HIT.
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Detector developments The above design studies allowed us to define the characteristics of
the silicon detectors. Following previous measurements with reduced size detectors, real size
detectors with 2 mm thickness, double-sided strip (1.4 mm pitch), and 96 × 96 mmi2 active area
are now under test at the IPNL laboratory (see figure 4.5). The integrated front-end electronics
has been developed at the IPNL electronics lab [DDK+12]. Figure 4.5 also shows the first version
of the ASIC on its test board. The next version, with 16 channels and improved performances, is
expected by Spring 2013. The energy resolution of these detectors is a key factor for the spatial
resolution of the Compton camera.
(a) (b)
Figure 4.5: Left: final size double sided silicon strip detector on test board for leakage current
measurements. Right: readout ASIC for silicon detector on test board.
A data acquisition system, with high data flux and processing capability, is under development
at LPC-Clermont-Ferrand (micro-TCA acquisition system).
Image reconstruction List-Mode Maximum Likelihood Expectation Maximization (LM-MLEM)
algorithms use to be employed for Compton camera image reconstruction. As already known for
nuclear medicine applications, they are able to faithfully reflect the physical processes taking
place during emission and detection, at the expense of sometimes considerable computational bur-
den [FZMP10]. The most costly and difficult to implement step is the computation of the system
matrix. For instance, for n detected events and N3 voxels in the image, the complexity of the
standard algorithm is O(nN3). During his PhD thesis at CREATIS, supported by the European
project ENVISION, Xavier Lojacono proposed a new calculation method [LMP11]. The method
provides a better precision when the camera has ideal detection properties and has the complexity
O(nN2). An extension aiming to account for measurement uncertainties was recently developed
and shown at the IMAGIV colloquium in Lyon [LHP+12]. The presentation also included some
of the results from the Master thesis of Estelle Hilaire and Rohit Prasad (2012, CREATIS).
Simultaneously, fast analytic reconstruction methods are investigated. Following ideas from
[MFP09], where a first analytic method capable to directly reconstruct images from standard
geometries was developed, a filtered backprojection algorithm leading to practical computer im-
plementation was proposed in [LMZ+11]. Recent advances were presented in 2012 at the XIème
Colloque Franco-Roumain de Mathématiques Appliquées in Bucarest [Max12], and should be pur-
sued with a Master thesis supported by the Labex PRIMES.
In a collaborative work between CREATIS and IPNL, presented at the IEEE NSS-MIC con-
ference [LRR+11] and submitted for publication at IEEE-TNS, the imaging properties of the
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simulated prototype described in section 4.2.1 were evaluated. The Point Spread Function and
the ability to detect the position of a point source in images reconstructed with both iterative
and analytic methods were analyzed. Iterative methods show to be well adapted for low statistics,
hadrontherapy-type applications, whereas analytic methods are both fast and precise as soon as
sufficient data are available [LRT+13].
(a) (b)
Figure 4.6: Reconstructed image of the gamma emission on the beam path. A PMMA phantom
of 15x20x15 cm3 and a Compton camera of 8 cm side for the scatterers, centered at (x, y) =
(0 cm, 5 cm) were simulated at IPNL. The geometry of the camera is shown in figure 4.4. The
position of the Bragg peak is supposed to be at y = 5 cm. Left: LM-MLEM image with 10
iterations and 7 × 103 detected events. Right: analytic reconstruction from 19 × 103 detected
events. Note the high activity close to the end of the beam range and the absence of emission
beyond the position of the Bragg peak. The color scale is in arbitrary units.
4.2.2 In-line beta+ imaging
Imaging of the beta+ activity is one of the three modalities envisaged for online control of ion-
therapy with secondary radiations. One can observe a correlation of the deposited dose and the
distribution of beta+ activity emitters that exhibits a falloff at the distal edge of the Bragg peak.
The spatial distribution of positron emitters is to some extent correlated with the range of the
ion.
It is possible to measure the spatial distribution of positron emitters during irradiation (in-
beam PET), keeping the patient in the treatment room (in-room PET) or outside the treatment
room (off-line PET). Off-line PET measurements with a clinical PET is disturbed by the metabolic
washout. This tends to relocate the spatial distribution of radionuclides. The research activity
of the LPC concerns development of in-beam PET-like detection system for the estimation of the
positron emitting nuclear fragments induced by the incoming beam. The foreseen solution relies
on four axes:
• the use of fast and luminous scintillators, like LYSO or LSO;
• fast response photosensors, like multichannel plates PMT (MCP-PMT);
• a fast sampling electronics, allowing, by numerical reconstruction with optimum filtering,
to reconstruct both the timing and the amplitude of each signal, with a common reference
clock.
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• the use of a fast DAQ system using microTCA technology
The contribution to the European project ENVISION (WP2) and to the PRRH consists in
developing a generic fast-acquisition electronics for PET and SPECT (prompt gammas). This
work is undertaken in the frame of a collaboration between IN2P3 laboratories (LPC-Clermont,
IPNL, IPHC, CPPM) and supported by the GDR MI2B.
Experimental beta+ activity measurement
Measurements performed during irradiation (in-beam PET) are strongly affected by the presence
of other secondary particles, like prompt gamma emission, that yields a high rate of random false
coincidence, depending on the beam time structure.
These prompt gammas are correlated to the beam spill, unlike gammas induced by positron
annihilation, which are uniformly distributed over time. In fact, random coincidences considering
PET acquisition could be rejected using some conditions integrated into the trigger process. The
research activity of the LPC concerns developments of in-beam PET like system for the estimation
of the positron emitting nuclear fragments induced by the incoming beam.
We check the advantages and the constraints of the on-line measurements of the yield and
the spatial distribution of positron emitters during hadrontherapy. These are based on some
experimental results with different characteristics of incident beams (proton and carbon).
The first experiments performed at GANIL in Caen (France) demonstrated that in-beam PET
acquisition could reasonably be achieved depending on specific beam configuration. GANIL ac-
celerator is a cyclotron with a radio frequency (RF) of around 12 MHz (83 ns period) and a beam
intensity of 108 carbon ions per second. Our experiments used two simple detectors operated in
coincidence during irradiation of a PMMA target by a 75 A.MeV 13C6+ beam.
Several detector devices were used: LYSO matrix coupled to Avalanche Photo-Diodes and
BaF2 / LaBr3 blocks (see Figure 4.7-a). For each triggered event, the analogue waveforms of the
two coincident detectors are sampled via custom-made electronic modules. Time mark and energy
of the signal are extracted off-line through waveform samples analysis. In case of this specific beam
time structure on can easily distinguish prompt radiation from delayed beta+ decay as shown on
the 2D energy-time diagram like on Figure 4.7-b below.
(a) (b)
Figure 4.7: (a) Experimental setup at GANIL, with small acceptance LYSO and BaF2 detectors.
(b) Energy vs Time distribution of coincidence events between the two detector heads. The beam
pulse is 1 ns in length, with a period of 80 ns.
Conclusion on the possibility of a PET acquisition between the ion bursts is quite different in
case of an increase of the duty cycle. An experiment performed at Curie Institute for protontherapy
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facility in Orsay (ICPO) demonstrated that, for continuous proton beams, one needs to improve the
on-line rejection method of the false coincidence using more elaborate trigger. ICPO accelerator is
a cyclotron with a radio frequency (RF) of around 106 MHz (9.4 ns period). Two simple detectors
operate in coincidence during irradiation of a PMMA target by the 86 MeV proton beam.
Figure 4.8 shows that when adjusting the beam intensity to get on average 3 protons at each
beam spill (4 Gy/min at the gantry nozzle), it is quite impossible to distinguish prompt radiation
from delayed beta+ decay as shown on the 2D energy-time diagram like on Figure 4.8-b.
(a) (b)
Figure 4.8: (a) Experimental setup at ICPO, with small acceptance LYSO detectors. (b) Energy
vs Time distribution of coincidence events between the two detector heads. The beam pulse is
1 ns in length, with a period of 9.4 ns.
Simulation work, including the time structure of the beam to study the feasibility of PET
acquisition during the irradiation, showed that one needs to improve the on-line rejection method
of the false coincidences. Thus one has to fully use the potentiality of the fast read-out electronics
to design more elaborate trigger of the event acquisition. This study is part of Loïc Lestand’s PhD
at LPC-Clermont [Les12].
beta+ activity simulation
Geant4 simulations have been performed in order to first assess the accuracy of some hadronic
models to reproduce experimental data. Two different kinds of data have been considered: beta+
emitting isotopes and prompt γ-ray production rates.
Beta+ emitting isotope yields as a function of depth were measured for 214, 260 and 337 AMeV
12C beam interacting with a PMMA target ([Fiedler-2006], [Priegnitz-2008], [Priegnitz-2012]1).
Figure 4.9 presents the comparison between experimental and simulated profiles. Each profile was
normalised to the total integrated area so only profile shapes are compared. Simulated profiles
are in reasonably good agreement with experimental ones. This is especially true concerning the
peak-to-plateau ratio which is well reproduced. In conclusion, the production rates and spatial
1 F Fiedler, P Crespo, K Parodi, M Sellesk and W Enghardt, 2006, The feasibility of in-beam PET for therapeutic
beams of 3He IEEE Trans. Nucl. Sci. 53, pp 2252–59.
M Priegnitz, F Fiedler, D Kunath, K Laube, K Parodi, F Sommerer and W Enghardt, 2008, A Novel Approach
for predicting the Positron Emitter Distributions Produced during Therapeutic Ion Irradiation, IEEE NSS Conf.
Record, pp 4516–19.
M Priegnitz, F Fiedler, D Kunath, K Laube and W Enghardt, 2012, An experiment-based approach for predicting
positron emitter distributions produced during therapeutic ion irradiation, IEEE Trans. Nucl. Sci., 59, pp 77–87.
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distribution of beta+-emitting isotopes induced by carbon beam interacting with PMMA target
are well reproduced by simulations using Geant4 toolkit version 9.4.
Figure 4.9: Experimental versus simulations: beta+-emitting isotopes depth profiles induced in a
PMMA target by a 214 AMeV carbon beam (a), 260 AMeV carbon beam (b). Fiedler et al (2006),
Priegnitz et al (2008, 2012)).
On the other hand prompt γ yield evaluation is important to estimate random false coincidence.
By tuning the tolerance factor of the photon evaporation model available in Geant4, we adjust
prompt γ-ray production rates until a very good agreement is reached with existing experimental
data.
Nevertheless, the results obtained are in a sufficiently good agreement, in order to design a
dedicated in-beam PET QA device. In other words, we are able to investigate, given simulated
counting rates, the feasibility of in-beam QA.This study is part of Loïc Lestand’s PhD at LPC-
Clermont [Les12] and was published [ [LMFP12].
TOF in-beam development
One way to improve the spatial resolution of beta+ activity reconstruction (in beam PET) by
means of time-of-flight selection of the two photons in coincidence should allow a considerable
gain in the data processing time to reconstruct an image. This would also reduce reconstruction
artefacts associated to the necessary limited size of an in-line PET for ion-therapy and provide a
much better image quality for a same counting statistics. The objective of this research and devel-
opment program, undertaken by the LPC-Clermont and IPNL Lyon laboratories, in collaboration
with IPHC Strasbourg and CPPM Marseille (IN2P3), is to achieve on the mid-term a detection
system with a time resolution of 200 ps, which corresponds to a spatial resolution of 3 cm, i.e. the
typical size of a tumour.
The achievement of a TOF-PET with 200-300 ps resolution will reinforce the relevance of
such an imaging modality for online ion-therapy monitoring. In particular, the faster the timing
resolution, the shorter the reconstruction times.
To achieve this goal developments will mainly focus on the use of micro channel plate based
photodetectors. First, Photonis and Hamamatsu multichannel MCPPMT will be used to check
what will be the ultimate TOF resolution accessible using such photodetectors.
The INCA Physique-Cancer project BETATRAC has been approved in 2011, in collaboration
between LPC Clermont and IPHC-Strasbourg to achieve these first studies and prepare the use
of large area MCP PMT under development in the LAPD collaboration at Chicago University.
First prototype of large area MCP-PMTs (8 in × 8 in) that presents a good time resolution, at
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
4.2 Overall 2011 assessment 27
Figure 4.10: Response of 3 of the 16 channels of a Hamamatsu MCPPMT exposed directly to a
fast optical pulse (yellow pulse). This led pulse is 20 ns in length.
relatively low cost will be available in 2013. LPC Clermont and IPHC Strasbourg collaborate with
LAPD collaboration to use this detector in TOF PET-like medical imaging.
4.2.3 Proton interaction vertex imaging
During carbon ion irradiations, the proton emission yields are quite high, and protons are directed
forward. This opens the way to a new imaging modality, in particular by means of interaction
vertex reconstruction (IVI), in which proton tracks are identified by several position sensitive
telescopes. A resolution of the order of the millimetre for vertex positioning is expected. Previous
preliminary measurements performed at GSI and GANIL allowed us to compare the measured
charged particle yields and the predictions by Geant4. The thesis of Pierre Henriquet (supported
by the PRRH 2008-2010) has demonstrated the ability of proton vertex imaging for online control
of carbon ion therapy [Hen11]. This feasibility study has been carried out with Geant4 simulations
to evaluate two detection techniques: a first one with double-proton detection by means of two
forward-located trackers, and a second one with single-proton detection, in coincidence with the
incoming carbon ion detected by means of a beam hodoscope. The first conclusion of this study
is that the single-proton detection appears the most promising with detection efficiency ten times
larger than the one of double-proton detection. Parameter influences have been considered with
head-like phantom (Figure 4.11-a). Figure 4.11-b shows reconstructed-vertex distributions in this
phantom for various ion beam energies (from 150 to 300 MeV/u). The smooth lines correspond
to fits with complementary error function which provides the position of the inflection point.
As expected, the shorter the ion range, the lower the reconstructed-vertex yields due to proton
attenuation in the target. There is a clear correlation between the ion range and the inflection-
point position of the vertex-distribution edge determined with fits of complementary error function
(Figure 4.11-c). This correlation is not strictly linear so that a calibration procedure is required to
set the function between the ion range and the inflection point position. Nevertheless the distance
between the four points of Figure 4.11-b and a linear fit does not exceed 10 mm which tends to
show that this calibration is not a critical issue to achieve millimetric precision. Moreover the
precision on the inflection point position determined by a complementary function fit has been
evaluated as a function of the incident ion amount: with the detection setup of Figure 4.11-a, this
precision is 5 mm (FWHM) with a number of incident ions close to 105 which corresponds to the
mean number of incident ions per raster position during a regular treatment of head-tumor.
In September 2011 we performed the first IVI measurements at GANIL, using CMOS-pixel
silicon detectors for secondary proton tracking, and a beam hodoscope to track the incident carbon
ion beam. A new experiment at higher ion energy took place in December 2011 at HIT – Heidelberg
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Figure 4.11: (a) Diagram of the spherical head phantom simulation: a hollow bone-equivalent
sphere in which cortical tissue-equivalent material is located. The sphere diameter and thickness
are 200 and 3 mm, respectively. (b) IVI reconstructed vertex distributions in the head phantom
(diameter of 20 cm) for various ion beam energies (300, 250, 200 and 150 MeV/u). The smooth lines
correspond to fits with complementary error function. (c) Inflection point position (determined
from fits) as a function of ion range. Number of incident ions per simulation: 106 (from [HTC+12]).
in the frame of the ULICE transnational access to infrastructure program. A third experimental
test dedicated to IVI was made in August 2012. Figure 4.12 shows the experimental setup at HIT,
with a beam hodoscope, a PMMA target block, and the 4-plane CMOS tracking detectors (2 × 2
cm2) located after the target, at an angle of 10°.
Figure 4.12: Sketch of the experimental setup for IVI imaging. The carbon ion beam is incident
on the top right (refer to text).
For the first time we could observe that the longitudinal profiles of proton vertices are correlated
to the carbon ion ranges in a homogenous phantom target. Figure ?? illustrates this correlation,
for ion ranges varying from 155 to 245 mm in PMMA.
Simulations were undertaken during the Master internship of Anne-Laure Pequegnot at IPNL,
and these simulations allowed to reproduce the shape of the experimental profile in the fall-off
region. The influence of heterogeneities located along the ion path was studied. The influence of
such heterogeneities close to the Bragg peak could not be pointed out.
The INCA Physique-Cancer project QAPIVI was approved in 2011, in collaboration between
IPNL, CREATIS, IPHC-Strasbourg to develop a IVI prototype. This detector development is the
thesis subject of Valérian Reithinger at IPNL (2011-2014).
Meanwhile we are collaborating with the TERA group in the framework of the ENVISION
(WP3) project. This group has developed such a charged particle telescope using GEM tracking
detectors. Common tests at carbon ion accelerator facilities are foreseen.
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Figure 4.13: Measured longitudinal distributions of reconstructed proton interaction vertices, for
various incident energies of the carbon ion beam. The calculated primary ion dose distribution
profiles are also shown.
4.2.4 Beam hodoscope for time of flight
The time-of-flight measurement is required for prompt secondary radiation imaging, as illustrated
above. To this purpose, an incident-ion beam tagging system is needed, whatever the time struc-
ture of the beam is. For ions issued from a synchrotron, the instant of impact of the incident
projectile is randomly distributed. For protons accelerated by cyclotrons, the passive or active
energy scanning systems will vary the phase between the HF pulse and the arrival time of beam
pulses in the patient body.
We have been developing a beam hodoscope made of two (horizontal and vertical) planes of
square scintillating fibers, read-out by a multi-anode photomultiplier. A first prototype was tested
at GANIL at the end 2009. The quite encouraging results have shown that the time resolution of
such a detector is about 500 ps (FWHM), and their resistance to ion irradiation damage allows
one to use such fibers with fluences of the order of 5× 1012 ions/cm2. This corresponds to several
weeks of clinical conditions utilization.
Since then we have built a larger prototype with 128×128 mm2 active area (see Figure 4.14-a).
A PhD thesis was defended in 2012 at IPNL (Shiming Deng, co-financed by ANR and the PRRH
for the period 2009-2012) [Den12] to design and build the integrated electronic readout of the
hodoscope. A first chip, made of current conveyor with charge preamplifier and discriminator (see
figure 4.14-b), has been tested in laboratory and under beam conditions. A second ASIC chip
designed by S. Deng has been submitted in 2012, integrating the Time to Digital Converter via a
delay-locked-loop. S. Deng has published an article and made several presentations in international
conferences about this electronic chip [DMDL11,DMD+12,DDL+12].
Beam tests at CAL-Nice in 2011, 2012, and at the Orsay Tandem in 2012, allowed us to evaluate
the response of the ASIC chip, and to measure the count rate capability of the Hamamatsu H8500
multi-anode photomultiplier. The latter is limited to 107 counts/s, which implies to use several
photomultipliers, in order to share the signals from adjacent fibers on different devices [DRDD+12].
Another type of photomultiplier, based on large area micro-channel plates (MCP-PMTs), was also
tested, but these tests did not present this kind of photomultiplier as a valuable alternative to
PMTs.
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(a)
(b)
Figure 4.14: (a) scintillating fibers hodoscope, made of two planes of 128 adjacent square scintil-
lating fibers (1 mm size), and optically connected to a 64-channel flat panel Photomultiplier. (b)
PMT connected to a test board containing the ASIC chip developed at IPNL.
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4.2.5 Nuclear physical data and models
Nuclear fragmentation experiments
Two experimental programs, aiming at carbon ion fragmentation measurements in targets of rel-
evance for ion therapy, were undertaken.
• At the national level, a collaboration with LPC-Caen, IPN-Lyon, IPHC-Strasbourg, GANIL
and CEA-Saclay is supported by the GDR MI2B. It concerns mainly the measurement of
nuclear fragmentation cross sections of carbon ions at energies less than 100 MeV/u. Such
cross sections are not well known. A first experiment took place at GANIL in June 2008,
where light fragments emitted from plastic (PMMA) targets of various thicknesses were
detected and identified at different angles by means of telescopes. The results published
in 2011 [BLB+11] exhibited noticeable discrepancies with Geant4 predictions. This moti-
vated a second experiment, to perform systematic measurements with thin targets, that was
performed in 2011 at GANIL. The data have been submitted for publication.
• At the European level, INFN physicists (supported by CNAO), in collaboration with GSI,
the CEA-Saclay, and the above French collaboration, have initiated the FIRST program for
fragmentation of light ions at energies between 100 and 400 MeV/u at GSI (Darmstadt).
This experiment was performed in July 2011.
In the long term, a program of systematic measurements with a dedicated setup at the Archade
research center will be implemented. This will contribute to provide inputs to physical data bases,
in order to constraint the theoretical models used for the estimation of the dose deposited by
secondary fragments. This is of particular interest for the present purpose of controlling online
the dose by nuclear imaging.
Secondary radiation for imaging
The experimental feasibility studies on prompt radiation imaging are combined with Geant4 sim-
ulations which, in a first step, provide direct comparison with theoretical models, and, in a second
step, will help for designing an optimized detection setup. First studies with Geant4 9.1 have
shown that this Geant4 version overestimated the overall prompt gamma yields by more than an
order of magnitude [LFCD+10]. Interactions with Geant4 developers have led to improvements in
the last version of Geant4 (9.4, December 2010), and further tuning of the QMD model provides
a reduced disagreement by only 20% between simulations and data (see figure 4.15). A com-
parison with other simulation packages like FLUKA (in collaboration with HIT-Heidelberg) and
MCNPX (in collaboration with the industrial partner IBA) was undertaken, in the framework of
the European ENVISION project (WP6), for which a post-doc (George Dedes) was recruited by
UCBL.
As a further step, we investigate improvements to the aforementioned Geant4 theoretical mod-
els, in order to achieve the desired prediction accuracy required in the context of development
and optimization of simultaneous prompt gamma and secondary proton imaging devices. This is
part of the thesis of Marco Pinto (2011-2014), recruited with a Marie-Curie fellowship under joint
supervision of IPNL and CREATIS (ENTERVISION program).
4.3 Perspectives for 2013 and beyond
Prototypes construction
In the next two years we will complete the technological developments of the collimated gamma
camera and the Compton camera, in order to deliver the first prompt-gamma imaging prototype
in 2013. Both cameras will be used with a dedicated beam hodoscope for TOF and a fast data
acquisition system.
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Figure 4.15: comparison between the prompt gamma profile measured at GANIL and simulations
using various models in Geant 4 [DDDR+12].
In particular, an optimised collimator will be developed in order to get the best compromise
between the field of view (and thus the detection efficiency), and the spatial resolution.
All the detector prototypes will be made available for the ETOILE therapy center.
We will also study the potential of the Compton camera for clinical and pre-clinical imaging.
Indeed, this new kind of camera, specially designed for high energy gamma rays, may open the way
to the imaging of new isotopes, and/or to measurements at high statistics or low doses. This work
is part of Jean-Luc Ley’s PhD (2012-2015), co-supervised by CREATIS and IPNL, and supported
by the Labex PRIMES.
For beta+ activity reconstruction, before using MCP-PMTs detectors to build a large accep-
tance detector DPGA, a preliminary configuration using a large number of simple channels using
crystal (LYSO) and simple PMT will be available in 2013. This Large Area Pixelised Detector
will be used first to test a high frequency sampling front-end electronic, as well as the MicroTCA
acquisition system, on a large scale. This detector will be used also to test on proton beam (CP
Orsay and Centre Antoine Lacassagne Nice) and Carbon (at HIT Heidelberg through ULICE
network) to check innovative protocol for dose control and monitoring with beta+ production.
Figure 4.16: Schematic view of the Large Aera Pixelised Detector that will be use first to test
on a large scale a high frequency sampling front-end electronic, as well as MicroTCA acquisition
system.
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4.3.1 Proton CT
A new research activity has recently emerged: proton radiography, in connection with ion-therapy.
Indeed, radiographic image guidance is used both at the treatment planning stage and immedi-
ately before the treatment fraction as a quality assurance tool. However, X-rays present several
shortcomings, notably:
i at the treatment planning stage, the mandatory conversion from Hounsfield numbers to
proton stopping powers leads to ∼3% or more uncertainties in proton range and
ii X-ray digital radiographs and/or cone beam CT (CBCT), used to ensure correct patient
positioning, suffer from artifacts and poor contrast in some anatomical regions, making it
difficult to see the tumor and/or distinguish critical organs.
Proton radiography presents potential advantages as compared to conventional X-ray CT.
Indeed, as each proton projectile is detected after the traversal of the patient, the information
carried (residual energy, direction) may be used for imaging purpose.
Therefore, proton imaging based on the tracking of individual protons is thought to have the
potential to improve treatment planning as well as in-room image guidance, with imaging doses
equal to- or lower than the dose from kV x-ray CBCT. One of the main expected outcomes of
proton imaging is a substantial reduction of range uncertainties in proton and carbon ion beam
treatment. Improved verification of the patient positioning will also significantly reduce the risk
of non-conformal dose delivery.
In the frame of the French GDR MI2B, we propose to design and develop a proton radiog-
raphy and computed tomography demonstrator, together with suitable reconstruction algorithms
based on the realistic modeling of the proton interactions. The goal is to go beyond the current
international state of the art, both in hardware and software aspects: millimeter accuracy in range
resolution and high counting- and data acquisition-rate capabilities (greater than 106 counts/s)
seem to be under reach, making it possible to acquire high-quality radiographs in a matter of
seconds, thus minimizing its cost.
The Physics-Cancer ProTom project, lead by CREATIS, was approved for a one year duration
in 2011, in collaboration between CREATIS, IPNL, LPC-Caen and IPHC-Strasbourg, in order
to assess the imaging potential by means of simulations. This project, lead by IPNL, involves
IPNL, CREATIS, IPHC-Strasbourg and the Centre Antoine Lacassagne (Nice). A group project,
in which IPNL and CREATIS are present, has been initiated within the GDR MI2B in 2012. This
activity should be also one of the federative activities of the PRIMES Labex.
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Radiobiological effects of carbon
ions
General organization for this theme
Axis 1
Lyon Sud: EMR 3738, équipe 4 - Laboratoire de Radiobiologie Cellulaire et Moléculaire,
Faculté de Médecine, Lyon Sud.
Scientific manager: C. Rodriguez-Lafrasse (PU-PH, UCBL/HDR, HDR)
Team members:
• D. Ardail (MCU-PH, UCBL/HCL, HDR)
• D. Poncet (MCU-PH, UCBL/HCL)
• G. Alphonse (Chargée d’étude HCL)
• N. Magné (PH radiothérapeute, ICL)
• S. Ferrandon (Doc UCBL)
• G. Bertrand (Doc PRRH/UCBL)
• C. Moncharmont (Doc ICL)
• M. Gilormini (Doc UCBL)
• E. Armandy (TCH UCBL)
• C. Malesys (TCH UCBL)
• P. Battiston-Montagne (ATCH UCBL)
• C. Gagnon (secrétariat, ATCH UCBL).
While in previous years we had access to the beam during three periods of time per
year at GANIL and two at GSI, this number was drastically reduced in 2012. Due to
the restructuring of the sites, only two beam-times were obtained at GANIL in 2012
and none at GSI. The time period attributed to biological experiments is too short and
does not allow developing research in radiobiology only devoted to the cellular response
to carbon ions. For this reason, the senior researchers and students have an equal share
in the number of hours of carbon beam and the rest of the year answer their question
with photon irradiation (320 KeV X-ray irradiator CERVO platform).
Axis 2
IPN Lyon, UCBL: scientific coordinator : M. Beuve (PR UCBL, HDR)
Team members:
• M. Bajard (IR IPNL, CNRS/IN2P3)
• L. Chollier (PhD IPNL, CNRS/IN2P3 - PRRH)
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• J. Constanzo (PhD IPNL, UCBL)
• M. Cunha (PhD IPNL, CNRS/IN2P3)
• D. Dauvergne (DR IPNL, CNRS/IN2P3)
• M. Fallavier (CR IPNL, CNRS/IN2P3)
• N. Pauna (MCU, LPC Clermont, Clermont Université)
• C. Ray (MCU HDR IPNL, UCBL)
• E. Testa (MCU IPNL, UCBL)
LPC Clermont-Ferrand: scientific coordinator G. Montarou (DR IN2P3)
Team members:
• D. Dabli (IE CNRS)
• F. Chandez (IR CNRS)
• M. Gautier (Ph-D. CNRS)
The physicists take part in all the experiments at GANIL.
A good knowledge of the physio-chemical and biological events triggered in reponse to carbon
therapy, and thier comparison to the results obtined with photon therapy, used as the reference
technique, is mandatory for a reliable and secured transfer toward the clinic. This objective may
be reached thanks to a multi-disciplinary approach gathering researchers with a unique expertise
in physics, chemistry, biology, simulation and radiotherapy.
The objective of this theme are:
• to eludicate and quantify the molecular events triggered by carbon ions in the tumoral and
sound tissues using various models (cellular, pre-clinical, and for patients) et various scales
of time (from femtosecond to a few years);
• to predict the response to tumoral and sound tissues for both types of radiation;
• to improve ou develop new models for treatment planning, and to enrich them with biological
parameters.
5.1 Axis 1 : Cellular and molecular response of tumors
to carbon ion and photon irradiation (comparison with
photons)
5.1.1 Overall 2012 assessment
The tumor and healthy cell responses to ionizing radiation depend on the balance between the
mechanisms (mainly oxidative stress) leading to cell death and those of protection against Reactive
Oxygen Species (ROS) and DNA repair. If the non-repaired DNA double strand breaks have been
considered for a long time as the sole determining factor of radiation-induced cell death, for several
years our group has contributed to the demonstration that plasma membrane and mitochondria
are also compartments significantly involved in the cell death process. Two tumor models were
used in this study:
• Head and Neck Squamous Cell carcinoma (HNSCC), including six cell lines with different
radiosensitivity and p53 status ;
• Glioblastoma, including 12 cell lines with different radiosensitivity, p53 and MGMT status.
Both types of tumors have a bad prognosis and generally escape cancer treatment including con-
ventional radiotherapy. They are thus a potential elective indication of carbon hadrontherapy.
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HNSCC model
Implication of cancer stem cells in radioresistance It is now well-established that heavy
ion radiotherapy can offer some potential benefit over conventional radiotherapy. The advantage
of this new method of treatment lies in the physical and biological properties of carbon ions.
We initiated studies on the mechanisms of cell death in two p53-mutated HNSCC cell lines with
opposite radiosensitivity following carbon ion and X-ray exposure [BAM+08], since recent clinical
trials have shown that local treatment of HNSCC by carbon hadrontherapy was much less efficient
than that of other radioresistant cancers.
We first showed that carbon ion irradiation does not modify the type of death involved, but
amplifies it. In the radiosensitive SCC61 cell line, an early ceramide-dependent apoptotic cell death
occurred after irradiation [AMBM+12]. In contrast, the radioresistant SQ20B cells underwent
G2/M arrest associated with Chk1 activation and Cdc2 phosphorylation. Furthermore, 5 days after
carbon ion irradiation, SQ20B cells bypassed the G2/M arrest and underwent mitotic catastrophe
[MAC+09]. Although a majority of SQ20B cells go beyond mitotic catastrophe by a ceramide-
dependent apoptosis mechanism, a subpopulation of cells was able to escape and continued to
proliferate.
Recently, the involvement of Cancer Stem Cells (CSCs) has been demonstrated in solid tumors
recurrences following conventional irradiation. We have then investigated whether CSCs might be
the subpopulation of SQ20B cells resistant to carbon ion irradiation.
We first demonstrated that a subset of SQ20B cells presents different markers of CSCs such
as CD44 expression, Hoechst eﬄux, ALDH over-activation and spheroid formation. We then sep-
arated a SQ20B/SP/ALDH+/CD44+ (CD44+) subpopulation as putative HNSCC cancer stem
cells. The radiation response of this subpopulation of cancer cells that are likely to be critical
for success or failure of cancer therapy was then studied. The CD44+ cells were more resistant
to photon as well as carbon ion irradiation than the non-cancer stem cells. After the analysis of
cell cycle we demonstrated that the lack of apoptosis induction, due to an extend G2/M phase
arrest induced by carbon ion irradiation, was responsible for this radioresistance. Moreover, we
also showed that the resistance of CSCs may result from exacerbated self-renewal and prolifera-
tive capacities. Among the different pathways of self-renewal, Bmi-1 appeared to be involved and
the high proliferative capacity of CSCs was related to a high aldehyde deshydrogenase (ALDH)
activity. We then attempted to modulate these different processes to sensitize CSCs to photon or
carbon ion irradiation.
Since irradiated CSCs do not undergo early apoptosis because of a transient arrest in G2/M
followed by mitotic catastrophe, treatment of CSCs with the inhibitor of the G2/M arrest UCN-01
triggered early apoptosis thus leading to radiosensitisation after photon and carbon ion exposure.
Concerning the self-renewal pathway, inhibition of Bmi-1 with artesunate significantly enhanced
sensitivity to high and low LET radiation by triggering apoptotic cell death. Finally, inhibition of
ALDH using all-trans retinoic acid induced differentiation of CSCs associated with a significant
decrease in cell survival after either carbon ion or photon irradiation.
The combination of ATRA and UCN-01 treatment with irradiation drastically decreased the
survival fraction at 2 Gy (SF2) of SQ20B-CSCs from 0.85 after photon irradiation to 0.38. Fur-
thermore, SF2 decreased from 0.45 in response to carbon ions to 0.21 when associated with ATRA
and UCN-01 [BMB+13,BMB+12,BMBM+12].
In conclusion, whatever the pharmacological strategies used, an important radiosensitisation of
CSCs was obtained. Adjuvant treatments targeting either the inhibition of survival/self-renewal
pathways or the triggering of apoptosis should improve the results for patients treated with radio-
or hadron- therapy.
Role of antioxidant defenses (glutathione) – Strategy of radiosensitization We previ-
ously reported that intracellular glutathione (GSH) levels correlate with a high level of radiore-
sistance in HNSCC cell lines. This high endogenous GSH content was shown to be involved in
the inhibition of the early triggering of pro-apoptotic signals generated at the plasma membrane
level [BHA+07]. We therefore designed a transient GSH depleting strategy before irradiation us-
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ing 2 pharmacological compounds (DMF + BSO) in order to reverse the resistance of tumour
cells to irradiation. This experimental approach was found to be effective in HNSCC stem- as
well as non-stem cells thus suggesting that this treatment could reduce local recurrence of cancer
after irradiation. Moreover, we further evaluated in vivo the potential radiosensitising effect of
DMF + BSO on nude mice bearing SQ20B tumors. Our data show a real efficacy in radiosen-
sitization since a decrease of 95% in the mean tumor volume was measured without apparent
toxicity [BHM+11]. Furthermore, carbon ions did not modify the nature of the signaling pathway
involved after treatment but had a strong influence on the intensity (more pronounced effect) and
the kinetics (earlier effect) of the biological response. Using this adjuvant strategy, we started
experiments in collaboration with S. Sauvaigo (LAN – CEA, Grenoble) in order to demonstrate
that GSH is able to directly regulate the DNA repair (single strand break) enzymes.
Effect of redox status on DNA damage, repair and chromosomal aberrations The
balance between oxidative stress and anti-oxidant defenses such as glutathione (GSH) or N-
acetylcysteine (NAC) influence the nature of DNA damage, repair and chromosome aberrations.
The GSH depletion strategy developed in the laboratory as well as the addition of NAC (powerful
antioxidant) can be used as tools to modulate the nature, amount or repair of DNA damage.
The study of radiation-induced lesions and their repair kinetics on SCC61 and SQ20B cell lines
displaying opposite radiosensitivity showed that depletion of endogenous glutathione potentiates
the effect of radiation on DNA, causing an increase in the number of lesions (double strand breaks,
single strand breaks and oxidation of bases) following exposure to photons and an increase in the
complexity of the lesions (lesions located on multiple sites and more deleterious to the cells) after
irradiation with carbon ions. This effect was reversible by the addition of NAC, suggesting the
involvement of oxidative stress or ROS in the generation of such damage. Moreover our results
demonstrated the involvement of an indirect effect of photon and also carbon ion radiation, on a
more local scale, in the generation of DNA damage [HBM+12]. Further studies were conducted
on Cal27 cell line exposed to carbon ions of different LET (33.6 and 100 keV/µm corresponding
to the plateau and the Bragg peak entry, respectively). The kinetics of repair of double strand
breaks (detected by γH2AX immunoassay) showed a slower rate of repair and a higher number
of residual breaks for cells exposed to carbon ions of 100 keV/µm, suggesting an increase in the
complexity of lesions with TEL. GSH depletion increased the number of initial lesions measured
for each TEL, increased the slowdown of repair and the number of unrepaired breaks. Glutathione
depletion amplified the involvement of the indirect effect in the generation of complex lesions on
a local scale regardless of the LET of the radiation.
Mis- or non-repaired DNA lesions may lead to the formation of potentially transmissible aber-
rations in the surviving cells and thus to the adaptation of cancer cells, which are considered to
be a risk of local recurrence. The cytome assay allowed the identification of the loss of chromo-
some or chromatid as a specific biological signature of carbon ions. Moreover, our analysis showed
that is the increase in the complexity of the lesions, but not their number, which could limit the
transmission of aberrations to the cancer cell progeny [HBM+12].
Prediction of tumor response to carbon ion irradiation
a. Histone H2AX phosphorylation as a predictor biomarker of radiosensitivity Anal-
ysis of the kinetics of appearance and disappearance of DSB after exposure to photons or
carbon ions, provides evidence of protection capacities and repair of cancer cells, in relation
to the intrinsic radiasensitivity of each line. The analysis of five HNSCC cell lines displaying
gradual radioresistance highlights the importance of such relationships. Following exposure
to photons or carbon ions, the rate of repair of these lesions, as well as the amount of resid-
ual unrepaired damage are correlated with cellular radiosensitivity; the most resistant cell
lines rapidly repairing breaks. Measurements of the accumulation of unrepaired lesions after
exposure to 1, 2, 5 and 10 Gy of photons or carbon ions show a linear relationship with
the D10 estimated from the clonogenic survival of each line. A statistical analysis is being
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conducted to evaluate the potential relationship between accumulation of these lesions and
the RBE of radiation.
b. Role of Nrf2 as a predictor biomarker of radiosensitivity Given the major role played
by the endogenous redox status of cancer cells in response to irradiation, we evaluated the
predictive importance of the transcription factor Nrf2 in tumor resistance to radiotherapy.
This factor is kept inactive in the cytosol via a protein, Keap1. In response to stress,
dissociation of the Keap1-Nrf2 complex causes the translocation of the latter in the nucleus.
This transcription factor, over-expressed in many cancers (including HNSCC) activates many
genes involved in cellular response to various stresses, particularly those involved in cellular
mechanisms of protection against oxidative stress. Having measured the basal expression
of Nrf2 and Keap1 by RT-PCR and Western blot in a collection of 7 HNSCC cell lines
of gradual radiosensitivity, we have developed the optimal conditions for the use of these
markers by immunohistochemistry. Collaboration with the INCA platform of Strasbourg
was initiated in order to validate the predictive potential of these two markers on tumor
sections of human biopsies obtained from patients clearly identified clinically.
Glioblastoma model
Glioblastoma (GBM) is a primary brain tumor with very poor prognosis. Despite the treatment
involving surgery, chemotherapy and radiotherapy, local recurrence is inevitable and patient sur-
vival rarely exceeds fifteen months. With its good ballistic and high RBE, hadrontherapy with
carbon ions is a promising technique for radiation treatment of this type of tumor. As very few
centers exist in the world, the amount of clinical studies is limited. Nevertheless, the first phase
I/II clinical trial on 32 GBM patients has combined X-ray radiotherapy (50 Gy/25 fractions),
concomitant chemotherapy (ACNU), and carbon ion hadrontherapy (8 fractions). Patients were
assigned to three carbon ion dose groups: a low-dose group (16.8 GyE), an intermediate-dose
group (16.4 to 24.8 GyE in 10% incremental steps), and a high-dose group (24.8 GyE). This trial
has shown improved efficiency in terms of overall survival (7, 19, and 26 months) and disease-free
survival (4, 7, and 15 months) in a manner dependent on the total carbon ion dose delivered,
without major side effects1. Two other clinical trials are currently realised in order to evaluate
carbon ion boost efficiency in GBM treatment (ICT01165671 and NCT01166308). These trials do
not use biological markers to include patients, but in the future, patient selection will be necessary,
owing to the cost of irradiation, technical constraints, and limited access to facilities.
Characterization of the cellular and molecular response of glioblastoma cell lines We
previously initiated studies to understand the response to photon or carbon ion irradiation of
10 human glioma cell lines of gradual radiosensitivity in order to determine whether the p53 or
MGMT status, the lack of production of ceramide, cell cycle arrest or the type of death, could be
considered as factors predicting radioresistance. Further experiments have been carried out this
year to complete the study. We confirmed that whatever the cell lines studied and their p53 status,
photon or carbon ion irradiation induced a G2/M phase arrest followed by mitotic catastrophe
leading finally to a ceramide-dependent apoptotic cell death. Determination of the RBE at 10%
survival gives data varying from 1.5 to 2.9 [AHH+12]. A statistical study was performed in
order to define a predictive factor that could improve treatment planning for particle therapy.
The spearman statistic test was used to compare the data obtained during the experiments.
A correlation was found between the SF2-photon and the SF2-Carbon (R2=0.94, p = 0.0002),
demonstrating that cell lines resistant to photons are also resistant to carbon ions. The ratio
between percentage of cells in G2/M phase after irradiation with 10 Gy photons and percentage of
control cells was calculated and a significant correlation was found between this ratio and the SF2
1J.E. Mizoe, H. Tsujii, A. Hasegawa, T. Yanagi, R. Takagi, T. Kamada, H. Tsuji, K. Takakura ; Organizing
Committee of the Central Nervous System Tumor Working Group. Phase I/II clinical trial of carbon ion radio-
therapy for malignant gliomas : combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J
Radiat Oncol Biol Phys. 2007:69(2):390-396.
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or the D10 of carbon ions. We may then postulate that, using a mathematical model, these results
could predict sensitivity to carbon ion irradiation (SF2 or D10) from the G2/M phase arrest after
irradiation by photons. Another positive correlation was found between the induction of mitotic
catastrophe (quantified by the number of polyploid cells, observed in fluorescent microscopy)
following photon irradiation and the RBE. These results will enable the treatment of patients to
be personalized by developing new mathematical models and ultimately improve the planning of
treatment.
Telomeric status and cellular response to carbon ions, towards the identification of
a predictive biomarker Long telomeres and high telomerase activity (TA) have been widely
associated with photon radioresistance in other cancers. Moreover, telomere protection, function,
and length also depend on the shelterin protein complex (TRF1, TRF2, TPP1, POT1, TIN2,
hRAP1). We thus decided to evaluate an enlarged telomeric status (telomere length (TL), telom-
erase catalytic subunit (hTERT), and the shelterin component expression level) as a potential
radioresistance biomarker in vitro using cellular models and ex vivo using patient tumor biopsies.
In addition, nothing was known about the role of telomeres in carbon ion response. We thus
evaluated telomeric status after both types of irradiation. We have shown [FSC+13] a significant
correlation between TL and the basal POT1 expression level and photon radioresistance in vitro,
and a significant increase in the survival of patients with long telomeres or a high POT1 level
in vivo. POT1 expression was predictive of patient response irrespective of the telomere length.
Strikingly, these correlations were lost in vitro when considering carbon irradiation. We thus pro-
pose to assess POT1 expression level and TL on patient tumor biopsies to identify radioresistant
patients who could benefit from carbon hadrontherapy.
5.1.2 Scientific objectives for 2013
HNSCC model
Metastatic capacity of Cancer Stem Cells We have previously demonstrated that CSCs are
good candidates to explain the recurrence of cancers, in particular through their radioresistance.
However, another explanation could be the strong migratory and invasive capacity of these cells.
Indeed, it has recently been shown that photon irradiation is capable of promoting migration of
pancreatic cancer- and glioblastoma cells. Hence our project will try to determine the effect of
ionizing radiation (photons and carbon ions) on migration and invasion of stem- and non-stem
HNSCC cells. The role of chemotherapy molecules traditionally used in the treatment of head and
neck cancer (Erbitux and Cisplatin) will also be considered.
Role of antioxidant defenses (glutathione) - Strategy of radiosensitization In order to
develop and characterize new adjuvant therapies to irradiation, we investigated the BCl-2 protein
family as a potential target for radiosensitization since mitochondria serve as a hub for responses
to cellular stresses. As Bcl-2 proteins were recently demonstrated to be involved in the transport
of GSH from the cytosol to the mitochondria, we make the assumption that inhibiting the BcL-2
family should result in the generation of massive intra-mitochondrial stress, thereby favoring the
triggering of apoptosis. This project will be performed in collaboration with W. Rachidi (LAN –
CEA – Grenoble) and P. Vernet (Clermont Ferrand).
Predictive biomarker to the response of radiotherapy
a. Keap 1 expression
Given the in vitro results on the correlation between the SF2 of the HNSCC cell lines and the
expression of Keap1 at the protein level, our goal will be to validate the role of this protein as
a predictor of response to both conventional radiotherapy and hadrontherapy by an immuno-
histochemical approach using a collection of HNSCC tumor biopsies (Collaboration with
INCA platform, Strasbourg).
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b. Tumor protein markers
This project is an ancillary radiobiological study associated with the “Medical assessment
and economic prospective randomized carbon ion radiotherapy for inoperable sarcomas and
adenoid cystic carcinomas tumors” hospital programme (PHRC) for which clinical hadron-
therapy results are better documented. The primary objective is to assess the positive
predictive value of the failure of a treatment strategy (photon-or carbon-therapy) from the
study of the selective expression of a panel of tumor protein markers (Bcl2/Bcl-XL, hsp27,
survivin, p53, Ki67, COX2) in a prospective cohort of 250 patients. This project will de-
velop a recruitment of patients for 3 years and provide an a posteriori indication of efficiency
of radiotherapy and decision support for the therapeutic orientation. Advanced statistical
analysis will determine if the selected markers enable the identification of patients resistant
to conventional photon radiation therapy and for which carbon-therapy or an alternative
treatment is necessary.
Glioblastoma model
Telomeric status and cellular response to irradiation Shorter telomeres and high telom-
erase activity are associated with shorter overall survival in glioblastoma patients. Our first
objective was to determine if the telomeric status (telomere size, telomerase activity (hTERT),
telomeric protein expression and localization) can predict the tumor response to photon and car-
bon ion irradiation. We established three stable cell lines expressing different levels of telomerase
and demonstrating increasing telomere size. Thanks to this model we confirmed a correlation
between increasing telomere size and higher radioresistance. This has been confirmed in a panel
of 10 glioblastoma cell lines. However cell response to carbon ions seems not to be closely linked
to the telomeric status in these two models. We have to confirm this result and understand the
telomeric molecular events induced by both carbon ion and photon irradiation at the origin of this
potential difference.
We have shown that telomeric status plays no preponderant role in cell response to carbon
ions, while it is a determinant factor for cell response to photons. This discrepancy between the
effects of carbon ions and photons was unexpected. As both types of irradiation produce major
DNA damage and the same type of cell death, the role of telomere damage in cell death under
the two conditions should be the same. However, two differences between carbon ion and photon
irradiation could explain this observation:
i The most quantitatively important effect of photon irradiation is the immediate production
of a high level of ROS, whereas the effect of carbon ion irradiation is not considered to
involve ROS2(which is why it is indicated for hypoxic tumor treatment). It is known that
guanine-rich (T2AG3 repeats) telomeric sequences are especially sensitive to oxidative stress
and produce more 8-oxoguanine and DNA breaks3 than other genomic sequences. Telomeres
should thus be a preferential target of photon irradiation within the genome and should play
a leading role in the cell response to photon exposure.
ii Carbon ions mainly act by producing DNA lesion clusters that are very difficult to repair.
LMDS are produced along the track of the beam and there is no reason for telomeres to be
damaged more than the other sequences in the nuclear genome and their damage should not
disproportionately affect the final cell response, as they represent only a small fraction of
the genome. Moreover, LMDS are mostly lethal for cells. Thus, there is no reason for the
cell response to carbon ions to be telomere-dependent.
To validate our hypothesis, we will evaluate the amount of telomeric damage in response to
carbon ion and photon irradiation in a glioblastoma cell line. We will thus check if the initial
telomeric damage is more extensive after photon irradiation than after carbon irradiation. Next
we will compare the effect of telomere length on the frequency of telomeric damage in both kinds
2Nakano T., et al. (2006) Clin. Cancer Res., 12 (7 Pt 1):2185-2190.
3Du G.,(2011) Radiation research 176 (6):706-715.
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of irradiation. Telomeric damage will be analyzed by confocal microscopy assessment of 53BP1
(DNA damage response protein) and TRF1 (telomeric protein) co-localization. Experiments with
anti-oxydant could also be performed to evaluate the role of ROS in telomere-driven cell death in
both types of irradiation.
5.2 Axis 2: Instruments, Methods and Modeling for radio-
biology
The acquisition of radiobiological data and knowledge relies on the development of innovative
instruments and methods:
1. To irradiate biological cells and rodents with a high level of efficiency and quality;
2. To imagine and measure relevant biological parameters;
3. To measure, store and analyze these data.
The resulting knowledge and better understanding will allow improvement of the treatments by
hadrontherapy.
However the ultimate optimization requires the incorporation of these data into biophysics
models to be implemented into the systems of treatment planning (TPS). In addition to this
synthesizing role, biophysics modeling has to contribute to the understanding of the early stage
following the impact of ionizing particles. This is particularly crucial for hadrontherapy since, the
biological efficiency of high-LET ions is due to the spatial distribution of primary physical and
chemical events at nano and microscopic scale.
5.2.1 Overall 2012 assessment
Oxidative stress and anti-oxidant defences: studies by physico-chemical simulations
Tumor response to ionizing radiation depends on the level of cell oxygenation. In conventional
radiotherapy, a reduction in tumor vascularisation leads to radioresistance. Fortunately this effect
is reduced in response to carbon irradiation and, as a benefit, hypoxic tissues are less radioresis-
tant with carbon irradiation. Understanding this specific response would help to include oxygen
effect in the biophysics models that are used for treatment planning and then to optimize hadron-
therapy treatment in cases of hypoxic tumors. Among the different scenarios that are proposed
in the literature, an increased production in superoxide anion O2− and perhydroxyl radical HO2
could explain the increased sensitivity of tissues to hadrontherapy. Chemically, both radicals are
indirectly toxic. Biologically, it has been shown that a large quantity of these radicals can trigger
cell death by necrosis or apoptosis.
We adapted our simulation model, dedicated to the simulation of the radical production by
water radiolysis, to quantify the production of these reactive oxygen species (ROS) in various
conditions of oxygenation. We also introduced a concentration of glutathione, which is known
to influence the oxygen effect, and observed that the production of O2/HO2 radicals in water
mimicked the variation of the oxygen effect with the LET and the partial pressure of oxygen.
These results were published in [Col09, CGRLB11] and were presented as invited talks in two
international conferences [BCGRL10,BCRLG11]. A detailed article describing the mechanisms of
production of O2−/HO2 has been submitted for publication to the Radiation Research Journal.
Besides, we have converted these observations into a method to take into account the oxygen
effect in ‘any’ hadrontherapy TPS for an adjustment of the irradiation parameters in the situation
for which regions of hypoxia are suspected to increase the radioresistance of patient tumours.
We have written a patent, which is still in the submission process, with the support of Lyon
Science Transfer.
The main objective of the work performed in Clermont-Ferrand in the mid-term will be to
correlate observable events characterizing early biological events resulting from energy deposition
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of ionizing radiations in cells. Physico-chemical models should be used to connect the effects of
radiations with some biological observables. In particular we wish to correlate not only the energy
deposition during irradiation in the different sub-volumes of the cell with these biological observ-
ables but also the produced radiolytic species such as free-radical distributions, (OH•, H••,eaq),
in a voxellised model of cell, focusing on the mitochondrial network.
Towards the new model Nanox of cell inactivation for treatment planning
Modelling the biological response of cells to carbon ion irradiations is required to take advantage
of the radiobiological efficiency of hadrontherapy. The procedure used in the Japanese centres
has yielded good results in hadrontherapy. However, this approach requires a large amount of
experimental data, which reduces the possibilities of optimization according to the type of tumour,
the irradiated healthy tissues and the patient’s sensitivity.
Alternatively Scholz et al.4 have proposed the Local Effects Model (LEM). After determining
the parameters of this model from experimental data obtained with radiations of low LET, this
model aims at predicting the fraction of inactivated cells depending on the ion nature, energy
and irradiation dose. This model is used for the treatments performed in Germany. However, We
showed that, to get correct predictions, the value of an important parameter should be fitted using
a set of data obtained with high LET radiations [BAM+08]. Moreover the comparison of the LEM
predictions5 with experimental data [BAM+08] showed interesting results, but highlighted signifi-
cant discrepancies that leaded the authors to improve the LEM6 [Elsasser 2007.2008]. Our studies
have shown that, beyond simple improvements, a radical reformulation of the LEM principles was
required [BCD+09,Beu09,Beu10]. We showed in particular that:
• the hypothesis of non-local effects should be considered in predictive models,
• the method of inserting experimental data obtained in response to X-ray radiation incon-
sistently mixes two scales of description: the scale of DNA damage and the scale of the
macroscopic dose delivered by the accelerator,
• the LEM prediction of the shoulders in cell-survival curves as a function of dose arises from
an artefact,
• the stochastic effects of the radiation had to be considered
Presently while the German group keeps on improving the LEM, the Japanese teams are
moving toward other biophysical models and in particular to the models of microdosimetry (Mi-
crodosimetry Kinetic Model MKM7). We have undertaken an experimental evaluation of the MK
model and compared its predictions to the LEM ones for the SQ20B SCC61 cell lines [Dab10].
We found that the relevance in the predictions of these models were comparable. However a great
advantage of the MKM is its consistence with the stochastic nature of the ionizing radiations. Fi-
nally, for both models, improvements are required to reduce the discrepancies between predictions
and experimental data. An article is in preparation.
Alternatively, we are developing a new model, Nanox, based on micro and nano-dosimetry,
which:
• is consistent with the stochastic effects of radiations,
• encompasses the advantages of the existing models
4Scholz, M., A. M. Kellerer, W. Kraft-Weyrather, and G. Kraft. Computation of cell survival in heavy ion
beams for therapy : the model and its approximation. Radiat. Environ. Biophys 36:59–66.1997
5Cluster Effects within the Local Effect Model. T. Elsasser and M. Scholz Rad. Res. 167, 319–329 (2007).
6Accuracy of the local effect model for the prediction of biologic effects of carbon ion beams in vitro and in vivo.
T. Elsässer, M. Krämer, and M. Scholz.. Int. J. Radiat. Oncol. Biol. Phys 71:866–872 (2008).
7Sato, Y. Kase, R. Watanabe, K. Niita, and L. Sihver, Radiation Research 171:1, 107-117 (2009).
A statistical theory of cell killing by radiation of varying linear energy transfer “R.B Hawkins, Radiation research
140, 366-374 (1994)
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• integrates physico-chemical effects, i.e. oxidative stress.
A first version of this model and its associated software have been developed during the PhD thesis
of Laurie Chollier [Cho12]. This work is continued through the PhD thesis of Micaela Cunha.
We have already:
• derived the basic postulates,
• achieved a first version of the codes,
• applied this model to the cell line V79 and obtain very encouraging but sill preliminary
results (see figure 5.1).
Since we are preparing a patent, this work was not presented, except for the preliminary results
during the invited talk at the international conference MMND IPCT in Australia [BCT12].
Figure 5.1: Cell Inactivation cross-section versus LET for various ion beam irradiating V79 cells.
Comparison of the Nanox predictions (simu) to experimental data (goal).
From in-vitro to in-vivo In the framework of collaborative work with the Centre of Particle
Therapy in Marburg and the University of Essen, we have undertaken a program to parametrize
and evaluate biophysical models with clinical data. This project is the objective of Marie-Anne
Chanrion’s PhD (2014). Until now, we have studied the sensitivity of TCP (Tumour Control
Probability) to the parameters of the LEM model. This work was presented as a poster at the
PTCOG 2012 conference in Korea [CLW+12].
Methods for radiobiological data acquisition, processing and analysis Some radiobio-
logical observables require more and more complex techniques for their acquisitions, processing
and analysis. The use of immunofluorescence techniques to mark the nuclear DNA damage is
one of the most common examples now. DNA damages induced by ionizing radiations produce
fluorescent foci corresponding to the recruitment of certain proteins or by specific modifications
such as phosphorylation of histones (eg γH2AX foci). These foci could be analyzed using im-
munofluorescent confocal microsocopy. Determining the spatial distribution of these foci in the
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nucleus, for different radiation qualities and their correlations with the initial energy deposition
requires the establishment of technical analysis in images obtained with confocal immunofluorecent
microscopes.
We have defined an automatic algorithm for non-parametric image processing and automatic
foci identification using the ImageJ software. Early work on small batches of 2D images, realized
at LPC [CM10] or IPNL [Wan10] showed that this type of application could be relatively efficient.
Nevertheless, obtaining statistically significant results involves the acquisition of a large number
of images by platforms and automated microscopy using confocal microscopy. Hence, the next
goal is to apply this type of treatments on a large number of images.
Development of irradiation platforms
1. The Radiograaff plaform
Because carbon beams are hardly available for radiobiology, we have considered the potential
of the Van de Graaff accelerator at IPNL. This accelerator can produce mono-kinetic beams
of protons with energy ranging from 1 to 3.75 MeV. According to the literature, the RBE (at
10% of survival) is about 1.5-1.8 for the reference V79 cell line irradiated by protons with
energy lower than 3.5 MeV. Performing experiments with such a beam will be interesting
for hadrontherapy. We are therefore developing the RADIOGRAAFF platform to provide
radiobiologists with a beam of high-RBE protons and a control of the absolute and relative
dose with a dose rate of 2 to 10 Gy/min. This platform will compensate for the current
lack of beam time and will provide a complementary beam (medium energy) to the future
ETOILE/research platform (high-energy).
Although the accelerator can produce a beam of protons in air, some developments were
necessary. Indeed with an energy of a few MeV, a proton’s range is very short (< 200 mi-
crometers), and the standard protocols of dosimetry and radiobiology would not be directly
applicable. Moreover, the standard flux of protons is very high because the accelerator was
designed for experiments in physics.
The development of this platform is the purpose of the Julie Constanzo’s PhD track (ending
in 2013). Up to now, we have:
• reduced the beam intensity to the desired levels,
• enlarged the beam to get a uniform irradiation with an accuracy of ± 2% (better than
the requested 5%),
• developed a system to control the irradiation based on photomultipliers and scintillating
optical fibers with a control in fluence under 5%,
• developed a robotized sample holder,
• developed a cave to encapsulate the sample holder in order to protect the samples from
biological contamination and to ensure a thermal control,
• designed some adapted “Petr” boxes.
The Radiograaff platform will include a room (“bio room”) with biological equipments,
temperature and air control, laminar flow cabinet, computers... to prepare and manage
biological samples before and after irradiations. The work on walls, floor and plumbing are
achieved. Part of the equipment is already bought.
Although the biological protocols and the Petri boxes still need to be improved, we have
already obtained encouraging results. The platform, its dosimetry evaluation and the pre-
liminary results on SQ2OB and SCC61 lines have been presented at the 39th European
Radiation Research in Italy.
2. The Pavirma plaftform
An irradiation platform combining in the same installation: an X-ray irradiator (320 kV X-
ray tube) and a low-energy (2.5 MeV)-neutron generator, is under way on the campus of the
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Clermont University. This cellular radiation-dedicated facility will produce low- and higha-
LET radiations. The installation of the first phase of this device (X-ray irradiation and
biology laboratory) was initiated in December 2011 and is now fully available for irradiation
since January 2012.
5.2.2 Perspectives for 2013 and beyond
Studies by simulations of the physico-chemical processes
We plan to:
• Evaluate our method for prediction of the oxygen effect by facing the results to a large set
of in-vitro experiments and also clinical data,
• Publish the method and the results,
• Contact private company for the exploitation of the patent if accepted.
We also plan to write an article gathering theoretical and experimental results on glutathione.
In parallel, we wish to undertake a medium-term program of quantum-based modeling to
improve the accuracy of the physico-chemical processes descriptions, in particular regarding the
recent experiments of femtolysis that give access to extremely short time. This programme has
started within a national collaboration by the funding of the nanobiodose project.
Models of cell inactivation for treatment planning
From in-vitro to in-vivo Because a detailed set of clinical data for carbon therapy is not avail-
able yet for prostate in the perspective of developing TCP models for its treatment by hadronther-
apy, we are developing a method to extrapolate the experience of neutrotherapy at an international
level to carbon therapy. A collaborative work with the team of Prof. J. Gueulette, a radiobiolo-
gist from Bruxelles, has started. This project is one of the goals of Marie-Anne Chanrion’s PhD
(ending in 2014).
Development of the Nanox model We propose to pursue the development of the Nanox
model of cell inactivation, by confirming and improving the Nanox predictions for V79 cell line,
rewriting the code for an easier transfer to the industry, protecting it by a patent, providing a set of
parameters for various tumour cell lines, incorporating the Nanox predictions into the international
Geant4 simulation platform for an efficient promotion and to attract private companies.
Application of the Microdosimetric Kinetic Model It is now generally accepted that
the linear energy transfer (LET) may not be the best quantity to express the relative biological
effectiveness (RBE) when measuring cell survival during irradiation of cells to different types of
heavy charged particles. Indeed, a variation with the type of particles, but with the same LET,
was clearly observed for several experimental measurements of RBE.
A great number of studies, performed on clinical lines in Japan and Germany, show that the
use of the formalism of microdosimetry, in particular variables such as lineal energy (y) was better
suited than the linear energy transfer (LET) for the use and application of the MKM model.
The MKM model was improved by Kase et al.8 (in terms of the saturation correction for
expressing the decrease of RBE owing to the overkill effect). In the improved model, the cell-
survival fraction for any type of radiations may be expressed as a function of only one parameter:
the saturation-corrected dose-mean lineal energy in domains, referred as to y∗ in the ICRU 369.
8Kase Y., Kanematsu N., Kanai T., Matsufuji N.Biophysical calculation of cell survival probabilities using
amorphous track structure models for heavy-ion irradiation. Phys. Med. Biol. 2008; 53:37-59
9International Commission on Radiation Units and Measurements. Microdosimetry. Bethesda, MD: ICRU;
1986. ICRU Report 36.
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However, the use of siumation-calculated lineal-energy distributions, requires experimental val-
idation. The spectra of microdosimetric lineal energy could be measured with a Tissue-Equivalent
Proportional Counter (TEPC). A TEPC is a gaseous detector that consists of a tissue equivalent
(TE) plastic sphere situated in a hollow aluminium shell. This may be understood by simulating
tissue-equivalent spherical volumes down to diameters of 1 micron or under. This effective diam-
eter may be made smaller or larger by variation of the gas pressure. The instrument is generally
used to accumulate a pulse-height spectrum proportional to the energy deposited in the sensitive
volume. This spectrum may then be transformed into a distribution of lineal energy with the
aid of computer processing. The microdosimetric experimental spectra could be measured for
different radiation quality (photon, proton, helium, carbon ions), on a large range of LET. As an
example Y. Kase et al.10 measured the microdosimetric spectra for high-energy beams of photons
and proton, helium, carbon, neon, silicon and iron ions (with a LET that ranges between 0.5 and
880 keV/µm), with a spherical walled tissue-equivalent proportional counter at various depths in
plastic phantoms, simulating a diameter of 1 µm.
We plan to assemble a full microdosimetric set-up, using a reliable 12” TEPC (from Far West
company) that will be used as a reference set-up to facilitate inter-comparisons of results with other
groups. This reference 12” TEPC will be implemented on the Pavirma regional platform irradiation.
The reference 12 inch TEPC will be used also on proton beams (ICPO Orsay and Medycic Nice)
or carbon ion beams (GANIL). The counter will be situated at the treatment position, in front
of the therapeutic beam, inserted in slab geometry phantoms composed of different thicknesses of
bone, lung, liver and water equivalent materials .
The main limitation of the reference 12” TEPC is that we could access only to equivalent
cellular volume between 500 nm and 1 µm. The only solution to access to smaller equivalent
volumes ( 100 nm) is to build a mini TEPC. There is no such commercial product currently.
After getting sufficient experience with the Far West TEPC, we plan to build, in the long term,
such a mini TEPC following the designs based on the work of Burmeister et al.11. The use of
this mini TEPC should provide access to distributions of microscopic linear energy in volumes
corresponding to components of the cell smaller than the nucleus.
Effect of dose rate on cell survival During a treatment with an active system, the deepest
part of the tumor will be irradiated in less than one second. Other parts of the tumor and most
of the normal tissues will be irradiated within minutes. Changing the irradiation period from 15
s to 20 min may induce changes in the radiosensitivity – due, for instance, to the response of the
cells (repair of DNA damage...). The effect of dose rate has been scarcely evaluated with ions of
high LET and we propose to quantify it. We are studying this dose-rate effect by measuring the
cell survival curves of our two HNSCC cell lines after carbon and argon ion irradiations with a
dose rate ranging from 0.4 Gy/min to 10 Gy/min. We have performed all the irradiations and
will develop statistical tools to analyze the results.
Effect of dose on DNA mitochondrial (ADNmt) It is now clearly assumed that although
damage to nuclear DNA is a well identified cause of carcinogenesis, the possible links between can-
cer and mtDNA mutations begin to be analyzed. Indeed, mtDNA alterations have been observed
in many cases of cancer and some of these mutations may increase the aggressiveness of the tumor
as it has been shown in some cases of prostate cancer. These mtDNA mutations may be linked
to other malfunctions during replication of these genomes, induced for instance by the presence
of reactive oxygen species (ROS) produced during the operation of the respiratory chain, but also
by an “ineffective” system of mtDNA repair. Recent insight into prostate cancer shows that the
mitochondrial DNA of human prostate-cancer cells were riddled with mutations.
10Kase Y., Kanai T.,Matsumoto Y., Furusawa Y., Okamoto H., Asaba T., Sakama M. and Shinoda H., Mi-
crodosimetric measurements and estimation of human cell survival for heavy-ion beams, Radiation Research, 166,
629–38, 2006.
11Burmeister J., Kota C., Maughan R.L. and Waker A.J, Characterization of miniature tissue-equivalent propor-
tional counters for neutron radiotherapy applications, Phys. Med. Biol., 47, 1633-1645, 2002.
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So we will focus on the effect of irradiation on three different tumor cell lines: HeLa cells
(adenocarcinoma), LNCaP (carcinoma) and PC3 (adenocarcinoma). But this study could be
extended to other cell lines in the framework of a Lyon-Clermont collaboration.
Development of irradiation platforms
The Radiograaff platform We need to develop one or several biological protocols to irradiate
cells at the Radiograaff platform since the present protocol works for some cell lines but not for
others. We will also terinate the room dedicated to the preparation of the biological samples.
Then the platform will be evaluated either by the production and the publication of experimental
results and by making it visible and available to external teams, as for instance the partners of
the PRIMES LabEx and the FranceHadron national infrastructures of Excellence.
The Pavirma platform The Pavirma platform combines two irradiation systems in the same
facility at the campus of Clermont University: an X-ray irradiator (X-ray tube 320 KV for low-
LET irradiation) and a low-energy neutron generator (2.5 MeV for high-LET irradiation), which
are under way to irradiate cells. The first phase of this dedicated facility (X-ray irradiator and a
biology laboratory) is complete. Inter-comparison measurements were performed with equivalent
irradiators at Lyon University and the Curie Institute in Orsay. The second phase (neutron
generator) should be finalized by the end 2013. Although the first phase was implemented in
an existing building, the final platform will consist of a new building including two bunkers for
irradiation and several rooms for biological preparations.
Platforms Radiograaff, Pavirma, and the X irradiator at the Lyon-Sud Medicine faculty will
be included into a national network of irradiation platforms, comprising either X irradiators or
other types of radiation modality (proton beams of various energies and intensity, light ions). The
network will develop common protocols and radiation dosimetry.
Methods of acquisition, processing and analysis of radiobiology data
The measurements of the biological observables rely on the use of the latest techniques in confocal
immunofluorescence microscopy. The number, the size, the light intensity and the spatial distri-
bution of foci may change depending on the nature and energy of radiations. To get significant
statistical results, one needs to have a large number of microscopy images, i.e., a large amount of
data that should be processed in an automatic way. Up to date, ImageJ is one of the most used
open source software for image processing in biology and medicine for treatment and analysis of
images acquired by microscopy. It allows viewing, editing, processing and analyzing most of the
existing file formats. ImageJ also offers a large number of algorithms for image analysis.
We have already some experience in using ImageJ to process H2AX foci distribution in 2D
immunofluorescence microscopy. We plan to extend this methodology to 3D images from im-
munofluorescence microscopy. However, when using confocal microscopy, the amount of data
(images) increases a lot. The LPC group started to test a prototype of Client/Server toolkit for
the storage and the distribution of microscopic images. This Client/Server software is based on
the open-source software OMERO (OME Remote Objects), which provides collaborative methods
in medical and radiobiological imaging to store, provide and analyze large collections of experi-
mental data (cellular microscopy images). The OMERO server is an application that provides to
client applications access through the web to share databases. The users (OMERO Client) may
therefore remotely manage the data stored on the OMERO server. Client applications could be
directly connected to microscopy platforms so that data storage could be processed automatically
during image acquisition.
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6.1 Main objectives of the research theme
Treatment planning relies on simulation tools making it possible to predict dose deposition in the
irradiated tissues. Simulation techniques have been successfully developed and widely used for sev-
eral decades in the case of photon or proton irradiations of organs at rest. However, more research
is still needed in the more complex cases, notably in the ion beam therapy field, when moving
organs (e.g. lung) are irradiated with intensity-modulated scanned pencil beams. Moreover, a
specific feature of ion beam therapy is the possibility of performing in-beam treatment monitor-
ing, using PET imaging (already available) and prompt radiation imaging (on-going research). A
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treatment planning system should therefore include the simulation of the emission of secondary
particles (positrons, prompt gamma-rays, charged fragments), used as input data for imaging. In
all of these simulations, temporal aspects have to be carefully taken into account (interplay effects
between the beam and organs dynamics, management of coincidences in detectors, etc.). As in
any complex simulation problem, two opposing characteristics are sought: physical realism and
speed. In the field of radiation-matter interactions, simulation approaches may be divided into
two main classes:
1. deterministic methods which are fast but not realistic enough for complex treatment plans;
2. Monte-Carlo methods which are very realistic but still far too slow for routine clinical ap-
plication.
Our interdisciplinary research group consists of medical physicists (CLB), physicists with expertise
in radiation-matter interactions and simulation techniques (IPNL, CREATIS), as well as computer
scientists and experts in signal processing (CREATIS). Our objective is to devise and develop
simulation tools making it possible to describe, in a realistic and fast way, the irradiation of a
patient with light ion beams, considering dose deposition in tissues as well as the emission of
secondary particles and their subsequent interactions in imaging detectors for treatment control
(potentially in real time). Our developments are mostly carried out in the framework of the Monte-
Carlo code Geant4 and within the OpenGATE community. Our research work is structured into
three main topics, as described below.
6.1.1 Simulation realism
Physical models All relevant physical phenomena taking place during ion beam irradiation
must be taken into account in Monte-Carlo simulations. One essential aspect, giving rise to
intense research effort at the international level, is the modeling of nuclear fragmentation processes
leading to the emission of neutrons, charged fragments, prompt gammas, and to the production
of positron emitters. As a general rule, all simulation developments must be validated against
existing or forthcoming experimental data. We take part in several collaborations aiming at
gathering experimental data of interest in ion beam therapy (fragmentation cross sections, prompt
gamma yields, beam characteristics, dose profiles, etc.), notably in the framework of the French
network Modeling and Instrumentation for Biomedical Imaging (GdR MI2B) and of the European
ENLIGHT++ network (FP7 ENVISION and ENTERVISION projects).
Medical realism The patient’s anatomical complexity, including moving organs, must be de-
scribed accurately in simulations. Medical data, such as CT scans, 4D CT and subsequent
segmented images are used as input data for simulations. Moreover, predicting the irradiation
biological effectiveness calls for specific algorithms taking into account radiation quality (parti-
cle spectrum with associated energy and LET distributions) and biological tissue characteristics.
These aspects will rely on the results of the radiobiology and moving organs working groups.
6.1.2 Acceleration of simulations
Massively parallel computing Distributing calculations on a large number of computing
nodes is a very effective way of accelerating simulations. Local clusters as well as computing
grids may be used. Another actively investigated option is the recourse to GPU (graphics pro-
cessing units). Recent developments in general-purpose GPU have lead to dramatically reduced
reconstruction times in CT for instance. Such advances will make it possible to accelerate MC
simulations considerably in the next few years.
Hybrid simulation approach Combining Monte-Carlo and deterministic calculations has al-
ready proven a fruitful approach for simulating multiple photon scattering in X-ray imaging and
synchrotron radiation therapy. We investigate the use of hybrid algorithms fro variance reduction
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
54 Simulation of the dose deposition for treatment planning
in Monte-Carlo to accelerate the simulation of secondary particle emission or dose deposition in
ion beam therapy. Such a hybrid approach is also under study for accelerating the simulation of
in-beam emission tomography experiments for treatment monitoring.
6.1.3 Inverse planning strategies
In intensity-modulated particle therapy (e.g. pencil beam scanning modality), not only does treat-
ment planning require an efficient and accurate dose calculation engine, but it also makes it
necessary to optimize the many irradiation parameters, such as beam directions, Bragg peak posi-
tions and fluence values (a treatment fraction typically involves thousands of beamlets). To pave
the way towards new strategies of irradiation ballistics, we investigate several optimization ap-
proaches, among which gradient techniques combined to genetic algorithms, as well as simulated
annealing.
6.2 Overall 2012 assessment
Recent and ongoing activities carried out by our group are listed below with mention of the
corresponding publications.
6.2.1 Simulation realism
• In the framework of the FP7 ENVISION project, work has been done to assess and improve
the physical models of interest for on-line monitoring of ion beam therapy [BB11]. We have
focused on the nuclear fragmentation processes leading to the emission of secondary particles,
in particular prompt gamma-rays. Several parameters have been identified in the available
models (notably the QMD model), which can be tuned to better reproduce experimental
measurements [DDDR+12].
• Active scanning delivery systems take full advantage of ion beams to best conform to the
tumor and to spare surrounding healthy tissues; however, it is also a challenging technique
for quality assurance. In this perspective, we upgraded the GATE/GEANT4 Monte Carlo
platform in order to recalculate the treatment planning system (TPS) dose distributions for
active scanning systems [GBF+12]. A method that allows evaluating the TPS dose distribu-
tions with the GATE Monte Carlo platform has been developed and applied to the XiO TPS
(Elekta), for the IBA proton pencil beam scanning (PBS) system. In homogeneous media,
a satisfactory agreement was generally obtained between XiO and GATE. The maximum
stopping power difference of 3% occurred in a human tissue of 0.9 g·cm−3 density and led
to a significant range shift. Comparisons in heterogeneous configurations pointed out the
limits of the TPS dose calculation accuracy and the superiority of Monte Carlo simulations.
The new capabilities of the platform were applied to a prostate treatment plan and dose
differences between both dose engines were analyzed in detail.
• The GATE package was also used to perform Monte Carlo hadrontherapy simulations of a
cancer treatment combined with the complete description of an associated positron emission
tomography (PET) imaging device for dose monitoring [JFS13]. This study demonstrated
that the GATE platform has the capability to perform realistic simulations in the field
of hadrontherapy, combining both dose and imaging systems. We defined the simulation
configuration as a carbon ion pencil beam scanning of a thorax CT phantom together with
a complete PET imaging system. We analysed the impact of dose delivery on PET image
quality and found a difference of 20% on the PET estimation falloff between doses of 10
Gy and 1 Gy. This study shows that GATE, implemented on a computing system with a
large number of CPUs (> 1000), has the potential to be used for quantitative evaluation of
imaging protocols for radiation monitoring.
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• Online dose monitoring in protontherapy is currently being investigated with prompt-gamma
(PG) devices. PG emission was shown to be correlated with dose deposition. This relation-
ship is to a large extent unknown under real conditions. We propose [GGD+12,GTL+12]
a machine learning approach based on simulations to create optimized treatment-specific
classifiers that detect discrepancies between planned and delivered dose. Simulations were
performed with the Monte Carlo platform Gate/Geant4 for a spot-scanning protontherapy
treatment and a PG camera prototype currently under investigation. The method first builds
a learning set of perturbed situations corresponding to a range of patient translations. This
set is then used to train a combined classifier using distal falloff and registered correlation
measures. Classifier performances were evaluated using receiver operating characteristic
(ROC) curves and maximum associated specificity and sensitivity. A leave-one-out study
showed that it is possible to detect discrepancies of 5 mm with specificity and sensitivity
of 85% whereas using only distal falloff leads to 77% on the same data set. The proposed
method could help to evaluate performance and to optimize the design of PG monitoring
devices.
• We have developed a filtered-backprojection reconstruction (FBP) algorithm for proton com-
puted tomography (pCT) that takes advantage of the estimation of the most likely path of
protons. Improvement in the spatial resolution has been observed on Monte Carlo simula-
tions compared to existing straight-line approximations. The improvement in spatial resolu-
tion combined with the practicality of FBP algorithms compared to iterative reconstruction
algorithms makes this new algorithm a candidate of choice for clinical pCT [RDF+13]. From
preliminary studies, we have shown that the electron density can be reconstructed to within
2.5% for a 3 mGy imaging dose [DRD+12].
6.2.2 Acceleration of simulations
• Hybrid algorithms have been implemented in GATE for fast simulation of the dose ab-
sorbed by the patient during kV x-ray irradiations (cone beam CT, stereotactic synchrotron
radiation therapy . . . ). The track length estimator approach is now available in GATE
6.2 [MBL+12]. A hybrid simulation scheme is also under development for fast simulation
of CBCT projections with accurate description of the scatter contribution. This work was
funded for 1 year (2010-2011) by the PRRH and additional funding (2012-2013) has been
obtained in a collaboration with the Catholic Louvain University and IBA company. Our
final objective is to improve the image quality of cone beam CT (quantitative imaging),
without increasing the dose to the patient.
• Following the GateLab [GCPG+11] project, we introduced an end-to-end framework for
efficient computing and merging of Monte Carlo simulations on heterogeneous distributed
systems [CPGFdS+13]. Simulations are parallelized using a dynamic load-balancing ap-
proach and multiple parallel mergers. Checkpointing is used to improve reliability and to
enable incremental results merging from partial results. A model was proposed to analyze the
behavior of the proposed framework and help tune its parameters. Experimental results ob-
tained on a production grid infrastructure showed that the model fits the real makespan with
a relative error of maximum 10%, that using multiple parallel mergers reduces the makespan
by 40% on average, that checkpointing enables the completion of very long simulations and
that it can be used without penalizing the makespan.
• Within the FP7 Envision project, we develop a Geant4 software module to accelerate the
simulation of prompt-gamma emission. This module, based on the track length estimator
approach, will substantially speedup the simulation of prompt-gamma imaging for online
monitoring of proton therapy treatments.
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6.3 Perspectives for 2013 . . . or beyond
The simulation of dose deposition and of online treatment monitoring in ion beam therapy is in a
very active phase of development with an increasing number of ongoing or forthcoming projects.
Our objectives are ambitious and must be considered in a long term perspective. The main tasks
for 2013 are the following:
• The work already carried out within the FP7 ENVISION project to improve the QMD
model will be prolonged within the FP7 ENTERVISION project (M. Pinto’s PhD thesis).
The work will first focus on the tuning of the nuclear fragmentation processes to reproduce
experimental measurements of prompt secondary radiation in proton therapy.
• A longer-term perspective is to devise a quality assurance methodology making it possible
to (i) plan the expected prompt-gamma depth-profile (which will require developing semi-
analytical fast algorithms) and associated camera response (in active beam delivery mode, on
a spot by spot basis) and (ii) determine criteria for deciding whether the profiles measured
online are within acceptable limits, with a certain level of confidence. We also plan to
work on the relationship between the dose and prompt-gamma profiles. The same kind of
methodology will be investigated for other types of secondary particles (e.g. protons) as well.
• A project devoted to cone beam CT imaging for proton therapy quality assurance has recently
started, in collaboration with the Université Catholique de Louvain (UCL) and the IBA
company. In this framework, we propose original reconstruction algorithms including a
hybrid (Monte Carlo – deterministic) simulation stage, the aim of which is to reduce the
artifacts and to provide quantitatively more accurate images, without increasing the dose to
the patient.
• In order to go a step further towards translating proton CT to clinic, further studies are
needed to propose design guidelines for a proton CT prototype, with a particular focus on the
identification of the basic detector requirements (in terms of energy and spatial resolutions)
and on the quantification of uncertainties in the proton range with a pCT-based treatment
planning system.
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7.1 Axis 1: image-guided radiotherapy
7.1.1 Overall 2012 assessment
Improving deformation registration of thorax CT with lung masks Deformable regis-
tration generally relies on the assumption that the sought spatial transformation is smooth. Yet,
breathing motion involves sliding of the lung with respect to the chest wall, causing a disconti-
nuity in the motion field, and the smoothness assumption may lead to poor matching accuracy.
In response, alternative registration methods have been proposed, several of which rely on prior
segmentations. In [VBR+12] we propose an original method to extract automatically a specific
segmentation, called a motion mask, from a CT image of the thorax.
The motion mask discriminates moving regions from less moving ones, conveniently allowing
simultaneous estimation of their motion, while providing an interface where sliding occurs. The
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sought segmentation is subanatomical and based on physiological considerations, rather than organ
boundaries. We therefore first extract clear anatomical features from the image, with respect to
which the mask is defined. Level sets are then used to obtain smooth surfaces interpolating these
features. The resulting procedure comes down to a monitored level set segmentation of binary
label images.
The method was applied to sixteen inhale-exhale image pairs. Registration using the motion
mask resulted in higher matching accuracy for all patients, and the improvement was statistically
significant. Registration performance was comparable to that obtained using lung masks when
considering the entire lung region, but the use of motion masks led to significantly better matching
near the diaphragm and mediastinum, for the bony anatomy and for the trachea. The use of the
masks was shown to facilitate the registration, allowing to reduce the complexity of the spatial
transformation considerably, while maintaining matching accuracy.
Thorax surface registration
In the framework of the European ULICE project and in collaboration with the groupe led by G.
Baroni, at Politecnico di Milano, we investigated thoracic surface registration. Indeed, real-time
optical surface imaging systems, such as VisionRT, offer a non-invasive way to monitor intra-
fraction motion of a patient’s thorax surface during radiotherapy treatments. Due to lack of
point correspondence in dynamic surface acquisition, such systems cannot currently provide 3D
motion tracking at specific surface landmarks, as available in optical technologies based on passive
markers.
In [SFR+12], we propose to apply deformable mesh registration to extract surface point tra-
jectories from marker-free optical imaging, thus yielding multi-dimensional breathing traces. The
investigated approach is based on a non-rigid extension of the iterative closest point algorithm,
using a locally affine regularization. The accuracy in tracking breathing motion was quantified in
a group of healthy volunteers, by pair-wise registering the thoraco-abdominal surfaces acquired at
three different respiratory phases using a clinically available optical system.
The motion tracking accuracy proved to be maximal in the abdominal region, where breathing
motion mostly occurs, with average errors of 1.09 mm. The results demonstrate the feasibility
of recovering multi-dimensional breathing motion from markerless optical surface acquisitions by
using the implemented deformable registration algorithm. The approach can potentially improve
respiratory motion management in radiation therapy, including motion artefact reduction or tu-
mour motion compensation by means of internal/external correlation models.
Usefulness of abdominal compression In [BAR+12], we aim to determine the usefulness
of abdominal compression in lung stereotactic body radiation therapy (SBRT) depending on
lobe tumor location. For that, 27 non-small cell lung cancer patients were immobilized in the
“Stereotactic Body Frame” (Elekta). Eighteen tumors were located in an upper lobe, one in the
middle lobe and nine in a lower lobe (one patient had two lesions). All patients underwent two
four-dimensional computed tomography (4DCT) scans, with and without abdominal compression.
Three-dimensional tumor motion amplitude was determined using manual landmark annotation.
We also determined the internal target volume (ITV) and the influence of abdominal compression
on lung dose-volume histograms.
We obtained the following results: the mean reduction of tumor motion amplitude was 3.5
mm (p = 0.009) for lower lobe tumors and 0.8 mm (p = 0.026) for upper/middle lobe locations.
Compression increased tumor motion in 5 cases. Mean ITV reduction was 3.6 cm3 (p = 0.039)
for lower lobe and 0.2 cm3 (p = 0.048) for upper/middle lobe lesions. Dosimetric gain of the
compression for lung sparing was not clinically relevant.
As a conclusion: the most significant impact of abdominal compression was obtained in patients
with lower lobe tumors. However, minor or negative effects of compression were reported for other
patients and lung sparing was not substantially improved. At our institute, patients with upper
or middle lobe lesions are now systematically treated without compression and the usefulness of
compression for lower lobe tumors is evaluated on an individual basis.
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Lymph node stations
Other researches have been undertaken by our team in the field of lung tumor, in particular
dedicated to the definition of lymph nodes stations in thoracic CT [LPB+13,PLCS12, SCR+12].
These researches were performed in collaboration with the group of Rod Lynch, MD, Geelong,
Australia.
7.1.2 Perspectives
Several research efforts are ongoing. First, considering that sliding motion is a challenge for
deformable image registration because it leads to discontinuities in the sought deformation, we
aim to build a method to handle sliding motion using multiple B-spline transforms. Second, we
investigated Proton CT (pCT) which has the potential to accurately measure the electron density
map of tissues at low doses. However, the spatial resolution is prohibitive if the curved paths of
protons in matter is not accounted for. We propose to account for an estimate of the most likely
path of protons in a filtered backprojection (FBP) reconstruction algorithm.
7.2 Axis 2 : biomechanical and geometrical modelling
7.2.1 Overall 2012 assessment
Model for the respiratory movement
When the tumor is located on a moving organ, the main difficulty is to target it during treatment.
This incertainty on the position makes indispensable the setting up of a strategy allowing the
prediction of tumoral movement. Indeed this allows to guide the ion beam so it follows the
tumoral movements. furthermore, the treatment by hadrontherapy alos requires access to a precise
description of the density of all the organs traversed by the beam, since the position of maximum
deposition of the the energy transported by the ions (Bragg peak) depends on it. Unfortunately,
the breathing movement is complex and its prediction is fairly difficult – in particular, breathing
is governed by the independant action of the rib cage muscles and of the diaphragm.
The known techniques based on imaging, such as the Cone-beam ou elastic registration, at-
tempt to predict the position of the pulmonary tumors. These methods assume that the movements
of the respiratory system are reproducible over time. Other techniques based on the use of two
X ray cameras (cyberknife, the tracking method implemented at the carbon ion facility of Heidel-
berg [HIT]) may allow the prediction of the tumor position when its segmentation and automatic
delineation is possible in real time. However, such methods are invasive, if not hazardous, and do
not llow to compute the evolution of nearby organs, an information indispensable to determine
the Bragg peak position. Thus, deducing the tumor movement from the sole use of sequences
of images seems unsufficient. A solution to this fact may be to develop a biomechanical model
of the respiratory system including the variability fo the respiratory movement. To be precise
enough, this solution must include models for the rib cage, the diaphragm and the lungs. It is
just as important for such a model to be monitored through parameters measured externally (3D
sensors, spirometer, etc.), in order to preserve a non-invasive character and to correlateinternal
movements with external movements of the thorax and abdomen, but also the air flow exchanges.
The changes in mechanical properties of the mediums entered by the beam must also be modelled
in order to satisfy the requirements of hadrontherapy. Finally, the complete simulation fo the res-
piratory dynamics induces the simulation of the diaphragm. In previous work we have developed a
biomechanical model for the lungs and throax. However, the diaphragm represents one the major
muscles in the action of breathing, the physiology and movements of which are very complex.
In 2011, we have developed a customized biomechanical model of the diaphragm structure
based on data provided by CT scan images (Fig. 7.1). This biomechanical model leans upon
an heterogeneous model (tendons and muscles) allowing elastic behaviour based on experimental
data. The results of the model show a good fit with experimental data. The zones of largest
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error are located in the sections of the thorax that are in contact with the ribs. A more complex
model (heterogeneous and hybrid) of mechanical deformation based on hyper-elastic behaviour is
being integrated, to take the presence of other elements (ribs, lung movement, heart beats) into
account. The movements and deformations are computed by a method based on finite elements.
The realistic model for the organ tissues is intended to help understand the effects of moving
organs on the distribution of dose, as well as the response of normal issues as they move during
treatment. Finite elements provide a better insight on the mechanical behaviour of organs and
their response, due to the fact that they are based on material properties, the complex organ
geometry and the anatomical limiting conditions.
Our biomechanical model for the respiratory system allows:
• to take the non reproductibility of the system into account;
• to adapt the model to the geometrical and physical information of the patients;
• its monitoring through external sensors during treatment.
Furthermore, this method should allow to compensate the differences between biomechanical
parameters from one patient to the other.
Dose deposition
Complementarily to this research, a study on control imaging during irradiation is being made
in collaboration with the CAS-PHABIO team at IPNL (Institut de Physique Nucléaire de Lyon,
UMR 5822), in the framework of the ENVISION project (European ENLIGHT++ network).
In fact, accurate 4D dosimetry calculations are essential for treatement planning verification
and evaluation. They require temporal information about the tumor position, size and shape,
as well as information regarding the tissue density variation along the beam path during treat-
ment. Several deformable image registration (DIR) algorithms are described in the literature1 to
investigate respiratory liver motion effects on 4D treatment planning for scanned proton therapy.
Techniques based on image registration are particularly challenging in the case of the liver, due
to low-contrast CT data, especially if no contrast enhancing agents are applied. Moreover, they
can induce important deviations in patient dose calculation during treatment due to the non re-
productibility of the breathing cycles. Velec et al2 use a biomechanical model-based method for
multi-organ registration of the abdomen between two extreme phases of the respiratory cycle, in
order to study the impact of respiratory-induced organ motion on dose calculation during liver
stereotactic body radiotherapy. They used CT images at the inhale and exhale stages to calculate
two dose distribution matrices for liver cancer treatment planning. Further on, they used linear
interpolation to modulate the dose distribution at intermediate breathing states. Unfortunately,
this approximation does not take into account density variations and assumes that dose values
vary in a linear way from one respiratory position to another. Moreover, the intermediate phases
are not reproductible from one respiratory cycle to another.
Consequently we developped an alternative patient-specific biomechanical-based model for 4D
dosimetry calculations during hadrontherapy simulations. As opposed to classical voxelized mod-
els, where the necessary information is distributed over a rigid structured grid of voxels, we repre-
sent the human anatomy with the use of a deformable grid of tetrahedra where the mass density is
1D. Rueckert et al., Non-rigid registration using free-form deformations: Application to breast MR images, IEEE
Trans. Med. Imaging, vol. 18, pp. 712-721, 1999.
J.P. Thirion, Imaging matching as a diffusion process: An analogy with Maxwell’s demons., Med. Image. Anal.,
vol. 2, pp. 243-260, 1998.
Y. Zhang, D. Boye, C. Tanner, A. J. Lomax and A. Knopf, Respiratory liver motion estimation and its effect on
scanned proton beam therapy, Phys. Med. Biol., vol. 57, pp. 1779-1795.
2M. Velec, J. Moseley, B. Math, C. Eccles, T. Craig, M. Sharpe, L. Dawson, K. Brock, Effect of breathing motion
on radiotherapy dose accumulation in the abdomen using deformable registration. Int. J Radiation Oncology Biol.
Phys., Vol 80, No. 1, 265-272, 2011.
W. Schneider, T. Bortfeld, W. Schelgel, Correlation between CT numbers and tissue parameters needed for Monte
Carlo simulations of clinical dose distributions, Phys. Med. Biol. 45; 459-478, 2000.
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Figure 7.1: Simulations of the ribcage and diagphram in the biomechanical model.
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distributed to the vertices of the grid. In this way, we can simulate at the same time and within the
same geometry, organ motion and mass density variations required for dose calculations, without
having to perform voxel tissue tracking. Using finite element analysis, deformations are described
by mesh vertex displacements, tissue tracking being implicit. Our method generates intermediate
density maps without using linear interpolation to approximate dose at intermediate breathing
states. The deposited energy is then accumulated over each deformable tetrahedral element during
treatment simulation and thus including internal motion when calculating dose distribution inside
the tumors and surrounding organs.
This research resulted in four publications over 2012-2013 ( [LSB+13, MAB+12, MAB+13a,
MAB+13b].
Correlating internal (tumor, organs) and external movements In parallel to the research
described above, and within the same team (SAARA, from the LIRIS laboratory), another research
has been ongoing for several years, with the objective to estimate the displacements of a given
tumor under the influence of the breathing mechanism. After preliminary studies over the first
half of 2000-2010, a new PhD student joigned the team, for a Master’s degree subject involving
the definition and implementation of an easily reproducible protocole to measure external move-
ments, and design algorithms to reconstruct the internal movements that it induced. The first
measurements of this inside-outside correlation between the movements observed with cameras
and the data obtained with a spyrometer and also using ultrasonic acquisitions in mode M and
B, during the same sequence, were achieved in 2011 [FJZM11]. Thanks to other research efforts
with another student in Chile using signal treatment and innovating techniques [CHJ+12], we are
now trying to analyze the diaphragm movements in order to help drive the biomechanical model
described above for human respiration, with the long term intent to predict the displacements of
moving organs and tumors in function of synchronized external acquisition.
Our research also involves a PhD thesis to be defended at the beginning of 2014, with support
from the 2007-2013 CPER in the framework of ETOILE, by Xavier Faure. The aim of this research
is to model and simulate in a realistic way the organs inside the human body from physiological,
anatomical characteristics, or data from multi-modal acquisition. In the long run, the model should
allow to obtain in real time all the information required by algorithms in the aptative treatment
modules (such as those for cancer treatments). Real time may only be achieved through the
optimization and parallelization of the simulation algorithms used in this domain. To reach this
goal, X. Faure focuses on modeling soft tissue using mass-tensors, an innovative technique and
an alternative to finite elements. He has developed the algorithms allowing to simulate linear
deformations and also deformations that are not linear in geometry [FZJM12b, FZJM12a]. The
extension and generalization to hyper-elastic models (non-linear for mecanics) is underway. The
GPU parallalization of these algorithms has been developed for the SOFA platform, with an
implicit integration method.
Treatment room control
The statistics published in 2010 by the French Board for Nuclear Security (ASN, http://www.
asn.fr) show that, in France, over the total amount of incidents reported during radiotherapy
treatments, 10% involved an error in the identification of the patient (or of the treatment that
he/she was supposed to be administered) and 67% were related to patient positionning. Ths
proves the utmost importance of developing new and efficient methods to improve control during
treatment as much as possible.
The SAARA team at LIRIS has undertaken the supervision of a CIFRE PhD with an industrial
partner (DOSISoft, Cachan, a French leader in the development of treatment planning systems).
This work, initiated in october 2008, ended in November 2011 with the defense of M. Portela-
Sotelo [PS11]. The research was centered on using video cameras to follow the movements of staff,
patients and equiments in a treatment room, using a precise geometrical model et techniques
to recognize movements on the filmed images. This research, which was co-supervised with two
radiophysicists at the Léon Béard Center (C. Ginestet and P. Dupuis), was not funded by the
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CPER, but is included in the framework of the ETOILE project. It is accompanied by a certain
degree of confidentiality for industrial property reasons. However, it was possible to publish
several papers describing the methodology in major conferences or journals [PSDM11a,PSDM11b,
PSDM+12,PSDP+12].
Figure 7.2: Movement detection in the treatment room. On the left image, virtual representation
of the room using the model; all its elements occupy a predefined, fixed rest position. Center:
image produced by one of the two cameras in the room at a given instant, inducing a random
position of the couch and irradiation arm. Right: superimposition, over the filmed image, of
the virtual model “registered” on the filmed positions of the various elements in the left image
(augmented reality). The differences in colour, distance, pixel, object-feature, texture, computed
for each frame of the filmed sequence, between the virtual and real images allow the registration,
and then the detection and analysis of movement.
7.2.2 Perspectives
We developed a patient-specific multiphysics model that integrates the geometry of organs, dis-
placement fields for the internal movements, the density and nature of biological tissues, the energy
deposited by ionizing rays. We wish to progress towards a global multi-physics and multi-scale
model of virtual human, merging the macroscopic (organ level) and microscopic (cellular level)
scales representations. Work in the latter area is already planned.
The developments will indeed continue in the multiple framework of PRRH (until end 2013),
the PRIMES Labex that was accepted in 2012, France Hadron (Infrastructures Biotechnologie pour
la Santé, also accepted in 2012) and ENVISION (2010-2014). The research on video surveillance
of the treatment room is on stand-by.
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Technological developments
Scientific coordinators
• Marcel Bajard (IR, CNRS)
Institutions & laboratories involved
• IPNL, CNRS/IN2P3 and Université Lyon 1
Full-time researchers with institutional links
• Marcel Bajard (IR, CNRS)
8.1 Overall 2012 assessment
The researches of this group ended with the termination of ULICE’s workpackage number 6
(gantries for carbon ion facilities) this year, and the retirement of Marcel Bajard who led the
group at IPNL.
67
Part III
Cumulated bibliographical
references for 2007-2013
68
Chapter 1
ETOILE Project
1.1 International conferences with reviewing committee
2011
[1] J. Balosso and ETOILE. Status of the ETOILE Center at the end of 2010. In 10th NIRS
International Symposium on Heavy Ions Radiotherapy and Advanced Technology, pages 59–63.
NIRS, NIRS, February 2011.
2007
[1] M. Bajard. Status of the etoile project. Eighth International Topical Meeting on Nuclear
Applications, august 2007.
1.2 Invited conferences
2009
[1] J. Balosso, J. Remillieux, and JM. Moreau. The medical-physical aspects of the etoile project.
BIR President’s Conference, London, may 2009.
2008
[1] J. Balosso, J. Remillieux, and JM. Moreau. The european implication of the etoile project.
MAESTRO meeting, Caen, France, may 2008.
2007
[1] J. Balosso, J. Remillieux, and JM. Moreau. Avancement du centre etoile et du programme
régional de recherche en hadronthérapie. Journées Scientifiques du Cancéropôle Lyon Auvergne
Rhône-Alpes (CLARA), Lyon, june 2007.
1.3 PhD / HdR
2008
[1] Y. Boudam. Utilisation des modèles NTCP et de carcinogenèse pour les choix balistiques et de
particules en hadronthérapie de l’adulte et de l’enfant. PhD thesis, Grenoble 1 Joseph Fourrier,
November 2008.
69
70 ETOILE Project
1.4 Oral communications
2008
[1] M. Bajard. Status of etoile project. séminaire franco-britannique sur les nouvelles technologies
venant de la physique appliquées au traitement et à l’imagerie en oncologie. Paris, Ambassage
de Grande Bretagne, march 2008.
2007
[1] J. Balosso and M. Bajard. Present status of etoile. Workshop MedAustron about Gantries
Vienne (Autriche), march 2007.
[2] M. Bajard. Status of etoile project. The associated research program and the National Research
Program on Hadron therapy. Eighth International Topical Meeting on Nuclear Applications
and Utilization of Accelerators. Pocatello (USA, Idaho), july 2007.
[3] M. Bajard. Present status of etoile. Joint Symposium on Medical Accelerators, Wiener
Neustadt, june 2007.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
Chapter 2
Medical project
2.1 International journals with reviewing committee
2012
[1] J. Thariat, PO. Védrine, S. Temam, AM. Ali, D. Orbach, G. Odin, M. Makeieff, R. Nicollas,
M. Penicaud, B. Toussaint, S. Vergez, A. Laprie, M. Rives, K. Montagne, N. Teissier, and
L. Castillo. The role of radiation therapy in pediatric mucoepidermoid carcinomas of the
salivary glands. J. Pediatry, 6, November 2012.
[2] C. Rodriguez-Lafrasse and J. Balosso. From the carbon track to therapeutic efficiency of
hadrontherapy. Cancer Radiother., 16(1):16–24, February 2012. Epub 2012 Jan 27.
[3] P. Pommier, M. Morelle, L. Perrier, R. De Crevoisier, A. Laplanche, P. Dudouet, MA. Mahé,
B. Chauvet, TD. Nguyen, G. Créhange, A. Zawadi, O. Chapet, I. Latorzeff, A. Bossi, V. Beck-
endorf, E. Touboul, X. Muracciole, JM. Bachaud, S. Supiot, and J-L. Lagrange. Prospective
economic evaluation of image-guided radiation therapy for prostate cancer in the framework of
the national programme for innovative and costly therapies assessment. Cancer Radiotherapy,
16(5-6):444–451, September 2012.
[4] G. Buiret, P. Céruse, A. Ramade, C. Carrie, and P. Pommier. Acinic cell carcinoma of the
parotid gland with skull base invasion: case study, managed by exclusive external 3d radiation
therapy. European Annals of Otorhinolaryngology, Head and Neck Disease, 129(2):111–114,
April 2012.
[5] G. Buiret, X. Montbarbon, B. Fleury, M. Poupart, JC. Pignat, C. Carrie, and P. Pommier.
Inverted papilloma with associated carcinoma of the nasal cavity and paranasal sinuses: treat-
ment outcomes. Acta Otolaryngol, 132(1):80–85, January 2012.
2011
[1] J. Thariat, S. Bolle, Y. Demizu, PY. Marcy, Y. Hu, J. Santini, J. Bourhis, and P. Pommier.
New techniques in radiation therapy for head and neck cancer: Imrt, cyberknife, protons,
and carbon ions, improved effectiveness and safety? impact on survival? Anticancer Drugs,
22(7):596–606, August 2011. PMID: 21051993.
[2] L. Claude, L. Todisco, J. Leseur, A. Laprie, C. Alapetite, and V. Bernier. New radiation
techniques in paediatric cancers. Bull. Cancer., 98(5):571–580, May 2011.
71
72 Medical project
2010
[1] P. Pommier, M-P. Sunyach, Y. Hu, E. Amsalem, L. Claude, D. Moncort-Boulch, P. Toutenu,
and J. Balosso. Radiotherapy for sarcoma: hadrontherapy, for whom and what for? Bull
Cancer, pages 97(6):657–72, June 2010. PMID: 20547480.
[2] P. Pommier, Y. Hu, M-H. Baron, O. Chapet, and J. Balosso. Particle therapy: carbon ions.
Bull Cancer, pages 97(7):819–29, July 2010. PMID: 20659870.
[3] P. Heudel, M.C. Biston, J. Fayette, A. Ramade, F. Gassa, and P. Pommier. Head and neck
sarcoma: report of a case treated by intensity-modulated radiation therapy. Int J Clin Oncol,
pages 15(3):305–9, June 2010. PMID: 20195682.
[4] Y. Boudam, G. Noel, R. Ferrand, Ch. Gautier, J-L. Habrand, J-J. Mazeron, M. Bajard,
J. Balosso, and ETOILE. Dosimetric evaluation of the usefulness of different beam line equip-
ments for protontherapy centres. International Journal of radiation oncology biology physics,
2010.
2009
[1] P. Pommier, M-P. Sunyach, C. Pasteris, D. Frappaz, and C. Carrie. Second cancer after
total-body irradiation (tbi) in childhood. Strahlenther Onkol., (;185 Suppl 2:13-6.), August
2009.
[2] C. Boskos, L. Feuvret, G. Noel, J-L. Habrand, P. Pommier, C. Alapetite, H. Mammar, R. Fer-
rand, G. Boisserie, and J-J. Mazeron. Combined proton and photon conformal radiotherapy
for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys, february
2009. PubMed PMID: 19203844.
2007
[1] L. Feuvret, G. Noel, DC Weber, P. Pommier, R. Ferrand, L. De Marzi, F. Dhermain,
C. Alapetite, H. Mammar, G. Boisserie, J-L. Habrand, and J-J. Mazeron. A treatment planning
comparison of combined photon-proton beams versus proton beams-only for the treatment of
skull base tumors. Int J Radiat Oncol Biol Phys, (1;69(3)), november 2007. PubMed PMID:
17889276.
[2] M. Fesneau, S. Chapet, L. Martin, P. Pommier, M. Alfonsi, B. Laguerre, N. Feham, G. Berger,
and G. Calais. Carboplatin, tegafur-uracil, leucovorin and concurrent radiotherapy for locally
advanced head and neck squamous cell carcinoma. results of the 2003-01 phase ii gortec study.
Int J Radiat Oncol Biol Phys, (69 : 423.), 2007.
2.2 National journals with reviewing committee
2012
[1] S. Patin, P. Pommier, Y. Hu, M-H. Baron, and J. Balosso. Étude d’incidence des cancers
éligibles pour une hadronthérapie : méthodologie. Revue d’épidémiologie et de santé publique,
60(supplément 2):S64–S65, September 2012.
2010
[1] D. Maucort-Boulch, M-H. Baron, P. Pommier, DC Weber, JE. Mizoe, J. Rochat, J-P. Boissel,
J. Balosso, ETOILE, H. Tsujii, and E-E. Amsallem. Rationale for carbon ion therapy in high-
grade glioma based on a review and a meta-analysis of neutron beam trials. Cancer Radiother.,
pages 14(1):34–41, January 2010. PMID: 20004126.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
2.3 National journals without reviewing committee 73
2009
[1] A. Ismail, JY. Giraud, GN. Lu, R. Sihanath, P. Pittet, JM. Galvan, and J. Balosso. Ra-
diotherapy quality insurance by individualized in vivo dosimetry: State of the art. Cancer
Radiothérapie, (13(3)), june 2009. PMID: 19272824.
2008
[1] Y. Hu, S. Bolle, J-P. Boissel, J. Balosso, and P. Pommier. Apport de l’hadronthérapie pour les
carcinomes épidermoïdes localement avancés de la sphère orl : revue de la littérature. Cancer
Radiother., (:12), 2008.
2007
[1] L. Feuvret, G. Noel, D. Weber, P. Pommier, R. Ferrand, F. Dhermain, C. Alapetite, H. Mam-
mar, J-L. Habrand, and J-J. Mazeron. Comparaison dosimétrique : irradiation photons et
protons versus protons seuls pour le traitement de tumeurs de la base du crâne. Cancer
Radiother., (11: 394-5), 2007.
2.3 National journals without reviewing committee
2010
[1] J. Balosso, S. Patin, P. Pommier, and G. Wasmer. Omérric, l’organisation qui permet de donner
accès aux centres d’hadronthérapie par ions carbone (hic). Bull cancer, 97:47, March 2010.
Université Joseph Fourier (Grenoble-I)/GCS ETOILE CRLCC Léon Bérard/ GCS ETOILE.
Contact : jacques.balosso@centre-etoile.org ;.
2009
[1] S. Patin, J. Balosso, G. Wasmer, and P. Pommier. Organisation de la prise en charge médi-
cale des patients atteints de cancers rares pouvant être traités par ric (radiothérapie par ions
carbone) : Intérêt de l’organisation en réseau des structures de lutte contre le cancer en région
rhône alpes. Oncologie, 11(9-10):462–463, September 2009.
2.4 National conferences with reviewing committee
2009
[1] P. Pommier, P. Gassa, F. Lafay, and L. Claude. Image guided radiotherapy with the cone
beam ct kv (elekta): experience of the léon bérard centre. Cancer Radiother., (:13(5):384-90),
September 2009. Epub 2009 Jul 28.
2.5 PhD / HdR
2008
[1] Y. Boudam, A. Baudré, R. Ferrand, I. Flandin, J-L. Habrand, and J. Balosso. A study of
deterministic and stochastic effects for head and neck tumors treated either by photons IMRT
or protons for pediatric conditions, a quantitative comparative approach. PhD thesis, Lyon,
November 2008.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
74 Medical project
2.6 Workshops without proceedings
2010
[1] P. Pommier, Y. Hu, M-H. Baron, O. Chapet, and J. Balosso. L’hadronthérapie : les ions
carbone. Bulletin du cancer, 97(7), July 2010.
2.7 Oral communications
2008
[1] E. Marcon and P. Pommier. L’ingénierie des soins : exemple de l’hadronthérapie dans etoile.
3èmes journées scientifiques du CLARA. Lyon., 2008.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
Chapter 3
Medico-economical simulations
3.1 International journals with reviewing committee
2012
[1] B. Ribba, G. Kaloshi, M. Peyre, D. Ricard, V. Calvez, M. Tod, B. Cajavec-Bernard, A. Idbaih,
D. Psimaras, L. Dainese, J. Pallud, S. Cartalat-Carel, JY. Delattre, J. Honnorat, E. Grenier,
and F. Ducray. A tumor growth inhibition model for low-grade glioma treated with chemother-
apy or radiotherapy. Clin. Cancer Res., 18(18):5071–5080, September 2012.
2010
[1] P. Pommier, Y. Lievens, F. Feschet, J. Borras, M-H. Baron, A. Shtiliyanova, and M. Pijls-
Johannesma. Simulating demand for innovative radiotherapies: an illustrative model based
on carbon ion and proton radiotherapy. Radiother Oncol, 96(2):243–9, August 2010. PubMed
PMID: 20452693.
[2] Y. Jacquemin, E. Marcon, and P. Pommier. Towards an improved resolution of radiotherapy
scheduling. European Journal of Operational Research, page Submitted, 2010.
2008
[1] R. Remonnay, M. Morelle, P. Pommier, F. Giammarite, and M-O. Carrère. Assessing short-
term effects and costs at an early stage of innovation: the use of positron emission tomography
on radiotherapy treatment decision making. Int J Tchnol Assess Health Care, (24:212-20),
2008.
[2] M. Pijls-Johannesma, P. Pommier, and Y. Lievens. Cost-effectiveness of particle therapy:
current evidence and future needs. Radiother Oncol, (89(2)), november 2008. PubMed PMID:
18707784.
[3] C. Dussart, P. Pommier, V. Siranyan, G. Grelaud, and S. Dussart. Optimizing clinical practice
with case-based reasoning approach. J Eval Clin Pract, (14(5)), october 2008. PubMed PMID:
19018901.
2007
[1] P. Pommier, J. Borras, M-H. Baron, E-E. Amsallem, and F. Feschet. Recruitment model for
decision making in innovative therapies: Application to carbon ions and protons radiotherapy.
Int J Radiat Oncol Biol Phys, 2007.
75
76 Medico-economical simulations
3.2 National journals with reviewing committee
2009
[1] L. Perrier, P. Pommier, M-O. Carrère, and P. Sylvestre Baron. Transférabilité des évaluations
de coûts en santé : analyse des facteurs de variabilité ? Revue Economique, 60(2), march 2009.
in press.
2008
[1] B. Pellet, P. Pommier, F. Albert, and E. Marcon. L’efficience médicale et économique des
centres de radiothérapie: application des outils de modélisation pour le dimensionnement du
futur centre etoile. Cancer Radiother, 12, 2008.
2007
[1] L. Perrier, SE. Combs, T. Auberger, L. Zucca, I. Naslund, M. Pijls-Johannesma, J. Rochat,
Y. Lievens, N. Gueye, G. Heeren, and P. Pommier. A decision-making tool for a costly inno-
vative technology. Journal d’Economie Médicale, 25(7-8), december 2007.
3.3 International conferences with reviewing committee
2010
[1] T. Wang, E. Marcon, and P. Pommier. Decision support tool for patient recruitment in a
hadrontherapy center. In 18th World Congress of the International Federation of Automatic
Control (IFAC 2011), page Submitted, Milano, Italy, 2010.
[2] A. Shtiliyanova, F. Feschet, JY. Boire, and P. Pommier. Modeling a tool for innovative thera-
pies. In World Congress on Medical and Health Informatics, Cape Town, South Africa, 2010.
[3] A. Shtiliyanova, F. Feschet, P. Pommier, and JY. Boire. Modeling: a tool for evaluation of
innovative therapies. Cape Town, South Africa, 2010. Medinfo 2010 Congress. (submitted).
[4] Y. Jacquemin, E. Marcon, and P. Pommier. A pattern-based approach resolution of radiother-
apy scheduling. In 18th World Congress of the International Federation of Automatic Control
(IFAC) 2011, page Submitted, Milano, Italy, 2010.
[5] Y. Jacquemin, E. Marcon, and P. Pommier. Towards an improved resolution of radiotherapy
scheduling. Venise, Italie, February 2010. IEEE Workshop on Health Care Management.
3.4 International conferences without reviewing committee
2007
[1] L. Perrier, P. Pommier, M-O. Carrère, and P. Sylvestre Baron. Assessing the generalisability
of cost evaluation results using the euclidean metric and principal component analysis: lesson
from a high cost innovation in oncology. In Value in Health Wiley, volume 10, Dublin, Irlande,
october 2007. 10th Annual European Congress of the International Society for Pharmacoeco-
nomics and Outcomes Research, Value in Health.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
3.5 National conferences with reviewing committee 77
3.5 National conferences with reviewing committee
2009
[1] L. Trilling and Y. Jacquemin. Le lean dans la santé. Annecy, October 2009. Journées du GDR
MACS.
[2] A. Shtiliyanova, F. Feschet, and P. Pommier. Outil d’évaluation médico-économique des
thérapeutiques innovantes. Lyon, October 2009. Symposium Sciences Humaines et Oncolo-
gies abstract/poster ;; CLARA.
[3] Y. Jacquemin, E. Marcon, and P. Pommier. Towards an improved resolution of radiotherapy
scheduling. Leuven, Belgique, July 2009. ORAHS.
[4] Y. Jacquemin, E. Marcon, and P. Pommier. Amélioration de la planification en radiothérapie.
Saint Etienne, November 2009. Journée IFRESIS.
[5] Y. Jacquemin, E. Marcon, and P. Pommier. La planification en radiothérapie. Lyon, October
2009. Symposium Sciences Humaines et Oncologies abstract/poster ; CLARA.
2008
[1] P. Pommier and N. Geoges. Protons et ions carbones. les particules de l’avenir ? Eurocancer.
Paris, 2008.
2007
[1] P. Pommier, N. Gueye, C. Buron, and S. Meyroneinc. Modélisation du coût de l’innovation
thérapeutique pour l’aide à la décision. application à la radiothérapie par ions carbone (projet
etoile). Systèmes d’information et santé, (10: 217-31), 2007.
3.6 National conferences without reviewing committee
2007
[1] L. Perrier, P. Pommier, M-O. Carrère, and P. Sylvestre Baron. Les évaluations de coûts en santé
sont-elles transférables ? mesures et application à une innovation très coûteuse en cancérologie.
In Université Catholique, Lille, France. 29ème Journées des Economistes Français de la Santé,
december 2007.
3.7 Workshops without proceedings
2010
[1] Y. Jacquemin, B. Pellet, E. Marcon, and H. Collela Fleury. Outil d’aide à la décision de
planification de traitement en hadronthérapie. In GISEH, Clermont-Ferrand, France, 2010.
3.8 Publications without classification
2009
[1] S. Oga. Déterminants du recrutement des patients pour les techniques innovantes en radio-
thérapie : enquête dans les centres de soins universitaires. master degree work, 2009.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
Chapter 4
In silico modelling
4.1 International journals with reviewing committee
2011
[1] B. Ribba, E Watkin, M. Tod, P. Girard, E. Grenier, B. You, E. Giraudo, and G. Freyer.
A model of vascular tumour growth in mice combining longitudinal tumour size data with
histological biomarkers. Eur. J. Cancer, 47(3):479–90, February 2011.
2009
[1] B. Ribba, B. You, M. Tod, P. Girard, B. Tranchand, V. Trillet-Lenoir, and G. Freyer.
Chemotherapy may be delivered upon an integrated view of tumor dynamics. IET Syst Biol,
2009.
[2] F. Billy, B. Ribba, O. Saut, H. Morre-Throuillet, T. Colin, D. Cresch, J-P. Boissel, E. Grenier,
and J. P. Flandrois. A pharmacologically-based multiscale mathematical model of angiogenesis
and its use in investigating the efficacy of a new cancer treatment strategy. J Theor Biol (in
press), 2009.
2008
[1] B. You, P. Perrin, G. Freyer, B. Tranchand, B. Ribba, E. HÖnin, A. Ruffion, V. Trillet-
Lenoir, and P. Girard. A new approach : "psa clearance" predicts biochemical relapse risk of
patients with prostate cancer in the first month following radical prostatectomy. Fundam Clin
Pharmacol, 2008.
[2] B. You, P. Perrin, G. Freyer, A. Ruffion, B. Tranchand, E. HÖnin, P. Paparel, B. Ribba,
M. Devonec, C. Flandry, C. Fournel, M. Tod, and P. Girard. Advantages of prostate-specific
antigen (psa) clearance model over simple psa half-life computation to describe psa decrease
after prostate adenomectomy. Clin Biochem, 2008.
[3] B. You, B. Tranchand, P. Girard, C. Falandry, B. Ribba, S. Chabaud, P. J. Souquet, I. Cout-
Fortune, V. Trillet-Lenoir, M. Tod, and G. Freyer. Etoposide pharmacokinetics and survival
in small cell lung cancer patients : results of a multicentre study. Lung Cancer, 2008.
[4] B. Tranchand, C. Falandry, B. You, P. Girard, B. Ribba, M. Tod, and G. Freyer. Pharmacology
of anticancer drugs in the elderly : tools for dose adjustment. Bull Cancer, 2008.
[5] F. Bekkal-Brikci, J. Clairambault, B. Ribba, and B. Perthame. An age-and-cyclin-structured
cell population model with proliferation and quiescence for healthy and tumoral tissues. J
Math Biol, 2008.
78
4.2 International conferences with reviewing committee 79
2007
[1] Y. Kogan, B. Ribba, K. Marron, N. Dahan, V. Vainstein, and Z. Agur. Intensified doxoru-
bicinbased regimen efficacy in residual non-hodgkin’s lymphoma disease : Towards a compu-
tationally supported treatment improvement. Mathematical Modelling of Natural Phenomena,
2007.
[2] M-A. Dronne, E. Grenier, T. Dumont, M. Hommel, and J-P. Boissel. Role of astrocytes in
grey matter during stroke: A modelling approach. Brain Res., 1138, 2007.
[3] J-P. Boissel, B. Ribba, E. Grenier, G. Chapuisat, and M-A. Dronne. Progress in biophysics
and molecular biology. Modelling methodology in physiopathology, 2007.
4.2 International conferences with reviewing committee
2007
[1] J-P. Boissel, M. Cucherat, P. Nony, S. Chabaud, F. Gueyffier, J-M. Wright, M. Lièvre, and
A. Leizorovicz. New insights on the relation between untreated and treated outcomes for a
given therapy. Journal of Clinical Epidemiology, 61(3), november 2007.
4.3 Workshops without proceedings
2008
[1] B. Ribba, B. You, P. Girard, B. Tranchand, V. Trillet-Lenoir, and G. Freyer. Mathematical
modeling of cancer: a fulcrum from fundamental to clinical research. Bulletin du Cancer, (95),
2008.
[2] F. Billy, O. Saut, H. Morre-Throuillet, T. Colin, D. Bresch, B. Ribba, and E. Grenier. Mul-
tiscale mathematical model of tumoral angiogenesis and application of the efficiency of anti-
angiogenic treatments. Bulletin du Cancer, (95), 2008.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
Chapter 5
Basic physical measures and
on-line control
5.1 International journals with reviewing committee
2013
[1] X. Lojacono, M. H. Richard, E. Testa, C. Ray, N. Freud, J.M. Létang, D. Dauvergne, V. Maxim,
and R. Prost. Image reconstruction for compton camera applied to 3d prompt-gamma imaging
in ion beam therapy. IEEE Trans Nucl Sci, submitted, 2013.
2012
[1] L. Lestand, G. Montarou, P. Force, and N. Pauna. In-beam quality assurance using induced
beta + activity in hadrontherapy: a preliminary physical requirements study using geant4.
Physics in Medicine and Biology, 57:6497–6518, 2012.
[2] P. Henriquet, E. Testa, M. Chevallier, D. Dauvergne, G. Dedes, N. Freud, J. Krimmer, J.M.
Létang, C. Ray, M. H. Richard, and F. Sauli. Interaction vertex imaging (ivi) for carbon ion
therapy monitoring: a feasibility study. Physics in Medicine and Biology, 57:4655–4669, 2012.
[3] S Deng, H Mathez, D. Dauvergne, Y Zoccaratto, and GN. Lu. Front-end multi-channel pmt-
associated readout chip for hodoscope application. Nuclear Instruments and Methods in Physics
Research A, 2012.
2011
[1] F. Roellinghoff, M. H. Richard, M. Chevallier, J Constanzo, D. Dauvergne, N. Freud, P. Hen-
riquet, F. Le Foulher, J.M. Létang, G. Montarou, C. Ray, E. Testa, M. Testa, and A. H.
Walenta. Design of a compton camera for 3d prompt-γ imaging during ion beam therapy.
NIMA, 648:S20–S23, 2011.
[2] M. H. Richard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, F. Le Foulher, J.M.
Létang, G. Montarou, C. Ray, F. Roellinghoff, E. Testa, M. Testa, and A. H. Walenta. Design
guidelines for a double scattering compton camera for prompt-gamma imaging during ion beam
therapy: A monte carlo simulation study. IEEE Trans. Nucl. Sci., 58(1):87–94, February 2011.
[3] B. Braunn, M. Labalme, G. Ban, M. Chevallier, J. Colin, D. Cussol, D. Dauvergne, JM.
Fontbonne, F. Haas, A. Guertin, D. Lebhertz, F. Le Foulher, C. Pautard, C. Ray, M. Rousseau,
M. D. Salsac, L. Stuttge, E. Testa, and M. Testa. Nuclear reaction measurements of 95mev/u
80
5.2 International journals without reviewing committee 81
12c interactions on pmma for hadrontherapy. Nuclear Instruments and Methods in Physics
Research Section B, 269(22):2676–2684, 2011.
2010
[1] M. Testa, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar,
F. Le Foulher, J.M. Létang, R. Plescak, C. Ray, M. H. Richard, D. Schardt, and E. Testa.
Real-time monitoring of the bragg-peak position in ion therapy by means of single photon
detection. Radiation and Environmental Biophysics, 49(3):337–343, March 2010.
[2] M. Frandes, A. Zoglauer, V. Maxim, and R. Prost. A tracking compton-scattering imaging
system for hadron therapy monitoring. IEEE Transaction in Nuclear Sciences, 57(1):144–150,
2010.
2009
[1] V. Maxim, M. Frandes, and R. Prost. Analytical inversion of the compton transform using the
full set of available projections. Inverse Problems, 25(9):1–31, 2009.
2008
[1] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, F. Le Foulher, N. Freud, J.M. Létang, J.-C.
Poizat, C. Ray, and M. Testa. Monitoring the bragg peak location of 73 mev/u carbon ions
by means of prompt gamma-ray measurements. Applied Physics Letters 93, 093506, 2008.
2007
[1] M. Taverne, M. Boutemeur, A. Buthod, L. Guigues, P. Henriquet, J. Lollierou, M-C. Ricol,
R. Rosset-Lanchet, M. Roubin, R. Saidi, D. Sappey-Marinier, and E. Testa. Detector char-
acterization for an inline pet scanner in hadrontherapy. Nuclear Instruments and Methods
in Physics Research A, 571, February 2007. Provided by the SAO/NASA Astrophysics Data
System.
[2] S. A. Pistrui-Maximean, N. Freud, J.M. Létang, A. H. Walenta, A. Koch, G. Montarou, and
D. Babot. Simulation study of the role played by intensifying or support layers in scintillation
screens. IEEE Transactions on Nuclear Science, 54(3), 2007.
[3] S. A. Pistrui-Maximean, J.M. Létang, N. Freud, A. Koch, A. H. Walenta, G. Montarou, and
D. Babot. Measurement and monte carlo modeling of the spatial response of scintillation
screens. Nuclear Instruments and Methods in Physics Research A, 581(3), 2007.
[4] M. Boutemeur and al. Requirements towards real time quality control in hadrontherapy. Nucl.
Inst. and Method., december 2007.
5.2 International journals without reviewing committee
2009
[1] M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar, F. Le Foulher,
J.M. Létang, R. Plescak, C. Ray, D. Schardt, E. Testa, and M. Testa. Prompt gamma profile
induced by carbon ions in water in view of real time ion therapy monitoring. GSI annual
scientific report 2008, 2009.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
82 Basic physical measures and on-line control
5.3 Journals without classification
2009
[1] F. Le Foulher, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar,
J.M. Létang, R. Plescak, C. Ray, D. Schardt, E. Testa, and M. Testa. Monte carlo simulations
of prompt-gamma emission during carbon ion irradiation. IEEE Trans. Nucl. Sci. (to appear),
2009.
5.4 International conferences with reviewing committee
2012
[1] E. Testa, D. Dauvergne, M. De Rydt, G. Dedes, N. Freud, J. Krimmer, J.M. Létang, M. Pinto,
C. Ray, and V. Reithinger. Online monitoring of the dose during ion therapy by means of
prompt secondary radiations. In Conference Swift Heavy Ions in Matter, Kyoto, 24-27 octobre
2012, October 2012.
[2] E. Testa, L. Balleyguier, J. Baudot, S. Brons, L. Caponetto, M. Dahoumane, D. Dauvergne,
S Deng, R. Della-Negra, M. De Rydt, G. Dedes, N. Freud, J. Krimmer, J.M. Létang, H Mathez,
K. Parodi, M. Pinto, C. Ray, M. H. Richard, V. Reithinger, I. Rinaldi, F. Roellinghoff, M. Win-
ter, and Y Zoccaratto. Real-time online monitoring of the ion range by means of prompt
secondary radiations. In Nuclear Science Symposium and Medical Imaging Conference. IEEE,
2012.
[3] F. Roellinghoff, A. Benilov, D. Dauvergne, G. Dedes, N. Freud, J. Krimmer, J.M. Létang,
D. Prieels, C. Ray, M. H. Richard, J. Smeets, F. Stichelbaut, and E. Testa. Real-time pro-
ton beam range monitoring by means of prompt-gamma detection with a collimated camera.
In ICTR-PHE, International Conference on Translational Research in Radio-Oncology and
Physics for Health in Europe. CERN, February 2012.
[4] V. Reithinger, C. Ray, J. Baudot, S. Brons, D. Dauvergne, M. De Rydt, G. Dedes, P. Henriquet,
J. Krimmer, K. Parodi, I. Rinaldi, E. Testa, and M. Winter. Proton interaction vertex imag-
ing with silicon-pixel cmos telescopes for carbon therapy quality control. In Nuclear Science
Symposium and Medical Imaging Conference, IEEE, 2012, October 2012.
[5] M. De Rydt, S Deng, D. Dauvergne, G. Dedes, N. Freud, J. Krimmer, J.M. Létang, GN.
Lu, H Mathez, K. Parodi, M. Pinto, C. Ray, V. Reithinger, M. H. Richard, I. Rinaldi,
F. Roellinghoff, E. Testa, and Y Zoccaratto. Real-time monitoring during ion therapy: Devel-
opment and evaluation of a beam hodoscope and its dedicated electronics. In Nuclear Science
Symposium and Medical Imaging Conference. IEEE, 2012.
[6] G. Dedes, D. Dauvergne, M. De Rydt, N. Freud, J. Krimmer, J.M. Létang, M. Pinto, C. Ray,
and E. Testa. Monte carlo nuclear models evaluation and improvements for real-time prompt
gamma-ray monitoring in proton and carbon therapy. In Nuclear Science Symposium and
Medical Imaging Conference. IEEE, 2012.
[7] G. Dedes, D. Dauvergne, M. De Rydt, N. Freud, J. Krimmer, J.M. Létang, M. Pinto, C. Ray,
M. H. Richard, F. Roellinghoff, and E. Testa. Real-time prompt gamma ray monitoring for
proton and carbon therapy: Monte carlo nuclear models evaluation and improvements. In
International Conference on Translational Research in Radio-Oncology – Physics for Health in
Europe, February 2012.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
5.4 International conferences with reviewing committee 83
2011
[1] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, G. Dedes, P. Henriquet, J. Krimmer, C. Ray,
N. Freud, J.M. Létang, R. Plescak, and D. Schardt. Interaction vertex imaging (ivi): a new
method of real-time control imaging for carbon ion therapy. In 50th International PTCOG
meeting (Particle Therapy Co-Operative Group), May 2011.
[2] X. Lojacono, V. Maxim, A. Zoglauer, F. Peyrin, and R. Prost. A filtered backprojection
reconstruction algorithm for compton camera. In Proceedings of the International conference
Fully3D 2011, Postdam, pages 96–99, January 2011.
2010
[1] P. Henriquet, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, S. Iliescu, S. Karkar,
F. Le Foulher, J.M. Létang, C. Ray, F. Sauli, D. Schardt, E. Testa, and M. Testa. Charged
particle imaging for real-time control during ion therapy. International workshop Physics For
health in Europe, CERN, January 2010, January 2010.
2009
[1] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, F. Le Foulher, N. Freud, J.M. Létang,
J.-C. Poizat, C. Ray, and M. Testa. Dose profile monitoring with carbon ions by means of
prompt-gamma measurements. Nuclear Instruments and Methods in Physics Research B, 267,
2009. available online at http://hal.archives-ouvertes.fr/hal-00283936/fr/.
[2] M. H. Richard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, F. Le Foulher, J.M.
Létang, G. Montarou, C. Ray, F. Roellinghoff, E. Testa, M. Testa, and A. H. Walenta. Design
study of a compton camera for prompt γ imaging during ion beam therapy. In IEEE Nuclear
Science Symposium, Medical Imaging Conference, October 2009.
[3] B. Braunn, M. Labalme, G. Ban, J. Colin, D. Cussol, JM. Fontbonne, F. R. Lecolley, C. Por-
tard, F. Haas, D. Lebhertz, M Rousseau, L. Stuttge, M. Chevallier, D. Dauvergne, F. Le Foul-
her, C. Ray, E. Testa, M. Testa, and M. D. Salsac. 12c nuclear reaction measurements for
hadrontherapy. In 12th International Conference on Nuclear Reaction Mechanisms, pages
531–538, June 2009.
[4] M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar, F. Le Foulher,
J.M. Létang, R. Plescak, C. Ray, D. Schardt, E. Testa, and M. Testa. Prompt-gamma-ray mon-
itoring during carbon ion therapy: comparison between measurements and geant4 simulations.
In First International Conference on Advancements in Nuclear Instrumentation, Measurement
Methods and their Applications (ANIMMA), june 2009.
2008
[1] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, F. Le Foulher, N. Freud, J.M. Létang,
C. Ray, and M. Testa. Detection of prompt gamma rays to monitor hadrontherapy. In IEEE
Nuclear Science Symposium, Medical Imaging Conference, October 2008.
[2] N. Freud, M. Bajard, M. Chevallier, D. Dauvergne, F. Le Foulher, J.M. Létang, C. Ray,
E. Testa, and M. Testa. Monitoring the bragg peak location by means of prompt-gamma mea-
surements. In European Science Foundation Exploratory Workshop "Advanced Instrumentation
for Cancer Diagnosis and Treatment", Oxford, UK, 23-26 Sept., 2008.
Rhône-Alpes Research Program on Hadrontherapy for ETOILE – June 16, 2013
84 Basic physical measures and on-line control
5.5 National conferences with reviewing committee
2013
[1] E. Hilaire, C. Robert, X. Lojacono, C. Lartizien, I. Buvat, and V. Maxim. Imagerie caméra
compton en protonthérapie : simulations gate et reconstruction d’images. page submitted.
XXIVe Colloque GRETSI - Traitement du Signal et des Images (GRETSI’13), September
2013.
2012
[1] X. Lojacono, E. Hilaire, R. Prasad, V. Maxim, and R. Prost. Algorithmes lm-mlem pour la
reconstruction d’images pour caméra compton. In Nouvelles méthodologies en imagerie du
vivant (IMAGIV), pages 9385–9385, December 2012.
2009
[1] N. Freud, M. Chevallier, D. Dauvergne, P. Henriquet, F. Le Foulher, S. Karkar, J.M. Létang,
G. Montarou, C. Ray, M. H. Richard, E. Testa, M. Testa, and A. H. Walenta. Nouvelles
méthodes d’imagerie en ligne pour le contrôle de l’irradiation en hadronthérapie. In 48èmes
Journées Scientifiques de la Société Française de Physique Médicale : Innovations et bénéfices
thérapeutiques : quelles limites ? Montauban, 3-5 juin 2009, 2009. Exposé invité.
5.6 Invited conferences
2012
[1] V. Maxim. Reconstruction tomographique pour l’imagerie spect avec une caméra compton. In
XIème Colloque Franco-Roumain de Mathématiques Appliquées, pages 74–74, August 2012.
2011
[1] E. Testa, D. Dauvergne, G. Dedes, N. Freud, J. Krimmer, J.M. Létang, V. Maxim, G. Mon-
tarou, C. Ray, M. H. Richard, and F. Roellinghoff. Imaging system for qa: present status and
future prospects. In Proceedings of NIRS-ETOILE 2nd Joint Symposium on Carbon Ion Ther-
apy, volume NIRS-M-243, pages 134–142, November 2011. Invited talk at the NIRS-ETOILE
2nd Joint Symposium, Lyon, November 25-27, 2011.
[2] J.M. Létang. Real-time monitoring of ion ranges. In 2nd Workshop on Hadron Beam Therapy
of Cancer, May 2011. Invited talk.
[3] D. Dauvergne. Online control of the dose during ion-therapy by means of prompt radiations,
April 2011. exposé invité, 3rd Workshop of the DFM/ISEC, Coimbra, Portugal, April 27,
2011.
[4] D. Dauvergne. Contrôle en ligne de l’hadronthérapie. In Rencontre MELUSYN - ETOILE,
Lyon, 8 février 2011, February 2011. exposé invité.
2009
[1] D. Dauvergne, M. Battaglia, G. Montarou, and M. Testa. New methods of real-time control
imaging for ion therapy. In H. Tsujii and J. Balosso, editors, NIRS-ETOILE Joint Sym-
posium 2009 on Carbon Ion Therapy, volume NIRS - M - 218„ 2009. Available online at
http://hal.in2p3.fr/in2p3-00363382/fr/.
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[1] M. H. Richard. Design Study of a Compton Camera for Prompt-Gamma Imaging during Ion
Therapy. PhD thesis, Université Claude Bernard Lyon 1, September 2012.
[2] L. Lestand. Etude de la mesure en ligne de l’activité beta+ induite lors des traitements
d’hadronthérapie, en vue de leur contrôle balistique. Thesis, Université de Clermont, September
2012.
[3] S Deng. Etude de conception d’ASICs de lecture et d’étiquetage en temps associés à des pho-
tomultiplicateurs pour un hodoscope de faisceau en hadronthérapie. Thesis, Université Claude
Bernard Lyon 1, November 2012.
2011
[1] P. Henriquet. Etude de l’émission de particules chargées secondaires dans l’optique d’un mon-
itorage faisceau et de la dosimétrie en ligne en hadronthérapie. Thèse, Université Lyon 1, July
2011.
2010
[1] M. Testa. Physical measurements for ion range verification in charged particle therapy. PhD
thesis, Université Lyon 1 Institut de Physique Nucléaire de Lyon, 2010.
[2] F. Le Foulher. Simulations Monte Carlo et mesures de l’émission de gamma prompts appliquées
au contrôle en ligne en hadronthérapie. PhD thesis, Ecole doctorale PHAST, October 2010.
[3] M. Frandes. Gamma-ray detection and Compton camera image reconstruction with application
to hadron therapy. PhD thesis, Ecole Doctorale Electronique, Electrotechnique, atomatique de
Lyon, September 2010.
2009
[1] C. Ray. Canalisation d’ions lourds dans les solides et applications à l’hadronthérapie. HDR,
IPNL-Lyon1, December 2009. Mémoire pour l’obtention de l’habilitation à diriger des
recherches, no d’ordre : 47-2009.
2008
[1] M-C. Ricol. Contribution à l’étude des processus nucléaires intervenant en hadronthérapie et
de leur impact à la délocalisation du dépôt de dose. PhD thesis, Université Lyon 1, november
2008.
5.8 Posters
2012
[1] E. Testa, L. Balleyguier, J. Baudot, S. Brons, L. Caponetto, M. Dahoumane, D. Dauvergne,
R. Della-Negra, S Deng, M. De Rydt, G. Dedes, N. Freud, J. Krimmer, J.M. Létang, H Mathez,
K. Parodi, M. Pinto, C. Ray, M. H. Richard, V. Reithinger, I. Rinaldi, F. Roellinghoff, M. Win-
ter, and Y Zoccaratto. Real-time monitoring of the ion range by means of prompt-secondary
radiation. In Nouvelles Méthodologies en imagerie du vivant, Lyon, 11-13 décembre 2012, page
9585, December 2012.
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2011
[1] M. H. Richard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, J. Krimmer, J.M. Létang,
C. Ray, F. Roellinghoff, E. Testa, and A. H. Walenta. Design guidelines for a compton camera
for prompt-gamma imaging during ion beam therapy. poster at the International conference
NDIP, Lyon, 4-7 July, 2011, July 2011.
[2] M. H. Richard, D. Dauvergne, M. Dahoumane, M. De Rydt, G. Dedes, N. Freud, J. Krimmer,
J.M. Létang, X. Lojacono, V. Maxim, G. Montarou, C. Ray, F. Roellinghoff, E. Testa, and
A. H. Walenta. Design of a compton camera for hadrontherapy on-line control using geant4.
In IEEE-NSS-MIC conference records, October 2011. IEEE NSS MIC conference, Valencia,
23-29 October 2011.
[3] X. Lojacono, V. Maxim, and R. Prost. Calcul de la matrice des probabilités de transfert en
imagerie compton 3d. In Proceedings of GRETSI, pages 1–4, 2011.
[4] X. Lojacono, M. H. Richard, C. Ray, D. Dauvergne, E. Testa, N. Freud, J.M. Létang, V. Maxim,
and R. Prost. Image reconstruction for compton camera applied to 3d prompt gamma imaging
during ion beam therapy. In IEEE-NSS-MIC conference records, October 2011. Conference
records IEEE-NSS-MIC, Valencia, 23-29 October, 2011.
[5] S Deng, H Mathez, D. Dauvergne, and GN. Lu. 16-channel readout ASIC for a hodoscope.
In Conference Internationale NDIP, Lyon, 4-7 Juillet 2011, 2011. Conference Internationale
NDIP, Lyon, 4-7 Juillet 2011.
2010
[1] M. Testa, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, S. Karkar, F. Le Foulher, J.M.
Létang, R. Plescak, C. Ray, M. H. Richard, F. Roellinghoff, D. Schardt, and E. Testa. Real
time monitoring of the bragg-peak position in ion therapy by means of single photon detection.
International workshop Physics for Health in Europe, CERN, 2-4 Février 2010, February 2010.
[2] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, S Deng, N. Freud, F. Le Foulher, J.M.
Létang, H Mathez, C. Ray, M. H. Richard, F. Roellinghoff, M. Testa, and Y Zoccaratto.
Monitoring the bragg peak location during hadrontherapy by means of a time-of-flight camera.
International Workshop On Radiation Imaging Detectors, Cambridge, July 2010.
[3] M. H. Richard, M. Chevallier, D. Dauvergne, N. Freud, S. Karkar, F. Le Foulher, J.M. Létang,
C. Ray, F. Roellinghoff, E. Testa, M. Testa, and A. H. Walenta. Design guidelines for a compton
camera for prompt-gamma imaging during ion beam. International workshop Physics for health
in Europe, CERN, 2-4 Février 2010, February 2010.
[4] F. Le Foulher, M. Chevallier, D. Dauvergne, N. Freud, S. Karkar, L. Lestand, J.M. Létang,
C. Ray, E. Testa, and M. Testa. Prompt-gamma-ray monitoring during carbon ion therapy:
comparison between measurements and geant4 simulations. International workshop Physics
for Health in Europe, February 2010.
[5] P. Henriquet, M. Chevallier, D. Dauvergne, N. Freud, S. Iliescu, F. Le Foulher, J.M. Létang,
C. Ray, F. Sauli, D. Schardt, E. Testa, and M. Testa. Charged particle imaging for real-time
control during ion therapy. international Workshop Physics for Health in Europe, CERN, 2-4
February 2010, February 2010.
2009
[1] P. Henriquet, M. Battaglia, M. Chevallier, and F. Sauli. Interaction vertex imaging for the
determination of beam interaction position in carbon ion hadrontherapy. In International
Workshop on Hadron Beam Therapy of cancer, Erice, Italie, 24 avril - 1er mai 2009, 2009.
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[2] M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar, F. Le Foulher,
J.M. Létang, C. Ray, D. Schardt, E. Testa, and M. Testa. Monitoring the bragg peak location
by means of prompt gamma measurements. In International Workshop on Hadron Beam
Therapy of cancer, Erice, Italie, 24 avril - 1er mai 2009, 2009.
2008
[1] M. Frandes, A. Zoglauer, V. Maxim, and R. Prost. Compton based imaging system for hadron
therapy monitoring. pages 4853–4859, Dresden, Germany, October 2008. IEEE Nuclear Science
Symposium and Medical Imaging Conference.
[2] M. Boutemeur and al. Requirements towards real time and in-situ dose delivery control in
hadrontherapy. Ion, Beams in Biology and medicine, Fachverbend für Strahlenschutz e. V.,
2008.
5.9 Workshops without proceedings
2007
[1] M. Boutemeur and al. Mechatronics for real time quality control in hadrontherapy. Tallin,
june 2007. 8th International workshop on Research and Education in Mecahtronocs.
5.10 Workshops without proceedings
2011
[1] C. Ray. Online control of the dose. exposé invité, November 2011. France-Hadron Workshop,
Lyon, 28-29 Novembre 2011.
5.11 Patents
2009
[1] E. Testa, C. Ray, and N. Freud. Procédé et dispositif de mesure en temps réel d’une dose locale
lors du bombardement d’une cible par des hadrons au moyens des gammas prompts. Brevet
IPNL n° FRFR 08 53038, soumis en demande d’extension internationale PCT/FR2009/050848,
2009.
5.12 Publications without classification
2012
[1] D. Dauvergne, W. Enghardt, A. Müller, and J. Smeets. Compilation of gamma-ray yield data.
ENVISION report D3.1, Février 2012., February 2012.
5.13 Oral communications
2012
[1] J. Krimmer. Progress in using prompt gammas for ion range monitoring during hadrontherapy.
In International Conference on Translational Research in Radio-Oncology – Physics for Health
in Europe, Geneva, Switzerland, 2012, March 2012.
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[2] S Deng, D. Dauvergne, GN. Lu, H Mathez, and Y Zoccaratto. Very fast front end asic
associated with multi anode pmt for a scintillating–fibre beam hodoscope. In TWEPP 2012
Topical Workshop on Electronics for Particle Physics, Oxford, 11-13 September 2012, page
2013 JINST 8 C01047. IOP PUBLISHING FOR SISSA MEDIALAB, September 2012.
[3] M. Dahoumane, D. Dauvergne, J. Krimmer, H Mathez, C. Ray, and E. Testa. A low noise
and high dynamic charge sensitive amplifier-shaper associated with silicon strip detector for
compton camera in hadrontherapy. In Nuclear Science Symposium and Medical Imaging Con-
ference, IEEE, 2012, 2012. 2012 Nuclear Science Symposium, Medical Imaging Conference and
Workshop on Room-Temperature Semi- conductor X-Ray and Gamma-Ray Detectors (2012
IEEE NSS/MIC/RTSD), États-Unis (2012).
2011
[1] E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, G. Dedes, P. Henriquet, J. Krimmer,
C. Ray, N. Freud, J.M. Létang, R. Plescak, and D. Schardt. Interaction vertex imaging (ivi):.
50th International PTCOG meeting (Particle Therapy Co-Operative Group), Philadelphia,
US, May 2011. oral communication.
2010
[1] F. Roellinghoff, M. Chevallier, J Constanzo, D. Dauvergne, N. Freud, P. Henriquet, F. Le Foul-
her, J.M. Létang, G. Montarou, C. Ray, M. H. Richard, E. Testa, M. Testa, and A. H. Walenta.
Design of a compton camera for 3d prompt gamma imaging during ion beam therapy: a geant4
simulation study. International conference Imaging 2010 - Stokholm, 2010.
[2] C. Ray, M. Bajard, M. Chevallier, J Constanzo, D. Dauvergne, N. Freud, P. Henriquet,
S. Karkar, F. Le Foulher, J.M. Létang, R. Plescak, M. H. Richard, F. Roellinghoff, D. Schardt,
E. Testa, and M. Testa. Dose monitoring in ion-therapy by means of prompt radiation.
PTCOG, June 2010.
[3] S Deng, H Mathez, D. Dauvergne, and Guo Neng Lu. 16-channel readout asic for a hodoscope.
In Electronics, Circuits, and Systems (ICECS), 2010 17th IEEE International Conference on,
pages 33–36. IEEE, December 2010. International conference ICECS, Athens, 12-15 December
2010.
2009
[1] M. Testa, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Henriquet, S. Karkar,
F. Le Foulher, J.M. Létang, R. Plescak, C. Ray, D. Schardt, and E. Testa. A novel tech-
nique for real time monitoring of the bragg-peak position in ion therapy by means of single
photons detection. In International Conference - Heavy Ions in Therapy and Space Symposium
2009, 12th Workshop on Ion Beams in Biology and Medicine (IBIBAM), Cologne, 6-10 juillet
2009, 2009.
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2013
[1] W. Rima, Sancey L, M.-T. Aloy, E. Armandy, GB. Alcantara, Epicier T, Malchère A, Joly-
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I, Pourchez J, Cottier M, S. Roux, C. Rodriguez-Lafrasse, and P. Perriat. Internalization
pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles. Biomaterials.,
34(1):181–195, January 2013.
[2] V Kepenekian, M.-T. Aloy, N. Magné, G. Passot, E. Armandy, E. Decullier, A. Sayag-Beaujard,
FN. Gilly, O. Glehen, and C. Rodriguez-Lafrasse. Impact of hyperthermic intraperitoneal
chemotherapy on hsp27 protein expression in serum of patients with peritoneal carcinomatosis.
Cell stress and Chaperon in submission, 2013.
[3] S Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, G. Alphonse, M. Beuve, C. Mal-
leval, J. Honnorat, T. Slatter, N. Hung, J. Royds, C. Rodriguez-Lafrasse, and D. Poncet.
Telomere profiling: Toward glioblastoma personalized medicine. Mol Neurobiol., 47(1):64–76,
2013.
[4] G Bertrand, M. Maalouf, A. Boivin, P. Battiston-Montagne, M. Beuve, A Levy, P. Jalade,
C. Fournier, D. Ardail, G. Alphonse, and C. Rodriguez-Lafrasse. Targeting head and neck
cancer stem cells to overcome resistance to photon and carbon ion radiation. Submitted in
Stem Cell Reviews and Reports, 2013.
2012
[1] C. Montcharmont, A Levy, M. Gilormini, G Bertrand, C. Chargari, G. Alphonse, D. Ardail,
C. Rodriguez-Lafrasse, and N. Magné. Targeting a cornerstone of radiation resistance: cancer
stem cell. Cancer Lett. 2012, 322(2):139–147, September 2012.
[2] M. Hanot, A. Boivin, C. Malesys, M. Beuve, A. Colliaux, N. Foray, T. Douki, D. Ardail, and
C. Rodriguez-Lafrasse. Glutathione depletion and carbon ion radiation potentiates clustered
dna lesions, cell death and prevents chromosomal changes in cancer cells progeny. PLoS ONE,
7(11):e44367, 2012.
[3] N. Foray, C. Colin, and M. Bourguignon. 100 years of individual radiosensitivity : how we
have forgotten the evidence ? Radiology, in presse, 2012.
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[4] G. Alphonse, M. Maalouf, P. Battiston-Montagne, D. Ardail, M. Beuve, R. Rousson,
G. Taucher-Scholz, C. Fournier, and C. Rodriguez-Lafrasse. P53-independent early and late
apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irra-
diation. BMC Cancer, Submitted, 2012.
2011
[1] I. Szumiel and N. Foray. Chromatin acetylation, β-amyloid precursor protein and its binding
partner fe65 in dna double strand break repair. Acta Biochim. Pol., 58(1):11–8, 2011. PMID:
21403922.
[2] P. Mowat, A. Mignot, W. Rima, F. Lux, O. Tillement, C. Roulin, M. Dutreix, D. Bechet,
S. Huger, Humbert. L, Barberi-Heyob. M, M.-T. Aloy, E. Armandy, C. Rodriguez-Lafrasse,
G. le Duc, S. Roux, and P. Perriat. In vitro radiosensitizing effects of ultrasmall gadolinium
based particles on tumour cells. J Nanosci Nanotechnol, Sep;11(9):7833–7839, 2011.
[3] M. Maalouf, M. Durante, and N. Foray. Biological effects of space radiation on human cells:
history, advances and outcomes. J Radiat. Res., 52(2), 2011. PMID: 21436608.
[4] A. Granzotto, C. Devic, M. Viau, M. Maalouf, A. Joubert, C. Massart, C. Thomas, and
N. Foray. Individual susceptibility to radiosensitivity and to genomic instability: Its impact
on low-dose phenomena. Health Physics, 100(3):282, March 2011.
[5] J. Gastaldo, Z. Bencokova, C. Massart, A. Joubert, J. Balosso, A.M. Charvet, and N. Foray.
Specific molecular and cellular events induced by irradiated x-ray photoactivatable drugs raise
the problem of co-toxicities: particular consequences for anti-cancer synchrotron therapy. J
Synchrotron Radiat., 18(Pt3):456–63, May 2011. PMID: 21525655.
[6] N. Foray. Comment to the paper "efficacy of intracerebral delivery of cisplatin in combination
with photon irradiation for treatment of brain tumors" from rousseau et al. J Neurooncol. in
press., 101(1):161–3 author reply 165–7, January 2011. PMID: 20495850f.
[7] C. Colin, A. Granzotto, C. Devic, C. Massart, M. Viau, G. Vogin, M. Maalouf, A. Joubert,
and N. Foray. Mre11 and h2ax biomarkers in the response to low-dose exposure: balance
between individual susceptibility to radiosensitivity and to genomic instability. International
Journal of Low Radiation, 8(2):96–106, 2011.
[8] C. Colin and N. Foray. Dna damage induced by mammography in high family risk patients:
Only one single view in screening. Breast, December 2011. PMID:22212747.
[9] C. Colin, C. Devic, A. Noel, M. Rabilloud, MT. Zabot, S. Pinet-Isaac, S. Giraud, B. Riche,
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mammographic screening procedures in human mammary epithelial cells. International of
radiation biology, 87(11):1103–1112, 2011.
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D. Ardail. Transient alteration of cellular redox buffering before irradiation triggers apoptosis
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173(6):856–858, 2010.
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and N. Foray. Radiation response of the neurofibromatosis type i syndrome: Impact of the
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2007
[1] C. Thomas, B. Fertil, and N. Foray. Very low-dose hyper-radiosensitivity: impact for radio-
therapy of micrometastase. Cancer Radiothérapie, 1, 2007.
6.4 International conferences with reviewing committee
2011
[1] A. Colliaux, B. Gervais, C. Rodriguez-Lafrasse, and M. Beuve. O2 and glutathione effects on
water radiolysis : a simulation study. Journal of physics : conference serie, 2011.
[2] G. Alphonse, M. Hanot, A. Boivin, G Bertrand, M. Maalouf, M. Beuve, C. Fournier, D. Ardail,
and C. Rodriguez-Lafrasse. Targeting the main causes of recurrence in head and neck squamous
cell carcinoma to overcome resistance to carbon ion radiation. 14th International Congress of
Radiation Research, August 2011.
2010
[1] M. Hanot, C. Malesys, A. Boivin, N. Foray, D. Ardail, and C. Rodriguez-Lafrasse. Modula-
tion of ros scavenging system as vector of radiosensitization of tumors combined to x-rays and
carbon-ion. European Radiation Research Society (ERRS), September 2010. Young investiga-
tor awarded.
[2] S Ferrandon, P. Saultier, P. Battiston-Montagne, C. Malesys, M. Beuve, A. Colliaux,
C. Rodriguez-Lafrasse, and D. Poncet. Determination of the telomeric status as a radiotherapy
response predictive in glioma. 2010.
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[3] A. Boivin, M. Hanot, M. Maalouf, G. Alphonse, C. Malesys, M. Beuve, D. Ardail, and
C. Rodriguez-Lafrasse. Implication of cellular redox buffering in hnscc tumor escape after
x-ray or carbon ion therapy. 13th Workshop of Ion Beam in Biology and Medecine, 2010.
[4] A. Boivin, D. Ardail, and C. Rodriguez-Lafrasse. Transient lowering of cellular reduced glu-
tathione content before irradiation triggers apoptosis in head and neck carcinoma stem and
non-stem cells : an in vitro and in vivo study. 4th Berder Meeting Biology of ionizing radiation,
September 2010.
6.5 International conferences without reviewing committee
2007
[1] M. Beuve, A. Colliaux, and E. Testa. Theoritical limits of lem. Workshop on Ion Beams in
Biology and Medicine: 11th Workshop of Heavy Charged Particle in Biology and Medicine
Heidelberg, Germany, september 2007.
6.6 National conferences with reviewing committee
2011
[1] M. Hanot, C. Malesys, D. Ardail, and C. Rodriguez-Lafrasse. From dna lesions to chromosomal
aberrations: a study to improve outcomes towards tumor recurrence of hadrontherapy using
carbon ions compared to x-rays. In BULLETIN DU CANCER, volume 98, page S103, March
2011.
[2] M. Hanot, C. Malesys, D. Ardail, and C. Rodriguez-Lafrasse. Glutathion et radioresistance :
Les effets biologiques différentiels en radiothérapie conventionnelle et hadronthérapie. 10ème
Colloque International de Radiobiologie Fondamentale et Appliquée, September 2011.
[3] G Bertrand, M. Maalouf, P. Battiston-Montagne, M. Beuve, C. Fournier, G. Alphonse, and
C. Rodriguez-Lafrasse. Ciblage des cellules souches cancereuses, une etape essentielle pour
augmenter l’efficacite de la radiotherapie dans les cancers epidermoïdes de la tete et du cou.
10ème CIRFA, September 2011.
[4] G. Alphonse, NH Hau, P. Heudel, P. Battiston-Montagne, S Ferrandon, D. Poncet, and
C. Rodriguez-Lafrasse. Marqueurs prédictifs de radiosensibilité de lignées de gliomes humains
traitées par radio ou hadron-thérapie. Journée Scientifique du CLARA, 2011.
2010
[1] M. Hanot, C. Malesys, A. Boivin, T. Douki, N. Foray, D. Ardail, and C. Rodriguez-Lafrasse.
Ciblage thérapeutique de tumeurs radiorésistantes par modulation du statut redox endogène.
effets différentiels en radiothérapie x et hadronthérapie. Bul Cancer, 97(80):S80, 2010. 5èmes
Journées Scientifiques du CLARA, Villeurbanne (France), 30-31 mars 2010. Bul Cancer.2010
:97(80)S80.
[2] M. Hanot, C. Malesys, A. Boivin, D. Ardail, and C. Rodriguez-Lafrasse. Modulation of ros
scavenging system combined to x-rays or carbon ions s a vector of tumor radiosensitization.
International Workshop on radiosensitization, 2010.
[3] M. Hanot, C. Malesys, A. Boivin, N. Foray, D. Ardail, and C. Rodriguez-Lafrasse. Modula-
tion du statut redox endogène comme vecteur de radiosensibilisation des tumours combine à
l’irradiation par rayon x et ions carbone. Journées d’Etudes de la Chimie sous Rayonnement
(JECR), May 2010.
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[4] S Ferrandon, P. Saultier, C. Malesys, C. Rodriguez-Lafrasse, and D. Poncet. Détermina-
tion du statut télomérique comme marqueur prédictif pour l’orientation des patients vers
l’hadronthérapie. Bul Cancer., 97(80):S77, 2010. 5èmes Journées Scientifiques du CLARA,
Villeurbanne (France), 30-31 mars 2010. Bul Cancer. 2010 :97(80)S77.
[5] A. Boivin, C. Malesys, C. Colin, O. Chapet, C. Rodriguez-Lafrasse, and D. Ardail. Sen-
sibilisation de cellules souches cancéreuses issues de carcinomes orl à la radiothérapie après
modulation de leur statut redox. Bul Cancer, 97(80):S67, 2010.
2009
[1] C. Rodriguez-Lafrasse, M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Col-
liaux, M. Bajard, C. Fournier, and G. Taucher-Scholz. Echappement tumoral en réponse à
l’irradiation par photons et ions carbone des carcinomes épidermoïdes de la tête et du cou.
9ème Colloque International de Radiobiologie Fondamentale et Appliquée (SIRLAF), AN-
NECY (France), September 2009.
[2] D. Poncet, P. Saultier, S Ferrandon, and C. Rodriguez-Lafrasse. Radiorésistance des glioblas-
tomes et statut télomérique. 9ème Colloque International de Radiobiologie Fondamentale et
Appliquée (SIRLAF), ANNECY (France), September 2009.
[3] M. Hanot, C. Malesys, A. Boivin, C. Colin, T. Douki, N. Foray, D. Ardail, and C. Rodriguez-
Lafrasse. Radiosensibilisation par modulation du statut redox intracellulaire : caractérisation
des lésions et des processus de réparation de l’adn impliqués en réponse à l’irradiation par
rayons x et ions carbone. 9ème Colloque International de Radiobiologie Fondamentale et
Appliquée (SIRLAF), ANNECY (France), September 2009.
[4] E. Hadchity, M.-T. Aloy, C Paulin, E. Armandy, A.P. Arrigo, A. Sabri, C. Diaz-Latoud,
and C. Rodriguez-Lafrasse. Protéine de choc thermique hsp27 : un rôle majeur dans la tu-
morigénicité et la radiorésistance des carcinomes épidermoïdes orl. 9ème Colloque International
de Radiobiologie Fondamentale et Appliquée (SIRLAF), ANNECY (France), September 2009.
[5] D. Dabli, G. Montarou, M. Beuve, and C. Rodriguez-Lafrasse. Application de la micro-
dosimétrie pour le calcul de la survie cellulaire pour des cellules irradiées avec des particules à
haut tel. 9ème Colloque International de Radiobiologie Fondamentale et Appliquée (SIRLAF),
ANNECY (France), September 2009.
[6] A. Boivin, C. Malesys, M. Maalouf, C. Colin, O. Chapet, C. Rodriguez-Lafrasse, and D. Ardail.
Sensibilisation aux rayonnements ionisants de cellules de carcinomes orl par déplétion transi-
toire en glutathion. 9ème Colloque International de Radiobiologie Fondamentale et Appliquée
(SIRLAF), ANNECY (France), September 2009.
[7] G. Alphonse, NH Hau, S Ferrandon, P. Battiston-Montagne, D. Poncet, and C. Rodriguez-
Lafrasse. Caractérisation de la réponse cellulaire et moléculaire de lignées de gliomes humains
irradiées par des photons ou des ions carbone. 11éme CIRFA, September 2009.
2007
[1] C. Rodriguez-Lafrasse. Les systèmes oxydant/anti-oxydant, pro/anti-apoptotique : deux déter-
minants essentiels de la réponse tumorale à l’irradiation. 8ème Colloque International Radio-
biologie Fondamentale Appliquée, La Londe les Maures, France, september 2007.
[2] M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Colliaux, A. Demeyer, M. Ba-
jard, C. Fournier, G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Caractérisation des processus
de mort activés en réponse à l’irradiation par ions carbone de carcinomes épidermoïdes tête et
cou. 8ème Colloque International de Radiobiologie Fondamentale et Appliquée. La Londe Les
Maures, (SIRLAF), september 2007.
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[3] D. Ardail, M. Maalouf, E. Armandy, and C. Rodriguez-Lafrasse. Libération du céramide en
réponse à l’irradiation : un mécanisme complexe et séquentiel. 8ème Colloque International
de Radiobiologie Fondamentale et Appliquée, La Londe les Maures, France, september 2007.
6.7 National conferences without reviewing committee
2011
[1] C. Rodriguez-Lafrasse, M. Hanot, A. Boivin, C. Malesys, and D. Ardail. Signature spécifique
de la réponse aux ions carbone ? MELUSYNE, 2011.
6.8 Invited conferences
2012
[1] M. Beuve, L. Chollier, and E. Testa. Toward the nanox model. MMND and IPCT Workshop,
Wollongong 6-9 Dec, 2012, (Australia), November 2012.
2011
[1] M. Beuve, A. Colliaux, C. Rodriguez-Lafrasse, and B. Gervais. O2 and glutathione effects on
water radiolysis by fast ions. 1ST NANO-IBCT CONFERENCE 2011, October 2011.
2010
[1] M. Beuve, A. Colliaux, B. Gervais, and C. Rodriguez-Lafrasse. Simulation of ho2/o2- pro-
duction by water radiolysis: influence of various parameters. COST Chemistry CM0603 Free
Radicals in Chemical Biology - MELUSYN Joint Meeting, March 2010.
[2] M. Beuve and E. Testa. Hadronthérapie : vers une dosimétrie clinique. Saint-François, Guade-
loupe, December 2010. Journées de réflexion CNRS/IN2P3 des applications sociétales de la
physique nucléaire : energie et santé.
[3] M. Beuve. Modélisation des effets radiobiologiques : échelles d’espace et de temps. Journée
thématique MELUSYN - SOLEIL, January 2010.
2009
[1] C. Rodriguez-Lafrasse. Molecular mechanisms of tumor cell radioresistance in head and neck
squamous cell carcinomas. In H. Tsujii and J. Balosso, editors, NIRS-ETOILE Joint Sympo-
sium 2009 on Carbon Ion Therapy, volume NIRS-M-218, 2009.
[2] Modeling of RBE: Difficulties and Needs for a New Model. In H. Tsujii and J. Balosso, editors,
NIRS-ETOILE Joint Symposium on Carbon Ion Therapy, january 2009.
2008
[1] M. Beuve. Statistical effects of dose deposition in track-structure modelling of radiobiology
efficiency. 7th International Symposium on Swift Heavy Ions in Matter (SHIM 2008), June
2008.
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2007
[1] M. Beuve, A. Colliaux, D. Dabli, G. Montarou, and E. Testa. Modèles microdosimétriques et
modèles de trace. 8ème Colloque International de Radiobiologie Fondamentale et Appliquée,
La Londe les Maures, France, september 2007.
6.9 PhD / HdR
2013
[1] S Ferrandon. Evaluation du statut télomérique : vers une thérapeutique personnalisée du
glioblastome. Application à l’hadronthérapie par ions carbone. PhD thesis, EDISS, January
2013.
2012
[1] L. Chollier. Modélisation biophysique de l’interaction des ions de hautes énergies avec la
matière vivante : application au traitement des tumeurs par hadronthérapie. PhD thesis,
UCBL, Villeurbanne, October 2012.
2011
[1] A. Boivin. Implication du Statut Redox et de sa modulation dans la réponse tumorale à
l’irradiation. PhD thesis, EDISS, UCBL, July 2011.
2010
[1] D. Dabli. Utilisation d’un modèle microdosimétrique cinétique (MKM) pour l’interprétation
d’irradiations cellulaires dans le cadre de l’hadronthérapie: Application de simulations Monte-
Carlo. PhD thesis, Université Blaise Pascal - Clermont-Ferrand II, Université Blaise Pascal -
Clermont-Ferrand II, February 2010.
2009
[1] M. Maalouf. Mort cellulaire et mécanismes de résistance des carcinomes épidermoïdes de la
tête et du cou en réponse à l’irradiation par ions carbone ou photons. PhD thesis, EDISS,
September 2009.
[2] E. Hadchity. Developpement d’une stratégie de radiosensibilisation par inhibition de
l’expression de la protéine de choc thermique hsp27 dans un modéle celluliare pré-clinique
de carcinome épidermoïde de la tête et du cou. PhD thesis, EDISS, 2009.
[3] A. Colliaux. Implication de l’oxygène et des anti-oxydants dans le processus de radiolyse de
l’eau induit par l’irradiation aux ions de haute énergie : simulations numériques pour la ra-
diobiologie. PhD thesis, Université Claude Bernard Lyon 1, December 2009.
2007
[1] C. Bionda. Implication des microdomaines rafts de la membrane plasmique dans la résistance
aux radiations ionisantes d’un modéle celluliare de carcinome epidermoïde de la tête et du cou.
PhD thesis, EDISS, december 2007.
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6.10 Posters
2012
[1] I Miladi, M.-T. Aloy, A. Berniard, E. Armandy, P. Mowat, M. Benchaib, N. Magné,
E. Noirault, C. Billotey, P. Perriat, F. Lux, O. Tillement, C. Rodriguez-Lafrasse, and
M. Janier. Gadolinium based nanoparticules as radiosensitizing agents for radioresistant
head and neck tumours. 7éme journéees Scientifique CLARA, Lyon, March 2012.
[2] I Miladi, M.-T. Aloy, A. Berniard, E. Armandy, P. Mowat, M. Benchaib, N. Magné,
E. Noirault, C. Billotey, P. Perriat, F. Lux, O. Tillement, C. Rodriguez-Lafrasse, and
M. Janier. Gadolinium based nanoparticules as radiosensitizing agents for radioresistant
head and neck tumours. World Molecular Imaging Congress, September 2012.
[3] M. Hanot-Roy, A. Boivin, C. Malesys, D. Ardail, and C. Rodriguez-Lafrasse. Trancient
glutathion depletion sensitize hnscc stem and non-stem cells to both photon and carbon
irradiation and decreases carbon ion induced genomic instability. 7éme Journées Scientifique
du Cancéropole CLARA, Lyon, March 2012.
[4] S Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, G. Alphonse, M. Beuve, C. Mal-
leval, J. Honnorat, T. Slatter, N. Hung, J. Royds, C. Rodriguez-Lafrasse, and D. Poncet.
Telomere profiling: toward glioblastoma personalized medicine. Telomeres and the DDR
meeting, October 2012.
[5] S Ferrandon, P. Saultier, P. Battiston-Montagne, M. Beuve, G. Alphonse, NH Hau,
C. Rodriguez-Lafrasse, and D. Poncet. Evaluation du statut télomérique comme biomar-
queur prédictif de réponse à la radiothérapie de lignées de glioblastome : orientation vers
l’hadronthérapie. 6ème journée scientifique du cancéropole PACA, February 2012.
[6] S Ferrandon, P. Saultier, P. Battiston-Montagne, M. Beuve, G. Alphonse, NH Hau,
C. Rodriguez-Lafrasse, and D. Poncet. Evaluation du statut télomérique comme biomar-
queur prédictif de réponse à la radiothérapie de lignées de glioblastome : orientation vers
l’hadronthérapie. 7ème journées scientifiques du Cancéropole Lyon Rhône-Alpes Auvergne,
2012.
[7] J Constanzo, M fallavier, G. Alphonse, C. Bernard, P. Battiston-Montagne, C. Rodriguez-
Lafrasse, D. Dauvergne, and M. Beuve. Radiograaff, a proton irradiation facility for radio-
biological studies at a 4mv van de graaff accelerator. 39th European Radiation Research
(ERR2012) 15-19 oct., Vietri sul Mare (Italia), 2012, 2012.
[8] M-A. Chanrion, U. Lejen, A. Wittig, L. Zink, R. Engenhart-Cabillic, M. Beuve, and W. Sauer-
wein. Influence of the local effect model parameters on the biologically weighted dose for
prostate cancer. 51st Annual Meeting of Particle Therapy Co-Operative Group (PTCOG51)
Goyang (Korea), May 2012.
[9] G Bertrand, M. Maalouf, A. Boivin, P. Battiston-Montagne, M. Beuve, G. Alphonse, and
C. Rodriguez-Lafrasse. Molecular mechanisms of tumor cell radioresistance in head and neck
squamous cell carcinomas. 7ème journées scientifiques du Cancéropole Lyon Rhône-Alpes
Auvergne, March 2012.
[10] G. Alphonse, NH Hau, P. Heudel, P. Battiston-Montagne, D. Poncet, S Ferrandon, M. Beuve,
and C. Rodriguez-Lafrasse. Predictive markers of intrinsic radiosensitivity in human glioma
cell lines irradiated with photon or carbon ions. 7ème journées scientifiques du Cancéropole
Lyon Rhône-Alpes Auvergne, 2012.
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2011
[1] M. Hanot, A. Boivin, C. Malesys, D. Ardail, and C. Rodriguez-Lafrasse. Transient glutathione
depletion sensitizes hnscc stem and non-stem cells to both photon and carbon irradiation and
decreases carbon ion induced genomic instability. NIRS-ETOILE, 2011.
[2] S Ferrandon, P. Battiston-Montagne, P. Saultier, M. Beuve, G. Alphonse, C. Rodriguez-
Lafrasse, and D. Poncet. Telomeric status and radioresistance in glioma : a predictive
biomarker for steering patient to hadrontherapy,. NIRS-ETOILE, 2011.
[3] S Ferrandon, P. Battiston-Montagne, P. Saultier, M. Beuve, G. Alphonse, NH Hau,
C. Rodriguez-Lafrasse, and D. Poncet. Telomeric status and radioresistance in glioma : a
predictive biomarker for steering patient to hadrontherapy. pages POS12–03. 14th Interna-
tional Congres of Radiation Research, 2011.
[4] G Bertrand, M. Maalouf, A. Boivin, P. Battiston-Montagne, M. Beuve, G. Alphonse, and
C. Rodriguez-Lafrasse. Molecular mechanisms of tumor cell radioresistance in head and neck
squamous cell carcinomas. NIRS-ETOILE, 2011.
[5] G. Alphonse, NH Hau, P. Heudel, P. Battiston-Montagne, S Ferrandon, M. Beuve, and
C. Rodriguez-Lafrasse. Predictive markers of intrinsic radiosensitivity in human glioma cell
lines irradiated with photon or carbon ions. NIRS-ETOILE, 2011.
2009
[1] M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Colliaux, M. Bajard,
C. Fournier, G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Implication des cellules souches
cancéreuses dans la radio-résistance des carcinomes epidermoïdes tête et cou (hnscc). 4ème
journée du Cancéropôle Lyon Auvergne Rhône-Alpes, march 2009.
[2] M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Colliaux, M. Bajard,
C. Fournier, G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Potential role of cancer stem
cells in the resistance of head and neck squamous cell carcinoma to high and low let radiation.
11th International Wolfsberg Meeting 2009 on Molecular Radiation Biology / Oncology, june
2009.
[3] A. Boivin, C. Malesys, O. Chapet, C. Rodriguez-Lafrasse, and D. Ardail. Une nouvelle stratégie
de radiosensibilisation tumorale par amplification du stress oxydant après déplétion transitoire
du glutathion cellulaire. 4ème journée du Cancéropôle Lyon Auvergne Rhône-Alpes, Archamps,
France, 2009, 2009.
[4] A. Boivin, C. Malesys, O. Chapet, C. Rodriguez-Lafrasse, and D. Ardail. The increase of
oxidative stress after transient glutathione depletion and irradiation triggers apoptosis in head
and neck squamous cell carcinoma. 8th Winter Research Conferences Oxidative DNA Damage:
From Chemical Aspects to Biological Consequences, 2009.
2008
[1] M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Colliaux, M. Bajard,
C. Fournier, G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Processus de mort cellulaire
differentiellement activés dans deux modèles cellulaires de hnscc en réponse à l’irradiation
(carbone et photons). 3ème journées scientifiques du cancéropôle Lyon Auvergne Rhône-Alpes
(CLARA)-Lyon, march 2008.
[2] M. Maalouf, G. Alphonse, P. Battiston-Montagne, M. Beuve, A. Colliaux, A. Demeyer, M. Ba-
jard, C. Fournier, G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Different mechanisms of cell
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death in radiosensitive and radioresistant p53 mutated head and neck squamous cell carci-
nomas exposed to carbon ions and x-rays. 36th Annual Meeting of the European Radiation
Research Society, Tours, France, september 2008.
[3] A. Boivin, C. Malesys, O. Chapet, D. Ardail, and C. Rodriguez-Lafrasse. Radiosensibilisation
d’un modèle de carcinome épidermoïde tête et cou (hnscc) par déplétion transitoire en glu-
tathion intracellulaire. 3ème journées scientifiques du canceropole Lyon Auvergne Rhône-Alpes
(CLARA)-Lyon, march 2008.
[4] A. Boivin, C. Malesys, O. Chapet, C. Rodriguez-Lafrasse, and D. Ardail. Transient glutathione
depletion before irradiation triggers apoptosis in head and neck cell carcinoma. 36th Annual
Meeting of the European Radiation Research Society Tours, France, september 2008.
2007
[1] M. Maalouf, G. Alphonse, M. Beuve, G. Taucher-Scholz, C. Fournier, and C. Rodriguez-
Lafrasse. Characterization of cell death induced by high let irradiation in head and neck
squamous cell carcinomas : implications for future clinical application in hadrontherapy. 11th
Workshop on Heavy Charged Particles in Biology and Medicine, Heidelberg, september 2007.
[2] M. Maalouf, G. Alphonse, M. Beuve, P. Battiston-Montagne, M. Bajard, C. Fournier,
G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Characterization of cell death induced by
high let irradiation in head and neck squamous cell carcinomas : implications for future clin-
ical application in hadrontherapy. 2nd symposium Novel targeting drugs and Radiotherapy
from the bench to clinic.13th International Congress of Radiation Research - San Francisco,
july 2007.
[3] M. Maalouf, G. Alphonse, M. Beuve, P. Battiston-Montagne, M. Bajard, C. Fournier,
G. Taucher-Scholz, and C. Rodriguez-Lafrasse. Different cell death pathways for radio-sensitive
and radio-resistant head and neck squamous carcinomas cells exposed to high and low let ra-
diation : Implications for future clinical application in hadrontherapy. 2nd symposium Novel
targeting drugs and Radiotherapy from the bench to clinic, Toulouse, june 2007.
[4] M. Maalouf, G. Alphonse, M. Beuve, G. Taucher-Scholz, C. Fournier, and C. Rodriguez-
Lafrasse. Caractérisation des processus de mort cellulaire activés en réponse a l’irradiation
par ions carbone de lignées tumorales humaines. 2ème journée du Cancéropôle Lyon Auvergne
Rhône-Alpes, Grenoble France, march 2007.
[5] M. Hollmark, M. Beuve, M. R. Edgren, T. Elsaesser, P. Kundrat, A.E. Meijer, C. Rodriguez-
Lafrasse, M. Scholz, M.P.R. Waligorski, and I. Gudowska. A comparison of radiobiological
models for light ion therapy. 11th Workshop of Heavy Charged Particles in Biology and
Medicine – Heidelberg, september 2007.
[6] M. Beuve, G. Alphonse, M. Maalouf, A. Colliaux, P. Battiston-Montagne, P. Jalade, M. Bajard,
and C. Rodriguez-Lafrasse. Hadronthérapie : Modélisation et mesure des effets biologiques
des ions légers. Journées Scientifiques du Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA),
Grenoble, march 2007.
[7] D. Ardail, C. Bionda, P. Battiston-Montagne, and C. Rodriguez-Lafrasse. Involvement of raft
microdomains in the resistance of human carcinoma cells to irradiation. 2nd symposium :
Novel Targeting Drugs and Radiotherapy. From the bench to the clinic, Toulouse, France,
2007.
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2010
[1] G. Wannous. Automated counting of gamma-h2ax foci to evaluate the dna double strand
breaks sites generated by ionizing radiation. Technical report, IPNL, January 2010.
[2] F. Chandez and G. Montarou. Analyse avec le logiciel imagej d’un lot d’images en microscopie
par immunofluorecence de cellules de fibroblastes irradiées en x à l’esrf. Technical Report
PCCF RI 1004, LPC Clermont, July 2010.
2007
[1] A. Joubert and N. Foray. Premiers resultats de radiobiologie sur amande-cadarache. Technical
report, Rapport Interne IRSN, 2007.
6.12 Patents
2008
[1] C. Rodriguez-Lafrasse and E. Hadchity. Treatment of squamous cell carcinoma with hsp27
abtisense oligonucleotides and radiotherapy. Brevet University of British Columbia n° 60 / 893
086, 2008.
6.13 Book chapters
2008
[1] N. Foray, V. Favaudon, and J. M. Cosset. RADIOTHERAPIE ONCOLOGIQUE, Enjeux et
concepts nouveaux en radiobiologie. Montrouge, john libbey eurotex edition, 2008.
[2] N. Foray and J. Balosso. RADIATION CHEMISTRY : From basics to applications in material
and life sciences, chapter Advances i. EDP Sciences, Les Ulis, 2008.
[3] V. Favaudon and N. Foray. RADIOBIOLOGIE, chapter Effets Cel. Hermann, 2008. nouvelle
édition, revue et augmentée.
6.14 Oral communications
2012
[1] D. Poncet, S Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, G. Alphonse, M. Beuve,
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Les effets biologique differentiels en radiotherapie conventionelle et hadrontherapie. 10éme
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[3] S. Camarasu-Pop, T. Glatard, R. Ferreira da Silva, P. Gueth, D. Sarrut, and H. Benoit-
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2012
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Journal of Electronic Imaging, 21(2), April 2012.
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7.2 International conferences with reviewing committee
2012
[1] F. Roellinghoff, A. Benilov, D. Dauvergne, G. Dedes, N. Freud, J. Krimmer, J.M. Létang,
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Electron density resolution determination and systematic uncertainties in proton computed
tomography (pct). In Nuclear Science Symposium and Medical Imaging Conference. IEEE,
2012.
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[4] L. Grevillot. Monte Carlo simulation of active scanning proton therapy system with
Gate/Geant4: Towards a better patient dose quality assurance. PhD thesis, INSA Lyon, ED
EEA, October 2011.
2010
[1] N. Zahra. Mesure de la dose physique par films radiochromiques et simulation Monte Carlo
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Mémoire pour l’obtention de l’habilitation à diriger des recherches.
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[3] S. Rit and D. Sarrut. Cone-beam projection of a deformable volume for motion compensated
algebraic reconstruction. In IEEE Engineering in Medicine and Biology Conference (EMBC),
Lyon, France, September 2007.
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